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Abstract 
Glioblastoma Multiforme (GBM) is a malignant primary brain tumour with an extremely 
poor prognosis. Following surgical resection, radiotherapy, and concomitant and adjuvant 
chemotherapy, median survival is only 12-15 months. New therapeutic approaches are 
therefore desperately needed. 
 
Accumulating evidence suggests that activated T cells are capable of selectively targeting 
and eliminating tumour cells, even in the brain, making vaccine-mediated immunotherapy 
a promising candidate for the treatment of brain cancers. However, cancer vaccination 
has generally been disappointing in the clinic, and is unlikely to bestow long-term survival 
unless suppressive mechanisms are overcome. Checkpoint blockade is a recent treatment 
modality that enhances naturally occurring T cell responses to cancer by relieving 
suppression mediated by immune checkpoints – molecular signals that prevent T cell 
function. While significant clinical responses are often seen, it is clear that most patients 
fail to respond to checkpoint blockade alone. Therefore, there is considerable interest in 
combining the different immunotherapeutic strategies, with vaccines providing an 
immunogenic stimulus to induce anti-tumour T cells, and checkpoint blockade to ensure 
T cell function is retained. 
 
An orthotopic murine model of glioma was utilised to examine this form of combined 
treatment. Immune responses induced with a unique whole-cell vaccine that utilises the 
adjuvant properties of invariant natural killer T cells (iNKT cells) were able to resist 
tumour challenge, but failed to eradicate established tumours. When the vaccine was 
combined with blocking antibodies to the immune checkpoint molecule cytotoxic T 
lymphocyte antigen-4 (α-CTLA-4) regression of established intracranial tumours was 
observed, whereas α-CTLA-4 was ineffective as a monotherapy. In contrast, combining 
the vaccine with antibodies to programmed death-1 (α-PD-1) or lymphocyte activation 
gene-3 (LAG-3) failed to provide any survival advantage. This was despite α-PD-1 being 
effective against the same tumour implanted subcutaneously, suggesting efficacy in the 
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orthotopic setting was limited by poor access of α-PD-1 to effector T cells within the 
brain. 
 
The effective combination of vaccine and α-CTLA-4 was associated with enhanced 
proliferation and accumulation of T cells in the lymphoid tissues without any obvious 
changes in the adjuvant function of iNKT cells or altered numbers of regulatory T cells, 
suggesting recently primed T cells were the targets of checkpoint inhibition. While 
tumours regressing under this combined treatment were highly infiltrated with a variety of 
leukocytes, tumour eradication was strictly dependent on CD4+ T cells. 
 
Further interrogation of the cell-types responsible for anti-tumour activity revealed that 
CD11b+ cells were required for therapy, although it remains to be established whether 
these cells were involved in T cell priming or served as anti-tumour effectors in their own 
right, possibly under the influence of activated CD4+ T cells. In addition, therapy was 
hampered, although not entirely eliminated, in hosts deficient in interferon-γ. Therapy 
was also reduced significantly, but not entirely, in hosts deficient in perforin. In vitro 
studies showed that restimulated splenocytes from animals that had received the 
combined therapy were able to kill glioma cells in a perforin and MHC-II dependent 
manner, suggesting that cytotoxic CD4+ T cells were important effector cells.  
 
Overall, these results demonstrate that immunotherapeutic vaccination can be combined 
effectively with checkpoint blockade to induce effective immune responses against glioma. 
The immune response induced in combination with CTLA-4 blockade differs from many 
other cancer models, with a strict dependence on CD4+ T cells that can serve either as 
cytotoxic effector cells, or potentially as modulators of other accessory cells. Furthermore, 
the tumour location presents new challenges, with access of inhibitors to the brain, 
particularly important if immune checkpoints on intratumoural effector cells are to be 
targeted. In this context, strategies to improve access of checkpoint inhibitors like α-PD-
1 and α-LAG3 to the brain warrant further investigation. 
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Chapter 1 
1  Introduction 
1.1 General Introduction 
Cancer, in its various iterations, has been present throughout human existence. From its 
first description on Egyptian papyri, a diagnosis of “a tumour and abscess of the breast”, 
through to present molecular methods to diagnose malignancies, the presence of both 
benign and malignant neoplasms seems to be an inherent consequence of our life as 
multicellular organisms. Cancer can be described as a group of diseases, resulting from a 
mutation at the DNA level, leading to abnormal cell growth and proliferation, with these 
cells having the potential to spread to other parts of the body. Treatments for cancer have 
varied throughout history. Initially radical debulking surgery was adopted. This method 
aimed to remove as much as diseased tissue as possible, as well as sites that it may have 
travelled to. As understanding of what caused disease deepened, more targeted therapies 
began to evolve. These included the use of chemotherapeutic agents aimed to interfere 
directly with cancer growth pathways. However, owing to the genetic instability of 
tumour cells, patients would often relapse, as cancer cells mutated to use different growth 
and survival pathways. Recently, the ability of the immune system to recognise tumours 
has come to the fore. This thesis aims to explore the use of immunotherapy for the 
treatment of cancer, using a murine model of glioma. 
1.2 Glioblastoma Multiforme 
Glioblastoma Multiforme (GBM) is highly malignant brain tumour and the most 
common occurring primary brain cancer in adults (1). With an incidence of 3.5 cases per 
100,000 people in developed countries, prevalence of disease is relatively low (2). Similarly, 
NZ has a tumour incidence of 4.1 cases per 100,000 people (3). However, GBM is 
currently incurable as tumours readily invade local brain tissue, making full tumour 
resection difficult. Furthermore, the presence of the blood brain barrier (BBB) limits 
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chemotherapeutic penetrance into the brain and tumour site. Post-operative radiotherapy 
is an effective treatment and doubles median survival when compared to surgery alone 
but recurrence is unavoidable (4). In 2005 a clinical trial showed the benefit of 
concomitant temozolomide chemotherapy with radiotherapy following surgical resection. 
Temozolomide is a DNA alkylating agent which causes DNA damage within tumours 
cells, ultimately triggering cell death. However, despite the inclusion of temozolomide 
into standard treatment schedules, median patient survival still remains only 12-15 
months following diagnosis; five-year survival is less than 10% and long term survival 
occurs only rarely (5).  
 
GBM is thought to arise from glial cells or astrocytes within the brain, however recent 
evidence has shed doubt on the cell of origin, showing dedifferentiation of neurons by 
oncogenes can also drive tumourigenesis (6). The World Health Organisation 
classification system has GBM designated as a Grade IV astrocytoma (where Grade I is 
the least severe and Grade IV is the most severe) (7). As genomic techniques have 
developed, it is now clear that GBM tumour cells are genetically heterogeneous. This has 
allowed the discrimination of GBM tumours into four distinct subtypes; classical, 
proneural, mesenchymal and neural, based on their genetic mutation profile (8). Tumours 
within the classical subtype carry extra copies of the epidermal growth factor receptor 
(EGFR) gene, resulting in over expression of EGFR. Additionally, classical GBM 
tumours rarely have mutated p53 (9). In contrast, proneural tumours have a high 
mutation rates in the p53 protein as well as the genes for platelet-derived growth factor 
(PDGFRA) and isocitrate dehydrogenase-1 (IDH-1). Proneural tumours are typically 
associated with a younger age of onset and a slightly better overall prognosis (8). The 
mesenchymal signature is characterised by the expression of mesenchymal markers and a 
high mutation rate in neurofibromin 1 (NF1) but fewer mutations in the EGFR gene as 
well as reduced expression of EGFR compared to other subtypes. Finally, the neural 
subtype harbours mutations in many of the same genes as the other groups but is further 
classified by the expression of neuron markers which are typically expressed by non-
transformed neuronal cells. Patients in the neuronal group are the oldest on average (8).  
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Importantly, as a consequence of the mutation profile, each of the GBM subtypes 
responds differently to therapy. Patient survival was examined following intensive therapy, 
defined as concurrent chemo- and radiotherapy or more than three subsequent cycles of 
chemotherapy, and compared to patients with non-concurrent treatment regimes, or 
short chemotherapy regimes. Here, aggressive treatment significantly reduced mortality in 
classical and mesenchymal subtypes. Some efficacy was suggested in neural subtypes but 
no survival advantage was observed within the proneural subtype (8). It is also important 
to note that while one of these subtypes can predominate in an individual tumour, a 
heterogeneous population of cells typically exists (10, 11), meaning that GBM can be 
viewed as being not simply one disease, but a complex combination of diseases, each 
potentially responding differently to therapy. 
 
Treatment of GBM is difficult due to many complicating factors. The tumours are highly 
resistant to radiotherapy and chemotherapy due to the presence of resistant cells within 
the heterogeneous makeup. Recent studies have shown that these resistant cells have 
properties that overlap with stem cells (12). Such stem cell-like cells are identified based 
on the expression of CD133, and are capable of recapitulating the full tumour phenotype 
after serial passage in vivo with as few as 100 CD133+ cells required, whereas other cells 
from the tumour mass are incapable of doing so unless greater than 10,000 CD133- cells 
were injected (13). A characteristic feature of stem cells is that they express high levels of 
expression of resistance genes such as BCRP, MGMT, Bcl-2 and Bcl-xL (14) and can 
promote radio-resistance by preferential activation of the DNA damage response (15). In 
addition, tumours are known to contain zones of hypoxia within the tissue which are 
resistant to radiotherapy due to activation of the hypoxia-inducible factor (HIF-1α) 
mediated pathway. Under normoxic conditions, HIF-1α is rapidly degraded, however 
under hypoxic conditions, degradation of HIF-1α is prevented, resulting in activation of 
the hypoxia response element and upregulation of target genes to promote survival in 
low-oxygen conditions. These include glycolysis enzymes, permitting ATP synthesis in an 
oxygen independent manner, and vascular endothelial growth factor (VEGF) to promote 
angiogenesis (16). New approaches using trans sodium crocetinate, an oxygen diffusion 
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enhancing compound which can act as a radio-sensitiser, are currently being investigated 
(17). 
 
While temozolomide has been shown to increase overall survival in GBM patients, 
expression of the O6-methylguanine-DNA methyltransferase protein, driven by the 
MGMT gene (18, 19) within tumour cells can lead to DNA repair, reversing the DNA 
damage caused by chemotherapy (19). While tumours remain difficult to treat, the brain is 
susceptible to collateral damage due to radiotherapy including progressive brain volume 
loss (20). Following such damage, the brain has a very limited self-renewal capacity. 
Finally, many drugs cannot pass into the tumour due to the presence of the blood brain 
barrier (21). 
 
As mentioned earlier, surgery is the first stage of treatment, with resected tissue used for 
pathological diagnosis, as well as reducing intracerebral pressure resulting from having a 
large mass press against the brain. The recent inclusion of the fluorescent dye 5-
aminolevulinic acid has helped guide resection (22), and removal of over 98% of the 
tumour mass results in a significant increase in progression free survival (23). However, 
the highly infiltrative nature of glioma throughout the brain makes complete surgical 
resection difficult, resulting in inevitable tumour relapse either near the original tumour 
site, or at a distant site due to satellite lesions within the brain. To limit relapse, resection 
is followed by radiotherapy and concurrent temozolomide chemotherapy (5). However, 
the overall prognosis for patients is still bleak with median overall survival remaining at 
12-15 months from initial diagnosis. Alternative therapeutic strategies with a good safety 
profile are desperately needed. For this reason immunotherapeutic approaches are now 
being investigated. 
1.3 Immunotherapy 
By the late 19th century, William Coley observed that some cancer patients who developed 
infections during their disease saw their tumours shrink. He used this knowledge to 
develop Coley’s toxins, a mixed bacterial vaccine consisting of killed Streptococcus pyogenes 
and Serratia marcescens that was administered either intravenously, intramuscularly or 
directly into the tumour (24, 25). While Coley’s treatments showed some spectacular 
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results (26), the treatment schedules were arduous (he maintained that high fevers should 
be induced at frequent intervals), and the agents he used often suffered from poor quality 
control. The development of radiotherapy, and then chemotherapy, ushered in a new era 
of cancer treatment, and immunotherapy was side-lined. A greater understanding of the 
nature of adaptive immunity in the 1980’s and 1990’s, particularly the pathways of antigen 
presentation to T cells, lead to renewed interest in cancer immunotherapy. An important 
step was in defining specific tumour-associated proteins that could serve as antigens for T 
cell attack (27). More recently, it is now recognised that many chemotherapeutics also 
have immune-modulatory function, with destroyed tumour tissue acting as a stimulus to 
prime anti-tumour immune responses (28). Stimulation of de novo immune responses, 
typically featuring T cells, remained the ultimate aim of immunotherapeutic research until 
a deeper understanding of T cell activation and regulation was determined, thus initiating 
the current era of “checkpoint blockade” immunotherapy where pre-existing weak 
responses are relieved from negative regulatory pathways.   
 
This thesis will describe an investigation into inducing adaptive immune responses to 
glioma in an orthotopic mouse model which is commonly used to model human GBM. 
The research described is an investigation into how to maximise the therapeutic benefit of 
a vaccine that had been developed earlier by colleagues in my laboratory (29). As this 
vaccine was shown to be dependent on T cells for activity, the following sections in this 
introduction will provide an overview of T cell development, differentiation and function. 
It will also include a description of negative feedback mechanisms that control T cell 
responses, and how these molecular pathways can be exploited for therapy. 
1.4 The Immune System 
The immune system consists of a series of organs and cells, which serve to coordinate the 
discrimination between entities that pose a danger to the body and those that are 
otherwise benign. The innate immune system consists of phagocytic cells such as 
macrophages and neutrophils, which ingest and kill microbes via production of toxic 
chemicals and degradation enzymes. Innate immune recognition is enabled by receptors, 
which recognise conserved regions of pathogens, such as pathogen associated molecular 
patterns (PAMPs), or danger associated molecular patterns (DAMPS) released in 
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response to injury or insult. This facilitates a rapid, yet relatively non-specific response, 
with no lasting immunological memory. 
 
Natural killer (NK) cells are a population of lymphocytes that do not undergo gene 
rearrangement to express diverse receptors. Rather, NK cell functions are controlled by a 
diverse array of germline encoded activating and inhibitory receptors, with activation 
determined by the balance of both stimulatory and inhibitory receptors. The expression 
of ligands for these receptors can be ubiquitous, or can become up-regulated or secreted 
in the presence of an infection or malignancy (30). 
 
Conversely, the adaptive immune system is antigen specific and does confer 
immunological memory. The cells involved in adaptive immunity are lymphocytes, like 
NK cells, which are generated in large numbers in the bone marrow before moving into 
the lymphoid tissues. Whereas NK cell activation is non-antigen specific, adaptive antigen 
specificity is enabled due to antigen receptors on the cell surface, with each cell expressing 
multiple copies of a unique receptor generated through a random rearrangement process. 
The high degree of variability of these receptors allows the recognition of a wide variety 
of antigens; indeed a person’s full repertoire contains over a billion lymphocytes (31) 
capable of recognising many foreign antigens. The two types of lymphocyte involved in 
adaptive immune responses are T cells and B cells, with each playing a distinct role in 
immunity. When an antigen binds to a B cell’s antigen receptor (BCR), it will proliferate 
and differentiate into a plasma cell. In the process, the BCR becomes expressed as a 
soluble effector molecule, or antibody, which is released from plasma cells in large 
quantities. Thus the antigen responsible for activation of the B cell becomes the target of 
antibodies that recirculate throughout the body. 
 
Antigen recognition via the T cell receptor (TCR) stimulates a T cell to proliferate and 
differentiate into an effector T cell. Effector T cells are capable of three distinct functions. 
Cytotoxic T cells have evolved to kill cells that present targeted antigens (the antigen 
presenting pathways will be discussed below), including infected cells or tumour cells. 
Helper T cells provide essential signals for the differentiation of cytotoxic T cells, and 
also provide signals to B cells to aid in antibody production and survival. The signals they 
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release include cytokines that can have effector functions in their own right, such as the 
interferons (IFNs) that serve to limit pathogen proliferation. Finally, regulatory T cells 
(Tregs) suppress the activity of cytotoxic and helper T cells, a mechanism needed to limit 
unwanted T cell function that could result in autoimmunity. 
1.5 Antigens 
The term antigen is used to describe any substance or entity that can be recognised and 
responded to by the immune system. Typically, proteins, polysaccharides and glycolipids 
of pathogens acts as antigens recognised by the immune system. Owing to the highly 
variable antigen receptors expressed on lymphocytes, many other structures can be 
recognised that are not pathogen-associated including drugs such as penicillin, plant 
products such as seeds and pollen and metals such as nickel. Furthermore, mutations in 
“self” proteins that are expressed on tumour cells allow the recognition of malignant 
tissue. These mutations can be patient specific, or can result in the overexpression of a 
protein across many patients.  
 
As this thesis will focus primarily on T cell-mediated adaptive immune responses, it is 
important to note that, in general, T cells recognise peptide fragments derived from 
protein antigens; these sequences are commonly described as T cell epitopes. A defining 
feature of a peptide epitope is that it must be capable of being presented on the surface of 
a cell via major histocompatibility (MHC) molecules; indeed it is only in the context of 
presentation via MHC that a T cell can truly recognise a given antigen in order to become 
activated, or to exert its effector functions. 
1.6 Tumour Antigens 
Activated T cells isolated from cancer patients have been shown to have specific activity 
against autologous tumour cells in vitro. By analysing these T cell responses, gene products 
can be identified that serve as targets for T cell recognition. In addition, so-called “reverse 
immunology” can be applied to identify candidate antigens based on expression in the 
tumour relative to healthy tissue. Here, antigens are theoretically predicted based on 
protein sequences before subsequent high throughput screening in silico. Candidate 
antigens are synthesised and those with potential to bind MHC molecules are predicted 
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using computer based modelling and algorithms. Finally, in vitro and in vivo testing can be 
performed to verify which of the predicted antigens has physiological function. Strategies 
such as these have resulted in definition of a number of antigens (32) and could 
contribute to personalised treatment approaches in the future based on the “mutanome” 
of a given patient’s cancer. 
1.6.1 Tumour Specific Antigens 
Unique peptide fragments spanning mutations found in tumour tissue, together with 
idiotype-specific peptides from neoplastic B or T cells, can be classified as tumour-
specific antigens (TSAs). Such antigens may be those involved in the driving the 
neoplastic process. Mutations in the p53 protein commonly limit the regulatory function 
of this protein in cell cycle progression and therefore contribute towards tumourigenesis. 
Additionally, neoepitopes can arise from the tumour’s genetic instability, reflecting an 
increase in both “driver” mutations that encourage tumour growth, or “passenger” 
mutations that have no such impact. Overall, if these mutations result in peptides that can 
be presented via MHC, they represent TSAs that are potentially unique to a patient’s 
tumour, with the resulting immune responses likely to be patient-specific. The 
identification and incorporation of neoepitopes into vaccines has the potential to 
introduce a personalised approach for onco-immunotherapy. 
 
Often seen in GBM is the amplification of the EFGR, bestowing these tumours a growth 
advantage. In a subset of cases, EGFR amplification is accompanied by gene 
rearrangement. The most common mutation observed is the EGFR variant III 
(EGFRvIII), which contains an in-frame deletion of 801 base pairs (bp). This causes in a 
loss of the ligand-binding domain of EGFR, resulting in ligand-independent constitutive 
phosphorylation of the receptor that is augmented by reduced internalisation and down-
regulation. The in-frame deletion results in the loss of exons 2 to 7, resulting in the 
generation of a novel glycine residue at the junction of exons 1 and 8. This 
unconventional juxtaposition within the extracellular domain of the EGFR creates a 
tumour specific and immunogenic epitope (33). Currently, immunotherapies targeting 
EGFRvIII are under investigation (34). 
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1.6.2 Tumour Associated Antigens 
Another group of antigens with abundant expression in tumours but restricted expression 
in healthy tissue are tumour-associated antigens (TAAs).  Within this group, the cancer-
testis (CT) antigens are the best characterised. CT antigens arise from epigenetic changes 
resulting in the differentiation of germ line cells into healthy adult testis, foetal ovary or 
placental trophoblasts. The expression of CT antigens in healthy people is typically 
restricted to “immune-privileged” sites such as the eyes and testicles, where physical 
barriers and reduced MHC expression protect the tissue from immune attack. 
 
A second group of TAAs are the differentiation antigens, which are expressed in the 
tumour tissue and in the tissue of origin of the malignancy, ideally with very little 
expression elsewhere. As melanocytes and astrocytes are derived from the neural 
ectoderm, there is some overlap between antigens identified in both melanoma and GBM. 
These include, but are not limited to, gp100 and TRP-2, which are implicated in normal 
processes of melanin synthesis or melanosome biogenesis (35). 
 
A third group of TAAs are the overexpressed antigens, which are expressed widely in 
normal tissues, but are significantly overexpressed in tumours. The anti-apoptotic protein 
survivin, also known as baculoviral IAN repeat containing 5 (BIRC5) functions to inhibit 
caspase activation, thereby leading to negative regulation of apoptosis. Survivin is 
expressed highly in human tumours and foetal tissue but is otherwise absent in terminally 
differentiated cells (36). Additionally, erythropoietin-producing hepatocellular carcinoma 
A2 (EphA2) is a receptor tyrosine kinase which is overexpressed in primary GBM 
compared to non-transformed tissues. Increased EphA2 expression is thought to be due 
to a decrease in the amount of ligand-mediated receptor degradation. As a consequence, 
receptor activation and subsequent degradation of EphA2 are decreased, producing a 
scenario whereby EphA2 is highly expressed yet significantly less activated (37). EphA2 
mediates signal transduction pathways in cells including those controlling growth, 
migration and differentiation (38). The activation of EphA2 has been shown to negatively 
regulate integrin mediated adhesion, cell spreading and adhesion (39, 40). Therefore, 
when EphA2 is present in an inactive state, the cells on which it is expressed are more 
motile, faster growing and more invasive. 
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1.6.3 Immunotherapy in absence of defined tumour antigens 
While the range of defined tumour antigens is increasing rapidly, there are still no 
validated targets for immunotherapy of GBM. In light of this paucity of information 
(which is also true for most cancers), immunotherapies have been developed which 
simply use the tumour itself as a source of antigens. This has taken many forms including 
killed tumours cells, tumour lysate or tumour derived RNA. The assumption in these 
therapies is that antigen-presenting cells acquire the tumour material after it is injected 
into patients, and then present it via MHC to T cells in the lymphoid tissues. As this form 
of “cell-based” immunotherapy is to be investigated in this thesis, the processes of 
antigen-presentation required will be reviewed here. 
1.7 Antigen Presentation by MHC molecules 
Due to the large diversity of TCRs, T cells have the ability to recognise almost all antigens 
a person will encounter in their lifetime. However, antigen cannot be recognised by T 
cells in its natural form. Rather, whole proteins are processed and “loaded” onto MHC 
molecules, a process known as antigen presentation. Even in a healthy state, proteins 
within a nucleated cell are constantly synthesised and degraded, with some peptide-
derivatives being presented on the cell surface via MHC molecules. In the case of an 
infection, or neoplasia, this repertoire of presented peptides starts to include peptides that 
are pathogen- or tumour-derived.  
1.8 Antigen Presenting Cells 
Antigen-presenting cells (APCs) are cells that display foreign antigens in the context of 
MHC molecules to initiate an immune response. They can be classified as either non-
professional or professional APCs depending on the constitutive expression of MHC 
class II (MHC-II); non-professional APCs do not constitutively express MHC-II. 
However, under inflammatory conditions, or in the presence of the cytokine interferon-γ 
(IFN-γ), MHC-II can be expressed. Professional APCs are efficient at internalising 
antigens either by phagocytosis, or receptor mediated endocytosis and displaying these on 
the cell surface to naïve T cells. In addition to MHC-II expression, professional APCs 
express the accessory molecules and factors that are needed induce T cell responses, once 
a T cell recognises peptide fragments in the context of MHC molecules. This includes 
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expression of adhesion molecules and costimultory molecules, and the ability to release 
cytokines to help drive T cell differentiation. Dendritic cells (DCs) have the broadest 
range of antigen presentation capabilities and are widely characterised as the most potent 
APCs due to their ability to activate naïve T cells. 
1.9 Antigen Processing and Presentation on APCs 
In order for APCs to induce an immune response, antigens must be appropriately 
processed into peptides of the right size and shape to be presented on MHC molecules. 
Two classical pathways exist that independently activate two different T cell populations; 
CD4+ T cells and CD8+ T cells. These are the MHC class I (MHC-I) presentation 
pathway, which presents antigen to CD8+ T cells, and the MHC class II (MHC-II) 
presentation pathway, which presents antigen to CD4+ T cells. More recently, an 
additional pathway of presentation to CD8+ T cells has been defined, called the cross-
presentation pathway, which can be broadly regarded as an exchange of antigen between 
the two classical pathways.  The relevance of each pathway will be discussed below. 
1.9.1 MHC-I antigen presentation pathway 
Antigens presented by the MHC-I pathway are peptides derived from cytosolic proteins, 
degraded within the proteasome. All nucleated cells express MHC-I and in a resting state, 
proteins within a nucleated cell are constantly synthesised and degraded. Each MHC-I 
molecule on the surface of the cell displays a peptide fragment of a protein, and these can 
either be of host origin, or in the case of an infection or tumour, can be pathogen derived. 
The proteasome is a macromolecule consisting of 28 subunits which functions to degrade 
intracellular proteins into small peptides of 8-12 amino acids, which are then released into 
the cytosol. Processed peptides are then translocated from the cytosol to the endoplasmic 
reticulum (ER) where they are met by MHC-I. The molecule “transporter associated with 
antigen processing” (TAP) facilitates peptide translocation into the lumen of the ER. The 
MHC-I molecule is then loaded with peptides within the lumen of the ER. The peptide 
loading process involves several other molecules which form a large multimeric complex 
consisting of TAP, tapasin, calreticulin, calnexin and Erp57. MHC-I molecules are 
heterodimers consisting of two polypeptide chains, α and β2-microglobulin (β2m). 
Once synthesised, calnexin acts to stabilise the α chains of MHC-I prior to β2m 
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binding. After assembly of the MHC-I molecules, calnexin dissociates. However, in the 
absence of bound peptide, the MHC-I molecule is inherently unstable and still requires 
the chaperones calreticulin and Erp57. Tapasin binds the MHC-I molecule and acts as a 
link to the TAP proteins, facilitating peptide loading. Following peptide loading, the 
complex dissociates and leaves the ER via the secretory pathway to reach the cell surface 
(Fig 1.1 A).  
1.9.2 MHC-II antigen presentation pathway 
Antigens presented by the MHC-II pathway are usually derived from extracellular 
proteins that accumulate as a consequence of dead and dying cells in perturbed or 
infected tissues. As the exogenous protein antigens have to be internalised to be 
presented, the MHC-II pathway is restricted to cells that can efficiently acquire antigens 
via phagocytosis or receptor-mediated endocytosis; these cells are referred to as APCs, 
including DCs, macrophages and B cells, among others. With differing degrees of 
efficiency, APCs can initiate T cell responses, as well as being required in the target tissues 
to redirect effector activities to their targets.  
 
Once internalised by APCs, antigenic proteins are degraded by peptidases into peptide 
fragments within the endosome, resulting in peptides that are between 12-24 amino acids 
in length. The MHC-II molecule is synthesised in the endoplasmic reticulum (ER), with 
the α and β chains complexed to a polypeptide called the invariant chain. The invariant 
chain acts as a chaperone and serves to stabilise the MHC-II complex and prevents 
MHC-II binding cellular peptides from the endogenous pathway. Binding of the invariant 
chain also facilitates export of MHC-II from the ER to the golgi apparatus, where fusion 
with the endosome containing peptide antigens occurs. The invariant chain is degraded by 
proteases called cathepsins, leaving a small fragment known as class II-associated 
invariant chain peptide (CLIP), which maintains blockage of the peptide binding groove. 
Finally, the CLIP fragment is removed, allowing the binding of peptides with higher 
affinities. The stable MHC-II molecule is then transported and presented on the cell 
surface (Fig 1.1 B). 
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1.9.3 Cross-Presentation Pathway 
Mice immunised with exogenous antigens can induce CD8+ T cell responses, suggesting 
overlap between the two classical antigen processing and presentation pathways (41). 
Cross-presentation refers to the ability of certain antigen presenting cells to internalise, 
process and present exogenous antigens on MHC-I molecules to CD8+ T cells. Such a 
process is necessary for immunity against tumours and viruses which do not readily infect 
APCs, or impair normal APC function. Additionally, cross-presentation is required for 
induction of CD8+ T cell-mediated immunity by vaccination with protein antigens. 
However, the classical antigen presentation pathways do not explain the mechanism 
underlying this phenomenon. It is thought that endocytosed proteins are transported out 
of the endosome and into the cytosol where they are processed by the proteasome into 
peptides, which are transported by TAP to the ER to facilitate MHC-I loading (42). Other 
studies have suggested that as the phagosome forms, it fuses with the ER to form an ER-
phagosome compartment (43). From here, TAP proteins transport proteins out of the 
ER-phagosome compartment and into the cytosol for degradation, before transport back 
into the compartment to allow loading onto MHC-I (Fig 1.1 C). 
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Figure 1.1 Antigen processing pathways in antigen presenting cells. 
(A) MHC-I molecules present peptides dertived from endogenous proteins degraded within the cytosol. (B) 
MHC-II molecules acquire exogenous peptides which are generated by proteolytic cleavage in the 
endosomal compartments. (C) Cross-presentatation is the process whereby exogenous antigen is transferred 
to the endocytic pathway for presentation on MHC-I molecules. Figure adapted from Villadangos and 
Schnorrer (44). 
 
1.10 Dendritic Cells 
Dendritic cells are present in both the blood and tissues where they act as sentinels for 
the immune system. They are very efficient at sampling the local environment through 
macro-pinocytosis, phagocytosis and receptor mediated endocytosis, and can process 
acquired antigens to be presented onto both classes of MHC molecules so these can then 
be displayed to CD4+ or CD8+ T cells (45). DCs can be broadly separated into migratory 
DCs which reside in the tissues and migrate to the lymph nodes, and lymphoid resident 
DCs which develop from blood precursors but do not recirculate through the tissues (46). 
Both DCs can be further delineated into subsets based on cell surface markers and 
function. All DCs are capable of presenting exogenous antigens to prime CD4+ T cells, 
however some DCs are particularly efficient at also cross-presenting exogenous antigen to 
CD8+ T cells (47, 48). Cross-presenting DCs in mice typically express the T cell co-
receptor CD8α, although the function of CD8α on these DCs is currently unknown (47). 
In addition to superior cross-presentation capacity, CD8α+ DCs also have higher 
expression of the C-type lectin domain (DEC205) compared to CD8α- DCs (49). While 
the ligand for DEC205 is unknown, it has been shown to be involved in the uptake of 
dying cells (50). As the aim of most anti-cancer therapies is to elicit strong T cell 
responses, there is substantial interest in targeting antigens to cross-presenting DCs (51). 
 
Interestingly, not all CD8α+ DCs are equally as efficient at cross-presenting exogenous 
antigen to CD8+ T cells. Within the CD8α+ subset, expression of the C-type lectin 
langerin (CD207) defines a subset of DCs with superior cross-priming ability (52). 
Depletion of langerin+ cells impairs the cross-priming of CD8+ T cells following soluble 
OVA and adjuvant administration in vivo (52). Langerin binds carbohydrates found on the 
surface of fungi and viruses and has been shown to mediate the uptake of the measles 
virus by DCs (53), suggesting that in some instances, langerin can act as a pathogen 
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endocytosis receptor. While CD8α+ langerin+ DCs are effective at cross-presentation in 
vitro (52), cross presentation of soluble OVA by CD8α+ DCs is not hampered in langerin-
deficient mice (54), suggesting langerin is not required for antigen uptake or processing in 
this setting. Alternatively, the superior cross-presenting ability of these DCs may be as a 
result of their anatomical location. Langerin+ DCs are found within the marginal zone of 
the spleen, and are optimally located to take up blood-borne antigens (55). 
 
A similar organisation of DCs exist within the peripheral tissues. In murine skin, two 
main populations of migratory DCs are present within the dermis in a quiescent state and 
can be defined based on the expression of CD11b+ and CD103+, with the CD103+ 
expressing subset efficient at cross-presenting skin-derived antigens within the draining 
lymph node (56). While CD8α+ and CD103+ DCs harbor the capacity for cross-
presentation, they also express DEC205, Clec9A and langerin and are dependent on the 
transcription factor BatF3 for development, suggesting they share developmental 
pathways (57). The dominant CD11b+ population within the skin is proposed to induce 
CD4+ T cell activation and humoral immunity (58). Furthermore, it has been proposed 
CD11b+ DCs play a role in peripheral tolerance as they are able to produce retinoic acid, 
promoting the conversion of naïve CD4+ T cells to regulatory T cells (Tregs), and their 
ability to induce Tregs in vitro (59, 60). More recently, in vivo studies showed that Treg 
induction in the resting state was restricted to migratory langerin+ Langerhans cells and 
dermal CD103+ langerin+ DC, suggesting that retinoic acid production may act in a 
paracrine loop to boost Treg induction by other migratory DC subsets (61). 
1.11 Dendritic Cell Activation 
The terms DC maturation, activation and licensing have been used to explain the 
phenotypic changes associated with a DC that acquires a greater stimulatory capacity. The 
term, “maturation” is often used to describe the process in which DCs respond to 
stimulation, typically by up-regulating MHC-II and costimulatory molecules. As this 
stimulation does not always result in cells with the full functional capability, the term 
“activation” is reserved for the process in which activatory stimuli convert resting DCs 
into effector DCs fully capable of priming T cells to both proliferate and differentiate into 
cytokine-producing effector T cells. Generally, maturation can be induced pro-
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inflammatory cytokine exposure, whereas activation usually involves the ligation of 
receptors on DCs. These receptors recognise “danger” stimuli such as DAMPs (62) or 
PAMPs (63). DAMPs and PAMPs are released from damaged tissue or infectious 
pathogens respectively and can ligate the nucleotide-binding oligomerization domain 
(NOD) receptors and Toll like receptor (TLR) families, leading to a signalling cascade, 
which results in activation of nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB) (64). Finally, “licensing” has been used to describe the process of DC 
activation whereby CD4+ T cells provide help for the generation of primary CD8+ T cell 
responses (65-67). This help occurs via the interaction of CD40L expressing CD4+ T cells 
with CD40 expressing DCs. Here the term will be used for any T cell (not just CD4+ T 
cells) that can provide positive feedback signals that improve the capacity of DCs to 
prime cytokine-producing effector T cells. 
 
Importantly, DC activation is necessary for the induction of a T cell immune response. In 
the absence of danger stimuli or effective licensing, presentation of peptides results in 
immunological tolerance, with antigen specific T cells being rendered anergic, or depleted. 
Instead, inappropriately activated DCs can induce Treg function, where T cells have 
suppressive activity. When activated, migratory DCs migrate to the lymph nodes where 
they interact with T cells (68). Alternatively, lymphoid-resident DCs such as langerin cells 
within the spleen will interact with T cells. While DCs are professional antigen presenting 
cells with a high capacity to drive T cell responses, it should be noted that other immune 
cells such as B cells, macrophages and microglia can act as APCs under inflammatory 
conditions.  
1.12 T Cell Development 
The term “T cell” reflects the fact that these cells undergo a critical developmental stage 
in the thymus. They originate from haematopoietic stem cells in the bone marrow, and 
then seed the thymus to mature into T cells with a rearranged TCR. Only T cells that can 
recognise MHC molecules, but don’t recognise self-antigens with high affinity, survive 
this process to leave the thymus and enter the lymphoid system. The common lymphoid 
precursors that enter the thymus are termed thymocytes and do not yet express a 
functional T cell receptor. Upon entering the thymus, cells express neither CD4 nor CD8 
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and are classed as double negative thymocytes. During this stage, the developing 
thymocyte expresses an invariant α-chain while the β chain of the TCR undergoes 
rearrangement. If the β-chain pairs successfully with the pre-TCR α-chain, rearrangement 
ceases. Due to the high level of rearrangement that occurs during this stage, a large 
number of β-chains are non-functional. If a non-functional β-chain is produced, it cannot 
pair with the invariant pre-TCR α-chain and the cell dies via apoptosis. 
 
After β-selection, thymocytes progress through a double positive (CD4+ CD8+) state 
before undergoing thymic selection. While these thymocytes possess a TCR, many will be 
non-functional as effector cells due to an inability to bind MHC molecules. To ensure 
MHC binding, thymocytes undergo positive selection, where cells that interact with 
MHC-I and MHC-II molecules are retained, while those that are incapable of binding 
MHC die. The ability to bind MHC molecules is afforded by the TCR co-receptors CD4 
and CD8, which bind to MHC-II and MHC-I respectively. In this process, MHC 
molecules loaded with self-antigens are presented by thymic cortical epithelial cells to 
double positive cells. Only those cells that interact with MHC appropriately, that is not 
too strongly or too weakly, receive a survival signal. Cells that bind either too strongly or 
too weakly will die by neglect. During positive selection, thymocyte fate is determined 
depending on which class of MHC it interacts with. Double positive cells which interact 
with MHC-I will downregulate expression of CD4+ and become CD8+ thymocytes, 
whereas interaction with MHC-II results in down-regulation of CD8+, leaving single 
positive CD4+ thymocytes. 
 
The developing thymocyte then progresses to negative selection, the removal of auto-
reactive thymocytes. Due to the random nature of gene rearrangement, there is the 
chance that thymocyte clones will develop that recognise self-antigens, resulting in 
autoimmunity. Negative selection selects thymocytes that are capable of strongly binding 
with MHC molecules presenting self-peptides for removal. If strong MHC binding occurs, 
cells receive an apoptotic signal, resulting in cell death. After negative selection, mature 
thymocytes exit the thymus as T cells and enter the circulation, entering peripheral lymph 
nodes in a naïve state. Selection prevents the formation of T cells that will recognise and 
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react to self-antigens, thereby preventing autoimmunity in the host. Negative selection 
however is not completely effective, with some auto-reactive T cells released into the 
periphery. To counter this, additional mechanisms exist to provide peripheral tolerance of 
self-antigens, including inducing an anergic phenotype in responding T cells, or deletion 
of these T cells from the repertoire after activation in the periphery. Also, some self-
reactive T cells can be diverted into a suppressive function, and thus function as Tregs. 
1.13 T Cell Activation and Proliferation 
Following antigen encounter, DCs migrate to the lymph node draining the site of antigen 
uptake or, if DCs are resident within a lymphoid organ such as the spleen, they remain 
within the organ and present peptides to naïve T cells. DCs passage through the spleen or 
lymph node, contacting T cells and displaying processed peptides on MHC-I and MHC-II. 
Due to the “open” structure of MHC-II, longer peptides are presented to CD4+ T cells, 
typically between 12 to 24 amino acids in length. Due to the “closed” confirmation of 
MHC-I, CD8 T cells will typically recognise “short” peptide antigens of 8 to 10 amino 
acids in length. 
 
Following antigen specific MHC-TCR interaction, T cells require a second signal for full, 
functional activation. In the absence of signal two, a T cell may become anergic and fail to 
proliferate and differentiate. The second signal is non-antigen specific and is known as 
costimulation. Costimulatory molecules CD80 and CD86 are expressed upon activation 
of an APC and upregulation of these costimulatory molecules typically occurs via the 
processes of DC maturation and activation. The costimulatory receptor expressed on T 
cells is CD28 and upon binding to CD80 and CD86, allows T cells to respond to antigen. 
Importantly, CD28 costimulation is essential for the production of interleukin-2 (IL-2) as 
it leads to the activation of the phosphoinositide 3-kinase (PI3K) pathway, increasing the 
production of activator protein 1 (AP-1) and NF-κB. The activation of transcription 
factors NF-κB, AP-1 and nuclear factor of activated T cells (NFAT) enables nuclear 
translocation and binding to the promoter region of the IL2 gene. The cytokine IL-2 is 
responsible for growth and proliferation of T cells and these transcription factors are 
essential for IL-2 production (69). The IL-2 receptor α subunit, CD25, has low affinity 
for IL-2. However, when complexed with the β and γ subunits, (CD122 and CD132 
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respectively), affinity for IL-2 is increased 100 fold, therefore heterodimerisation of the β 
and γ subunits of IL-2R is essential for T cell signalling. (69, 70). Additionally, PI3K 
activation aids in activation of the protein kinase Akt that promotes cell survival and 
growth, increasing the total production of IL-2 by activated T cells. 
1.14 CD4+ T Cells 
In addition to proliferation following costimulation, CD4+ T cells differentiate from a 
naïve proliferating cell into a specialised functional cell. The third signal required for 
differentiation (after signal one, antigen, and two, costimulation, that are both required 
for activation and proliferation) is the provision of cytokines that influence T cell 
differentiation programmes. Cytokines, in addition to transcription factors within the cell 
aid in determining the lineage commitment of a T cell. Each subset has a unique set of 
functions and these effector subsets can be characterised based on different cytokine 
expression profiles and are termed Th1, Th2, Th17, Tfh and Treg. The most well defined 
cytokines in these scenarios are interleukin-12 (IL-12) and IFN-γ, which drive Th1 
polarisation, and interleukin-4 (IL-4), which is responsible for Th2 polarisation (71).  
 
Th1 differentiation occurs in the presence of IL-12 and IFN-γ and serves to activate both 
innate cells such as macrophages, as well as provide help to adaptive CD8+ T cell 
responses (72). Additionally, Th1 cells have cytotoxic ability and may have direct 
tumouricidal ability via Fas-Fas Ligand (FasL) interactions (73). Expression of the master 
regulator transcription factor T-box transcription factor TBX21 (T-bet), encoded for by 
the gene Tbx21, drives Th1 polarisation (74). T-bet expression induces IFN-γ production 
through remodelling of the Ifng gene and by upregulation of IL-12Rβ2, thus promoting 
IFN-γ production and selective Th1 cell differentiation in response to IL-12. 
 
Th2 responses are induced following presentation of antigens in the presence of IL-4 (75). 
These responses are essential for the clearance of helminth parasites and play a major role 
in allergic responses. GATA3 is the master regulator for Th2 differentiation. Additionally, 
GATA3 is critical for the development of CD4+ T cells and can be detected at low levels 
in naïve CD4+ T cells. Th2 differentiation is abolished both in vitro and in vivo in the 
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absence of GATA3, as demonstrated in mice harbouring Gata3 deletion in peripheral T 
cells (76). Additionally, Th1 and Th2 cells counter-regulate each other, with IL-4 
inhibiting IFN-γ and vice versa (77), resulting in a high Th2/Th1 cell ratio within the 
tumour microenvironment being suggested to be pro-tumourigenic (78-80).  
 
Th17 cells have been recently described as responsible for clearance of fungal pathogens. 
Differentiated in the presence of transforming growth factor-β (TGF-β) and interleukin-6 
(IL-6), interleukin-21 (IL-21) and interleukin-23 (IL-23), Th17 cells have also been 
implicated in playing a role in autoimmunity (81). Tfh cells are primarily localised to the B 
cell follicles in secondary lymphoid organs and play a role in antibody isotype switching 
and antibody production (82). The differentiation pathway for these cells is currently 
unknown, but it is distinct from aforementioned CD4+ T cell subsets. Tfh can be defined 
based on the expression of CXCR5 and inducible T cell costimulator (ICOS) (83). 
 
To maintain immune homeostasis, Tregs act to oppose T cell activation. Tregs are either 
thymus derived, and are referred to as natural Tregs, or differentiated in the periphery 
from naïve CD4+ T cells in the presence of cytokines including TGF-β  (85). Peripherally 
differentiated Tregs are referred to as induced Tregs. Distinguishing between the two 
populations is difficult as there is little consensus surrounding the best markers to use. 
While forkhead box P3 (FoxP3) is the key transcription factor for Tregs, there is some 
suggestion that Helios could be used to define induced Tregs (86). It now clear that 
Helios+ and Helios- cells exist within the natural and induced FoxP3+ populations (87). 
 
As well as this capacity to differentiate into distinct effectors subsets, CD4+ cells provide 
“help” to dendritic cells in the form of CD40 ligand, a process defined earlier as DC 
licencing. When APC expressed CD40 is ligated, the APC will upregulate the expression 
of CD80 and CD86 molecules as well as CD137L, allowing more potent costimulation 
(65-67). CD4+ T cells also have the ability to directly promote CD8+ activation via IL-2. 
 
It is generally believed that effective immunotherapies for cancer will elicit CD8+ T cell 
responses, supported by Th1 CD4+ T cells. Production of IFN-γ by Th1 cells promotes 
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antigen presentation by upregulation of MHC class I and II on both immune and non-
immune cells (88). Additionally, IFN-γ production and CD40-CD40L interactions 
enhance the ability of macrophages to kill tumours and intracellular infections (89-91). 
However, cytotoxic CD4+ T cells have been described in a mouse model of melanoma. 
Here, CD4+ T cells induced upregulation of MHC-II on melanoma cells by secreting 
IFN-γ before directly killing tumour cells via granzyme B (73). In a mouse model of 
glioma, CD4+ T cells were required for prophylactic vaccine efficacy, as protection was 
lost following antibody-mediated depletion, or when experiments were performed MHC-
II-/- mice (29). 
1.15 CD8+ T Cells 
CD8+ T cells can differentiate into cytotoxic T cells, which are specialised in their capacity 
to kill tumour cells as well as virally infected cells and cells infected with intracellular 
bacteria. Once activated, CD8+ T cells can kill target cells expressing as few as one 
peptide-MHC complex (92-95). 
 
Similarly to CD4+ T cells, IL-12 and IL-4 exposure during CD8+ T cell priming generates 
effector CD8+ T cells referred to as Tc1 and Tc2, based on the production of IFN-γ or 
IL-4 respectively. It is also notable that T-bet, which is required for Th1 differentiation, 
has only a minor effect on the generation of Tc1 cells (96). Regardless of the cytotoxic 
differentiation profile, both Tc1 and Tc2 cells are capable of eliciting tumour immunity by 
contrasting mechanims. Briefly, adoptive transfer of Tc1 and Tc2 cells into tumour 
bearing hosts resulted in endogenous T cell recruitment and type 1 immune responses, 
host memory CD8 T cell induction, with production of IFN-γ and tumour necrosis 
factor-α (TNF-α) and accumulation of both Tc1 and Th1 cells at sites of tumours growth 
(97). 
 
Interest has been focused on CD8+ T cells for their tumouricidal activity since cells 
isolated from melanoma patients were shown to be capable of killing autologous tumour 
cells ex vivo following a restimulation period with peptide pulsed dendritic cells (98). In the 
presented context, and for use throughout this thesis, the term “pulsed” refers to cells co-
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incubated with either peptide or α-GalCer, with excess peptide or glycolipid washed away 
before downstream use. Indeed, persistence of the cells in vivo was observed following 
transfer, with T cell trafficking to the tumours. Additionally, responses could be measured 
in the blood and quantified with MHC tetramers (98). Analysis of tumour biopsies after T 
cell administration revealed a high concentration of adoptively transferred antigen specific 
T cells within sites of metastatic burden. However no clinical responses were observed 
which is perhaps not surprising as it is now recognised that tumours will typically appear 
larger on CT or MRI scans following immunotherapy which is a result of the influx of 
immune cells (98). Despite this, no complete responses were observed either (98).  
1.16 T Cell Migration 
Whereas B cells can differentiate into antibody-secreting plasma cells and mediate antigen 
clearance from a distance, T cells require cell contact to mediate cytotoxic function. 
Therefore, differentiated T cells must leave the secondary lymphoid organs following 
activation, proliferation and differentiation and traffic to peripheral sites to perform 
effector functions. When a DC migrates to the lymph node to present antigen to T cells, 
it will also imprint a signature on the T cell to allow the T cell to home to the antigenic 
target. In some instances, the expression of homing molecules is a reflection of the site of 
priming. T cells that undergo activation within the gut associated lymphoid tissues 
upregulate α4β7 integrin and CCR9 which are both important for homing to the small 
intestinal mucosa (99, 100). Similarly, T cells activated within the skin-draining inguinal 
lymph nodes upregulate E-selectin and P-selectin ligands as well as CCR4 which are 
associated with homing to the skin (101, 102). Conversely, T cells can be “educated” 
following transit through the lymphoid tissues. Adoptive transfer of in vitro activated T 
cells, specific for myelin basic protein (MBP) only acquire the ability to enter the central 
nervous system (CNS) and induce experimental autoimmune encephalomyelitis (EAE) 
after a period of transit through the lungs and mediastinal lymph node (103). Here, T cells 
up-regulated ninjurin 1, a molecule which participates in T cell intravascular crawling 
along cerebral blood vessels (103). Exit of effector T cells from the lymphoid tissue to 
sites of effector function is regulated by their responsiveness to the chemotactic lipid 
sphingosine 1-phosphate (S1P). Additionally, effector T cells will downregulate the 
expression of the lymph node homing marker L-selectin (CD62L), further permitting 
 23 
egress from the tissue. The loss of CD62L is compensated by the increased synthesis and 
expression of the integrin α4β1 (VLA-4). VLA-4 binds to the adhesion molecule VCAM-
1, which is expressed on endothelial cells.  
1.17 Impact of Blood Brain Barrier on T cell migration 
In the context of immunotherapy of glioma, it is necessary for T cells to migrate to the 
brain to eradicate tumour tissue. Medawar’s seminal discovery in 1948, that skin (allo- or 
xeno-) grafts implanted into the brain were rejected more slowly than orthotopic control 
transplants, implied that the CNS is an immune-privileged site (104). However, 
autoimmune diseases of the CNS featuring T cells, such as multiple sclerosis (MS) 
indicate that cells of the immune system have the capacity to cross the blood barrier and 
mount an effector response (105). The limited rejection of transplanted tissue was 
mediated by the presence of the blood brain barrier (BBB), a highly selective permeable 
barrier that separates the central nervous system from circulating lymphocytes. The BBB 
is formed by endothelial cells with a unique complex of tight junctions. Surrounding the 
endothelial cells are pericytes which play a critical role in vesicle trafficking (106). Under 
homeostatic conditions, astrocytes maintain the integrity of the barrier. However, in 
inflammatory conditions such as EAE, the murine model of human MS, T cells are 
capable of crossing the blood brain barrier. This is facilitated by the expression of 
adhesion molecules and integrins that are capable of “unlocking” the BBB. In 
malignancies of the central nervous system, such as glioma, dedifferentiation of astrocytes 
is hypothesized to result in loss of integrity of the BBB, permitting the entrance of T cells 
from the circulation directly to the brain tissue. Alternatively, primary cultures derived 
from GBM can actively degrade tight junctions in vitro, possibly reflecting BBB disruption 
in invaded brain tissue (107). While detrimental in the case of EAE, breach of the BBB is 
imperative for T cells to clear tumour tissue. CD4+ T cells play a critical role in 
pathologies of the CNS owing to their preferential expression of integrins, allowing 
transport across the blood brain barrier (108). Current evidence suggests T cells may gain 
the capacity to enter the CNS after a transition through the lung. From the lung, T cells 
migrate to the mediastinal lymph node before entering the blood and finally the CNS 
(103). 
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1.18 T cell cytotoxicity 
Upon acquisition of effector function, T cells kill target cells expressing cognate antigen 
on MHC complexes in a contact dependent manner. When a specific TCR recognises the 
MHC-peptide complex, the T cell can induce cell death by apoptosis. Apoptosis is a form 
of regulated cellular suicide, which causes a cell to undergo nuclear blebbing, altered 
cellular morphology and eventual DNA fragmentation. Following DNA fragmentation, 
the target cell will shed its membrane as vesicles and continue to degrade itself from 
within. One of the hallmarks of apoptosis is the nuclease dependent fragmentation of 
DNA. Induction of apoptosis in a target cell by a cytotoxic T cell can involve release of 
cytotoxic granules, or via the interaction of FasL, expressed on activated T cells, with Fas 
on the target cell. In each case, an intracellular caspase cascade is induced that ultimately 
leads to the activation of nucleases responsible for DNA fragmentation (109). 
 
In addition to Fas mediated cell death, cytotoxic T cells carry intracellular stores of 
proteins that can trigger apoptosis. These proteins remain in an active form within 
cytolytic granules and are released upon recognition of antigen on target cells. The first of 
these proteins is perforin, which perforates the cell membrane of the target cell (110). 
Also packaged with perforin are the granzymes, a family of serine proteases (111). 
Following the formation of a cytotoxic synapse between an effector and target cell and 
the release of perforin, granzymes are released into the cytosol of the target cell. From 
here, granzyme B will cleave caspase-3, resulting in the activation of the apoptosis 
pathway (112). Granzyme B can also cleave the protein Bid, resulting in a change in 
mitochondrial membrane permeability, leading to the release of cytochrome C (113). The 
formation of a cytolytic synapse ensures both perforin and granzymes are delivered to a 
specific target cell, and acts to limit collateral damage to bystander cells. 
 
Finally, cytokines released by effector T cells can also induce cell death. TNF-α is a 
cytokine produced by many cell types including T cells and NK cells as well as 
macrophages and neurons (114-116). Secreted TNF-α binds to the TNF receptors 
TNFR1 and TNFR2, resulting in an intracellular signalling cascade, ultimately terminating 
in the recruitment of caspase-8. High concentrations of caspase-8 induce autoproteolytic 
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activation, leading to caspase mediated apoptosis (117). In addition to apoptosis induction, 
TNF-α release creates a pro-inflammatory environment, activating innate immune cells 
and also induces vascular permeability, easing immune cell extravasation (118, 119). The 
TNF-related apoptosis-inducing ligand (TRAIL) is a member of the tumour necrosis 
factor superfamily and is produced by most cells. Binding of TRAIL to the death 
receptors DR4 and DR5 results in caspase-8 mediated apoptosis, similarly to TNF-α 
(120). IFN-γ inhibits tumour angiogenesis and has immunomodulatory functions, 
including inducing the upregulation of MHC-I and MHC-II expression on tumour 
cells, thereby enhancing tumour cell susceptibility to T cell mediated cytotoxity (73, 121).  
 
While CD8+ T cells have been studied for their cytotoxic abilities, it is thought CD4+ T 
cells can also perform these functions. Another mechanism by which T cells can serve as 
useful effector T cells in anti-tumour response is to activate innate immune cells. This 
involves the activation and differentiation of Th1 cells which can interact with 
macrophages through MHC-II and CD40-CD40L interactions (89, 90). Macrophages are 
recognised as playing a role in tumour regression or progression based on their 
phenotypic and functional characteristics. A functional spectrum of macrophages exists, 
with the populations at either pole described as “M1” and “M2”. Classically activated 
macrophages, or M1 skewed macrophages arise following interactions with Th1 CD4+ T 
cells, and exposure to TNF-α and IFN-γ in a pro-inflammatory environment (122-124). 
Alternatively activated macrophages, or M2 skewed macrophages have been shown to 
play a role in helminth infection clearance and differentiate under the influence of IL-4 
and IL-13 produced by Th2 cells (125, 126). In addition to distinct differentiation 
pathways, M1 and M2 skewed macrophages are functionally distinct. M1 macrophages 
produce high levels of pro-inflammatory cytokines including TNF-α, IL-1, IL-6 and IL-
12 and increase intracellular concentrations of nitrogen and oxygen radicals. Furthermore, 
M1 macrophages increase expression of MHC-I and class II to further activate T cells 
(127). Conversely, M2 macrophages express the mannose receptor and IL-10, which 
result in M2 macrophages playing a role in parasite clearance, tissue remodelling, immune 
modulation and tumour progression (127, 128). Tumour associated macrophages (TAMs) 
have been shown to be the predominant leukocyte population within solid tumours and 
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have both tumour promoting and anti-tumour roles (129, 130). In creating an 
inflammatory environment, macrophages promote angiogenesis, facilitating both tumour 
growth and metastatic potential (131, 132). 
1.19 T Cell Inhibition via immune checkpoints 
One of the characteristic features of a T cell response is that once T cells have undergone 
an intense period of proliferation after activation, there is then a significant reduction in T 
cell numbers as cells die by apoptosis, ultimately resulting in a small population of long 
lived memory cells. There are many mechanisms that are responsible for the reduction in 
cells numbers including extrinsic cell-receptor and caspase-dependent apoptosis, intrinsic 
mitochondria- and caspase-dependent apoptosis, or by caspase-independent cell death. 
Autonomous cell death occurs in the absence of survival signals such as cytokine 
deprivation or activated cell autonomous death (133). In addition, TCR engagement of 
effector T cells in the absence of appropriate costimulation leads to activation-induced 
cell death, a process where activated T cells undergo death following engagement of cell 
death receptors such as Fas (134, 135). The removal of activated T cells following clonal 
expansion and subsequent pathogen or tumour clearance is important to maintain 
homeostasis. Furthermore, it has recently been shown that activated T cells upregulate 
several proteins after activation that are involved in amendment of the costimulatory 
signal or negative regulation of T cell function. These inhibitory pathways are often 
referred as “immune checkpoints”, and they limit T cell activity. Under normal 
physiological conditions, immune checkpoints are vital for the maintenance of self-
tolerance (136). Additionally, they are required to protect tissues from damage during 
immune responses (137). Immune checkpoints provide a negative feedback loop to T cell 
activation, and are typically up-regulated 24-72 hours following TCR stimulation. In this 
capacity, checkpoint molecules can attenuate the activatory signal received by a T cell, 
resulting in a higher threshold for T cell activation. This limits unwanted T cell activity to 
self-antigens and maintains self-tolerance. The possibility of improving vaccine induced T 
cell response by blocking inhibitory checkpoints is a major focus of the research within 
this thesis. The key checkpoints investigated will be discussed below, with a brief review 
of the mechanism by which they function. Further mechanistic detail will be provided 
within the context of the research presented in later chapters of the thesis. 
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1.19.1 Cytotoxic T Lymphocyte Antigen 4 and Ipilimumab 
After the 1987 cloning of cytotoxic T lymphocyte antigen-4 (CTLA-4) in mice, sequence 
similarities with CD28 were noticed, as well as the conservation of molecule expression in 
humans. While CD28 was identified as a T cell costimulatory molecule, early studies 
suggested CTLA-4 was also a costimulatory molecule (138) however subsequent studies 
identified CTLA-4 as a negative regulator of T cell activation (139, 140). CTLA-4 binds 
costimulatory molecules CD80/86 with up to 20 times more affinity than CD28 (85). 
This competition for CD80/86 binding results in an inhibitory signal to the T cell 
mediated by inhibition of TCR signalling as well as inhibition of Akt signalling resulting in 
inhibition of IL-2 production, ultimately causing cessation of T cell proliferation (141, 
142). During immune quiescence, CTLA-4 is localised intracellularly within T cells where 
it is associated with clathrin-associated complexes (143, 144). Relocation of CTLA-4 to 
the cell surface occurs rapidly following T cell activation, followed by internalisation (145). 
Expression of CTLA-4 mRNA has been shown to peak between 24 to 48 hours after 
activation (138, 146) and functional effects in mice have been shown as early as 12 hours 
post activation (147). Consistent with the role for CTLA-4 in regulating immune priming, 
expression on T cells is typically restricted to the secondary lymphoid organs. Additionally, 
CD80/86 ligation by CTLA-4 results in signal transduction within the APC, resulting in 
upregulation of indoleamine 2,3-dioxygenase (IDO) (148). IDO is a catabolic enzyme 
which catalyses the breakdown of tryptophan to N-formylkynurine. T cell activation is 
then limited due to sequestration of the essential amino acid tryptophan, and also due to 
the immunosuppressive nature of N-formylkynurine. Krummel and Allison conceived the 
idea of CTLA-4 blockade as a means to enhance T cell activation, with initial studies 
showing CTLA-4 signalling inhibited T cell responses (139). From here, injection of 
antibodies aimed at blocking CTLA-4 signalling were performed which demonstrated that 
CTLA-4 blockade enhanced T cell responses in mice responding to vaccines (149). 
Application of these findings to tumour models were the first real validation that 
enhancement of the immune system could induce anti-tumour responses (150). The 
mechanism of action of these antibodies is currently under investigation and is likely to be 
multifactorial, with effector intrinsic (73, 151) and extrinsic (151, 152) mechanisms 
described in pre-clinical models. 
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Positive responses observed in preclinical testing promoted licensing of the patent for 
MDX-101 to Bristol Squibb Meyers where studies were advanced to clinical trials. The 
landmark study published in 2010 by Hodi and colleagues, which resulted in Food and 
Drug Administration (FDA) approval, aimed to compare ipilimumab combined with a 
vaccine to gp100, a melanocyte antigen, to each intervention as a lone agent. Here, 
efficacy was observed in the absence of gp100 vaccination, with 20% of patients having 
sustained anti-tumour responses as measured by overall survival (153). 
 
As mentioned earlier, ipilimumab blockade acts in the lymph nodes, blocking CTLA-4 
signalling to prevent attenuation of costimulation through CD28. Enhanced 
costimulation is thus received by T cells, promoting proliferation and effector function. 
Recent studies have examined the T cell repertoire in melanoma patients before and after 
ipilimumab therapy. Using tetramers to detect antigen specific CD8+ T cells, Kvistborg 
and colleagues observed a broadening of the T cell response, suggesting that in the 
clinical setting, CTLA-4 blockade may lower the threshold for T cell activation, 
potentially permitting immune responses against antigens with lower MHC-I affinity 
which would otherwise drive anergy (154). 
1.19.2 Programmed Death-1, Pembrolizumab and Nivolumab 
Programmed death-1 (PD-1) was cloned in 1992 as a trans-membrane protein and has 
two known ligands – programmed death 1 ligand 1 and ligand 2 (PD-L1 and PD-L2). 
PD-L1 is constitutively expressed on a wide range of cells whereas PD-L2 is 
predominantly induced on APCs during activation. The expression of PD-1 can be 
detected 24 hours after activation, and is further up-regulated and maintained until at least 
5 days following activation (155, 156). Treatment of α-CD3 stimulated T cells in vitro with 
PD-L1-Ig results in reduced T cell proliferation and IFN-γ production (137). Reduced T 
cell proliferation correlated with diminished IL-2 secretion, which could be rescued with 
the addition of exogenous IL-2 or α-CD28 antibodies (157). 
 
In contrast to CTLA-4, the major role of PD-1 is to regulate T cell responses at within 
the tissues. Inflammatory cytokines within the tissues induce the expression of PD-L1 
which downregulate the activity of T cells and therefore limit collateral damage in 
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response to either an infection or malignancy. The best-characterised signal for inducing 
PD-L1 expression is IFN-γ, which is produced by effector T cells. Several tumour cell 
lines have been shown to upregulate the expression of PD-L1 in vitro following treatment 
with IFN-γ (158, 159). When co-cultured with activated T cells, target tumour cells are 
poorly lysed. Conversely, in vitro cytotoxicity could be restored by administration of α-
PD-L1 antibodies, or by genetic ablation of PD-1 in T cells. Many studies have revealed 
the expression of PD-L1 on a wide variety of tumour types, thus in the context of 
immunotherapy, the prevailing view is that PD-L1 expression on tumour cells engages 
PD-1 expressing T cells, suggesting the PD-1/PD-L1 axis is co-opted by tumour cells to 
prevent immune mediated killing (160, 161). 
 
As CTLA-4 negatively regulates T cell responses and has shown success in an 
immunotherapeutic tumour setting, PD-1 has independently been investigated as a target 
for immunotherapy. Antibodies against both PD-1 and PD-L1 have been shown to have 
pre-clinical efficacy (162, 163), with two PD-1 antibodies currently FDA approved for 
clinical use (162). Pembrolizumab, formerly known as lambrolizumab, was the first FDA 
Approved α-PD-1 antibody. Interrogation of efficacy in patients with advanced 
melanoma included patients who had disease progression while receiving ipilimumab 
therapy. In this study, patient response rates were at 38% as evaluated by Response 
Evaluation Criteria in Solid Tumours (RECIST) criteria, with the best responses observed 
in the cohort receiving the highest dose of 10 mg/kg body weight every 2 weeks (162). 
Nivolumab is another FDA approved α-PD-1 antibody, which was compared to 
ipilimumab treatment, or as a combination treatment in metastatic melanoma patients. 
Both nivolumab as a monotherapy, and nivolumab combined with ipilimumab showed 
statistically improved progression free survival when compared to ipilimumab 
monotherapy (164). As these clinical trials were performed in late stage melanoma 
patients, overall responses were modest yet durable. As ipilimumab monotherapy results 
in durable response rates in 20% of patients, with some patients surviving greater than 10 
years, there is interest in combining ipilimumab with other agents to increase efficacy. 
Recently, combination therapy with ipilimumab and nivolumab has been explored as a 
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means to increase both progression free survival and overall survival in lung cancer 
patients (165). 
1.19.3 Late Activation Gene-3 preclinical and clinical studies 
Late activation gene-3 (LAG-3) is currently being investigated for clinical application as a 
checkpoint molecule. The inhibitory role of LAG-3 was first shown in vitro with improved 
T cell proliferation observed in the presence of a blocking antibody (166). Further studies 
demonstrated that simultaneous signalling through the TCR and LAG-3 on activated T 
cells resulted in a lower calcium flux than signalling through the TCR only (167). Ligation 
of LAG-3 acts to negatively regulate cellular proliferation, activation and homeostasis of 
T cells, in a similar fashion to CTLA-4 and PD-1 (168, 169). Similarly, tumour lines 
transfected with LAG-3 have been used as cancer vaccines (170). Finally, overexpression 
of LAG-3 lead to impaired T cell proliferation in an antigen specific context (171). 
Whereas CTLA-4 and PD-1 are expressed on T cells, LAG-3 is expressed on T cells (172), 
NK cells (173), B cells (174) and plasmacytoid DCs (175). The ligand for LAG-3 is MHC-
II to which it binds with a higher affinity than CD4 (176). Interestingly, whereas CTLA-4 
and PD-1 are both membrane bound, a soluble form of LAG-3 exists (177). In mice, 
cross-linking of MHC-II on APCs inhibits DC activation (178) thus, engagement of 
MHC-II by LAG-3 expressing T cells in the presence of cognate antigen, inhibits CD86 
upregulation and IL-12 secretion (178). In these studies, LAG-3 lacking the cytoplasmic 
tail was sufficient to confer regulatory activity to T cells, consistent with the notion that 
signalling through MHC-II on APCs, rather than direct signalling through the T cell, is 
responsible for inhibition of DC activation, limiting T cell activation (178). In addition to 
its role in T cell homeostasis, LAG-3 has reported to play a role in Treg suppressive 
function (175). 
 
As a cancer therapy, two approaches are being explored. The first is the soluble form of 
LAG-3, aimed at increasing the activation of T cells via direct effects on DCs. Due to 
interactions between MHC-II and LAG-3 resulting in the down-regulation of CD4+ T cell 
proliferation and cytokine secretion, as well as inhibition of human allo-responses, soluble 
LAG-3 was initially touted as an immunosuppressant (179). However, after Triebel et al 
successfully produced a soluble fusion protein in 1995, further studies demonstrated 
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soluble LAG-3 as a DC activator (180). As a clinical compound, soluble LAG-3 is being 
developed as IMP321 (181). Preclinical interrogation has revealed effectiveness of 
IMP321 both in vitro and in vivo in murine and human systems (182-186). The first phase I 
clinical trial was conducted in renal cell carcinoma patients as a dose escalation study with 
patients receiving up to 30 mg per injection per fortnight. As well as safety and efficacy, 8 
patients exhibited significant CD8+ T cell activation when administered IMP321 at 6 mg 
and 30 mg as measured by increased CD27 and CD28 expression (187). A dose escalation 
study has also been conducted in pancreatic cancer patients in combination with 
gemcitabine. The combination was found to be safe, however no differences were found 
when comparing pre and post-treatment levels of monocytes, DCs and T cells, with the 
lack of immune cell activation attributed to the relatively low dose of 2 mg administered 
to patients (188). Furthermore, a phase IIa clinical trial has been completed in metastatic 
breast cancer. In this study, patients received IMP321 one day following paclitaxel, with 
the investigators aiming to create a chemo-immunotherapeutic environment. Here, 
paclitaxel creates tumour debris, with IMP321 acting to further activate the DCs, which 
have taken up the debris. Interestingly, response rates were observed at the six-month 
follow up period according to RECIST criteria. In addition to decreased tumour burden, 
a sustained increase in numbers of NK cells, monocytes and CD8+ T cells were observed 
in patients, suggesting immune cell activation (189). In line with current 
immunomodulators, are antibodies aimed at preventing negative regulation of T cell 
responses. A phase I dose escalation and safety and efficacy study is underway to assess 
BMS-986016 administered alone, and in combination with nivolumab (190). 
 32 
 
 
Figure 1.2 Immune checkpoints in cancer immunotherapy. 
(A) The cytotoxic T-lymphocyte antigen-4 (CTLA-4)-mediated immune checkpoint is induced in T cells 
following initial exposure to antigen. The level of expression of CTLA-4 is dependent on the strength T cell 
receptor (TCR) signalling. High affinity ligands induce higher levels of CTLA-4 expression, which 
counteracts the initial TCR signalling. (B) Programmed cell death protein 1 (PD-1) acts to regulate T cell 
effector function in the peripheral tissues. Activated T cells upregulate PD-1 and maintain expression 
within peripheral tissue and tumour sites. Ligation of PD-1 acts to downregulate the activity of T cells and 
therefore limit collateral damage to healthy tissues. T cells frequently express PD-L1 as a means to limit 
effector T cell activity. (C) Differential outcomes of lymphocyte activation gene-3 (LAG-3) splice variants. 
Signalling through MHC-II on DCs following ligation by soluble LAG-3 results in dendritic cell activation. 
By contrast, signalling thorugh membrane bound LAG-3 on T cells following MHC-TCR interactions 
negatively regulates T cell activation. Figure adapted from Pardoll (191) 
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1.19.4 Future immune checkpoints 
Currently, only two molecules have been approved for targeted therapy, however the 
clinical success of ipilimumab, pembrolizumab and nivolumab has invigorated the search 
for new molecular targets. 
 
T-cell immunoglobulin domain and Mucin domain 3 (TIM-3) is expressed on activated T 
cells and has a role in regulating cytokine expression (192). Primary studies investigated 
the role of TIM-3 in the setting of autoimmunity. Here, antibody mediated blockade of 
TIM-3 worsened disease in EAE, providing the first indication that TIM-3 acts as an 
immune checkpoint (193). Further evidence in preclinical tumour models showed TIM-3 
expressing CD8+ T cells were the most dysfunctional population in both solid and 
haematologic malignancies (194, 195). Ligation of TIM-3 by galactin-9 on tumour cells 
induces aggregation and death of T cells in vitro and administration of galactin-9 in vivo 
results in selective loss of IFN-γ producing cells (196). B- and T-lymphocyte attenuator 
(BTLA) expression is induced following activation of T cells. Similarly to CTLA-4, BTLA 
interacts with a B7 homologue B7H4 (197). However, unlike CTLA-4, T cell inhibition 
occurs via interactions with tumour necrosis family receptors, notably tumour necrosis 
factor receptor superfamily member 14 (TNFRSF14) (198). Signalling through BTLA has 
been shown to inhibit the function of human CD8+ specific cancer specific T cells (199). 
V-domain Ig-containing suppressor of T-cell activation (VISTA) is another negative 
checkpoint regulator which is expressed predominantly on myeloid and granulocytic cells, 
with weaker expression on T cells (200). Interestingly, T cells both express and respond 
to VISTA and administration of VISTA-Fc fusion protein is suppressive to T cell 
activation (201). The first indication of VISTA as an immune checkpoint were observed 
in a preclinical murine model of methylcholine 105-induced fibrosarcoma (196, 200). 
Intriguingly, immunotherapy targeting VISTA has been observed to be effective without 
detectable VISTA expression on tumour cells, and that VISTA blockade works even in 
the presence of high PD-L1 expression (202). This suggests VISTA may have a broad 
clinical application and is advantageous over PD-1 or PD-L1 blockade which may only be 
effective when expressed within the tumour microenvironment. T-cell immunoglobulin 
and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) is 
expressed on NK and T cells (203). Both genetic ablation and antibody blockade have 
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been shown to enhance NK cell killing and CD4+ T cell priming both in vitro and in vivo 
(204-206). Additionally, the severity of CD4+ T cell mediated diseases such as EAE can 
be exacerbated following TIGIT blockade in vivo (206). 
 
As well as inhibitors of negative regulation, antibodies are being developed for 
stimulatory T cell molecules. Both CD27 and CD28 provide a stimulatory signal to T cells, 
there is interest in developing agonistic antibodies against these targets. In preclinical 
work, CDX-1127, an agonistic CD27 antibody has shown to be effective in T cell 
receptor stimulation (207). Similarly, CD28 has been targeted with a “superagonist” 
antibody TGN1412 (208). However, phase I trials resulted in hospitalisation of all six 
patients who received the drug, resulting from cytokine release syndrome (209). 
Glucocorticoid-induced TNFR family related gene (GITR) is expressed on Tregs and also 
plays a role in promoting T cell proliferation (210). Antibodies to GITR have been shown 
to promote anti-tumour immune reponses through the loss of Treg lineage stability (211). 
ICOS is a cell surface molecule expressed on activated T cells (212). Currently ICOS is 
being adapted as a pharmacodynamic biomarker for ipilimumab treatment (213). In 
addition, engagement of the ICOS pathway enhances the efficacy of CTLA-4 blockade in 
murine models of cancer (214). Tumour necrosis factor receptor superfamily member 9, 
also known as CD137 or 4-1BB is expressed on activated T cells as well as DCs, NK cells 
and granulocytes (215, 216). The best-characterised activity of CD137 is costimulatory 
signalling, resulting in enhanced T cell proliferation, IL-2 secretion and cytolytic activity 
(217, 218). Finally, OX40 is transiently expressed following TCR engagement and plays a 
role in the differentiation of effector and memory T cells (219, 220). Phase I clinical 
testing has revealed α-OX40 antibody blockade to have an acceptable toxicity profile and 
regression of at least one metastatic lesion in 12 out of 30 patients (221). 
1.20 T cell memory 
Following the resolution of a pathogen or tumour, 90-95% of the effector T cells will be 
eliminated as a means to return to homeostasis. Clearance of the effector T cell pool 
involves multiple pathways including Fas and FasL, TNF and TNFRI and TNFRII as 
well as CD40 and CD40L signalling. In addition, IL-2 withdrawal starves T cells of 
proliferative and survival signals (135, 222, 223). The 5-10% of cells that remain will 
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become long-lived memory T cells (224). These cells will activate genes responsible for 
cell survival such as Bcl-2. Memory T cells are more sensitive to antigen re-encounter than 
a naïve T cell experiencing antigen for the first time. As such, they respond more 
vigorously to produce key cytokines including IL-2, IFN-γ and TNF-α. Similar to naïve T 
cells, memory T cells rely on interleukin-7 (IL-7) and interleukin-15 (IL-15) for 
homeostatic maintenance (225). 
 
Various populations of memory T cells exist, with distinct effector function and location. 
Effector memory T cells (Tem) patrol the tissues, typically at barrier sites, but also the 
blood and spleen. Upon antigen recognition, Tem rapidly mature to effector T cells and 
produce large amounts of IFN-γ early after antigen re-encounter. These cells lack CCR7 
expression but express high levels of β integrins, suggesting they are specialised for rapid 
entry into inflamed tissue. Central memory T cells (Tcm) do express CCR7 and 
recirculate to lymphoid tissues. Upon antigen re-encounter, central memory T cells lose 
expression of CCR7 and differentiate into effector T cells (226, 227). Whereas Tem can 
rapidly respond to antigen re-encounter, Tcm cells require antigen processing and 
presentation (228). In this capacity, Tcm can supplement new immune responses within 
the lymph node. 
 
Stem memory T cells (Tscm) have a naïve-like CD44lo CD62Lhi phenotype and display 
stem cell-like properties but reside within the blood. It is thought these cells are the 
earliest and longest lasting developmental stage of memory T cells, exhibiting a gene 
profile which is considered to be a mixture of both naïve and Tcm cells (229, 230). In 
murine immunotherapy studies, Tscm have garnered interest due to their self-renewal 
capacities and superior anti-tumour responses, compared to other memory T cell subsets 
(231, 232). Tissue resident memory T cells (Trm) are another memory T cell subset which 
populate peripheral tissues without recirculating. In this capacity, they provide a rapid 
response against infections re-encountered at body surfaces such as the gastrointestinal 
and reproductive tracts. Indeed, Trm cells have been described within the brain following 
vesicular stomatitis virus (VSV) infection and their maintenance is dependent on the 
expression of the integrin αE (CD103). These T cells do not function or survive well 
 36 
after dissociation from the tissue in which they reside, suggesting tissues specific 
adaptations, or that cells become dependent on factors within the environment to 
maintain survival (233). 
 
The developmental pathway of memory T cells from effectors is uncertain, however, 
three models are currently assumed to describe how memory T cells are generated. The 
“linear” differentiation model suggests that T cells develop into effector T cells, which 
either die, or differentiate further following antigen clearance. Here, Tem are described as 
an intermediate phenotype between the effector and Tcm phenotypes i.e Naïveà 
Effector à Tem à Tcm (234). The “divergent” model suggests that the fate of naïve T 
cells is predetermined, that is some cells are destined to die as terminally differentiated 
effector T cells, while others are destined to become memory T cells following priming 
(235). Additionally, the “bifurcative” differentiation model suggests primed T cells 
undergo asymmetrical cell division, with each daughter cell having a different fate to that 
of the mother cell (235). 
 
It is likely that each of the models may be correct, as experiments which tracked the fate 
of naïve CD8+ T cells revealed cells that had acquired effector function were still capable 
of differentiating into memory T cells (236). While it is likely that all cells must be initially 
activated to undergo memory differentiation, there is accumulating evidence that two 
distinct phenotypes emerge during the primary immune response. Short lived effector 
cells (SLEC) and memory precursor effector cells (MPEC) can be distinguished by the 
expression of the IL-7 receptor (CD127) and low expression of killer cell lectin-like 
receptor G1 (KLRG-1) (237). 
 
While there is evidence of CD4+ T cell memory, our current understanding is lacking 
compared to that of CD8+ T cells. Both linear and divergent differentiation models have 
been proposed (238, 239). Upon restimulation, CD4+ memory T cells have been observed 
to proliferate, however, this proliferation is less than a naïve T cell responding to antigen 
for the first time (240). The reduced proliferation was attributed to increased production 
of IFN-γ and decreased production of IL-2, therefore CD4+ memory T cells have 
impaired proliferative capacity when compared to CD8+ memory T cells (241). Protection 
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can be generated following vaccination with Bacillus Calmette-Guérin (BCG), resulting in 
cytokine producing memory CD4+ T cells providing defense from subsequent disease 
caused by Mycobacterium tuberculosis (242, 243). Taken together, it suggests memory CD4+ T 
cells may not be involved in the direct killing of pathogens, but act as catalysts to provide 
help to other cells.  
 
The generation of T cell memory has considerable implications for tumour-
immunotherapy where the goal of therapy is not only to generate effective effector 
responses, but also generate robust memory capable of preventing relapse (244). 
1.21 The Cancer Immunoediting Hypothesis 
The idea that the immune system can limit the growth of tumours originated in the 1900s 
and has been a topic of debate ever since. However, at the time so little was known about 
the immune system that it was difficult, if not impossible to challenge this hypothesis and 
validate this prediction. As our understanding of the immune system developed, and 
tumour associated antigens were identified, this idea again came to the fore. These 
advances lead to the formation of the cancer immune-surveillance hypothesis by Burnet 
and Thomas, which stipulated that the immune system was responsible for preventing 
tumour growth in immune-competent hosts (245). Subsequent studies however showed 
little support for this hypothesis. Experiments performed by Stutman showed that cancer 
susceptibility in immune-competent mice was comparable to the incidence seen in 
immune-compromised hosts (246). It was argued that tumour cells lacked the necessary 
DAMPs required for optimal APC activation, and therefore were silent to the immune 
system (247). Additionally, it was thought the immune system would not be able to 
discriminate between tumour cells and normal cells, as they would be too similar and 
hence drive a tolerogenic phenotype (248). 
 
Later studies showed that the nude mice used in these experiments were not totally 
immune-compromised but still had low but detectable levels of T, NK and NKT cells 
(249, 250). As mouse models developed and improved, and pure genetic background 
strains were developed, the role of the immune system in the prevention of tumour 
outgrowth could be reassessed. Following the development of the recombination-
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activating gene KO (RAG2-/-) mouse (lacking functional T, NKT and B cells) (251), and 
the IFN-γ-/- mouse (252, 253), it was discovered that these mice were more susceptible to 
tumour formation (to both carcinogen induced and transplanted tumours) when 
compared to wild type (WT) controls (254). 
 
As tumours from these mice were analysed, it became apparent that tumours that 
developed in immune-compromised hosts were more immunogenic when compared to 
tumours that had arisen in immune-competent hosts. A tumour mass does not exist as a 
homologous population of tumour cells, but rather a heterogeneous population of 
tumour cells of varying degrees of differentiation as well as local stromal and immune 
cells. Due to this complex relationship of distinct populations, there is a level of interplay 
that exists. This lead to the notion that the immune system not only plays a role in 
preventing tumour development, but also influences shaping tumours which do develop. 
From here, the cancer immune-editing hypothesis was formed. This hypothesis proposes 
that three phases of cancer development exist, elimination, equilibrium and escape (253, 
255).  
1.21.1 Elimination 
Elimination postulates that both the innate and adaptive immune system are constantly 
surveying the body to detect the presence of developing tumours. The mechanisms that 
lead to immune cell activation in vivo in this setting are currently unknown, but could be 
attributed to Type 1 interferons released during the early transformation process (247), or 
to DAMPs released by either dying tumour cells such as high mobility group box 1 
(HMGB1), or from damaged cells as tumours begin to invade nearby tissue (256). In 
addition, stress ligands expressed by tumour cells such as H60 and RAE-1 (mouse) or 
MICA/B (human) are expressed on the surface of tumour cells. These ligands bind to 
activating receptors on NK cells, leading to the release of pro-inflammatory cytokines, 
resulting in an environment that is permissive to an anti-tumour response (257). While 
innate immunity can be protect against the development of some tumours, experimental 
evidence suggests the both CD4+ and CD8+ T cells are required for the recognition of 
tumour antigens and thus effective tumour clearance. In this setting, the coordination of 
both arms of the immune system are required for effective tumour clearance, and the 
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effective clearance of a developing tumour before it has the chance to establish embodies 
the end of the elimination phase (Fig 1.3 A). 
1.21.2 Equilibrium 
Equilibrium can be observed in tumour variants that survive the elimination phase, but 
lack the capacity to “take off” and grow while being held in check by the immune system. 
During this phase, the immunogenicity of the tumour is sculpted in a constant back and 
forth between the possibilities of elimination and escape (258). This phase may be one of 
the longest of the cancer immune-editing process and can perhaps exist for the lifetime of 
the host. During this phase, the tumour can persist in a dormant state before regaining 
the capacity to grow or metastasise to a distant site. This was made evident by 
experiments performed in immune-competent mice that were treated with low dose 
methylcholanthrene (MCA). These mice harboured minor tumours that were non-
apparent. Following administration of antibodies against T cells and IFN-γ, tumours 
developed swiftly at the original injection site (259). Deeper analysis revealed the 
requirement for IL-12, IFN-γ, CD4+ and CD8+ T cells in maintaining equilibrium. The 
necessity for adaptive immunity in this setting distinguishes elimination and equilibrium 
and suggests that, once a tumour has developed past the elimination phase, adaptive 
immunity is paramount in ensuring growth inhibition (Fig 1.3 B). 
1.21.3 Escape 
Escape is the final phase of cancer immune-editing, where a tumour has been sculpted by 
the equilibrium phase to favour expression of tumour antigens that are not recognised by 
the immune system. Additionally, immunosuppressive mechanisms can be co-opted and 
secreted by the tumour to limit immune cell activation. Now unrecognisable to the 
immune system, the developing tumour is free to proliferate unhindered (255, 260, 261). 
When a tumour accumulates enough mutations it will proliferate faster than it can be 
killed by the immune system. This abnormal turnover rate will result in the accumulation 
of further mutations, increasing the chance that the mutations will arise in key regulatory 
pathways. 
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Starting with the tumour, increased resistance to immune mediated cytotoxicity can occur 
via upregulation of anti-apoptotic pathways or the activation of oncogenic pathways. 
Antigen loss is the best described mechanism of tumour escape. The equilibrium phase 
can select for tumour cells that lack rejection antigens. Furthermore, tumour cells can 
downregulate or lose expression of MHC-I or MHC-II, limiting antigen presentation to T 
cells. In addition, tumour cells can be defective in both the TAP and MHC presentation 
pathways resulting in the inability to produce epitopes and load these onto MHC-I or 
MHC-II (255, 261). These changes are caused due to the genomic instability of tumour 
cells, resulting in a selection process for tumour cells that are invisible to the immune 
system. In addition to mutations in antigen processing pathways, favourable mutations 
can arise in pathways pertaining to cell death resistance. For example, overexpression of 
Bcl-2 and Bcl-XL promote cell survival, limiting the effectiveness of apoptosis induction 
(262). Additionally, down-regulation of Fas and other death receptors render tumour cells 
immune to contact dependent cytotoxicity (263). 
 
Outside of the tumour, an immunosuppressive microenvironment can be generated due 
to the secretion of cytokines and enzymes including TGF-β, IL-10 and prostaglandin E2 
(PGE2) and IDO (264-269). This leads to the generation of thymic derived Tregs, or the 
conversion of tumour infiltrating CD4+ T cells into Tregs. In addition to Tregs, myeloid 
derived suppressor cells can also act to limit immune activation within the tumour 
microenvironment (270). Indoleamine 2,3 dioxygenase is an enzyme that catalyses the 
breakdown of tryptophan to N-formylkynurine. This acts both limit the amount of the 
essential amino acid tryptophan available to T cells, and generates a suppressive 
environment owing to the presence of N-formylkynurine. Similarly, secretion of IL-10 
and TGF-β by tumour cells can create a suppressive environment through the conversion 
of tumour-associated macrophages (TAMs) from an M1 to an M2 phenotype. 
Macrophages that are M2 skewed can release more IL-10 as well as producing oxygen 
radicals, which are toxic to infiltrating lymphocytes (271). Finally, the ligation of the 
checkpoint molecule programmed death 1 (PD-1) can limit the activation of T cells (272). 
When the combination of suppressive mechanisms outcompete the cytotoxic ability of T 
cells, tumour outgrowth is achieved and tumour escape is complete (Fig 1.3 C). 
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Figure 1.3 The cancer immunoediting process. 
(A) The elimination phase consists of the recognition fo transformed cells by the innate and adaptive 
immune system, resulting in the destruction of these cells. (B) The equilibrium phase describes tumour 
persistence which is unable to expand due to immune pressure. (C) The escape phase beings when the 
equilibrium phase is shifted in favour of tumour outgrowth. This can occur as a result of immune 
exhaustion or as a result of tumour variants that are no longer recognised by the immune system.  This 
phase concludes with the appearance of detectable, progressively growing tumours. Figure adapted from 
Dunn et al (273). 
 
1.22 Immunotherapy for Glioma 
Immunotherapeutic approaches under clinical development for GBM can broadly be 
classified into cellular therapies, monoclonal antibody therapy, checkpoint blockade and 
vaccine therapy. With T cells recognised for their anti-tumour capability, as evidenced by 
the immune-editing studies, they have been the focus of many studies. As tumours 
originate from otherwise benign cells, the recognition of T cell receptors to tumour 
antigens was thought to be low or impossible to detect. However some antigens are 
highly expressed such as those on haematologic cancers (274). 
 
Chimeric Antigen Receptor (CAR) T cells are T cells that have been genetically modified 
to lose expression of the αβ TCR, with it being replaced with the fragment antibody-
binding (Fab) region of an antibody to a defined tumour antigen. The Fab region is linked 
to an intracellular T cell signalling domain via a CD28 transmembrane portion. CAR T 
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cells are unique in their ability to recognise antigen, without the need for MHC 
presentation and to bypass traditional costimulation due to a genetically modified TCR. 
This facilitates the recognition of whole protein as opposed to processed peptide. To date, 
success using CAR T cells has been observed in the clinic with cells targeting CD19 on B 
cell lymphoma (275). While this results in the depletion of both malignant and benign 
cells, patients can be rescued with IgG replacement therapy (276). Whereas hematologic 
cancers have set the benchmark for CAR therapy, little success has been observed in solid 
malignancies. This may be due to the tumour antigen heterogeneity in solid tumours as 
well as the highly suppressive tumour microenvironment limiting both the T cell target, as 
well as their function (277). This approach may hold promise for GBM as 30% of 
patients harbour a mutation in the EGFR, resulting in constitutive activation of the 
receptor. This mutation, EGFRvIII, is currently being targeted by Novartis using CAR T 
cell therapy (277, 278). 
 
In addition to cellular therapy, monoclonal antibodies can be utilised to target either 
tumour cell surface proteins, or factors, which facilitate tumour growth. Bevacizumab is 
an antibody that blocks angiogenesis by inhibiting VEGF-A and has been FDA approved 
for the treatment of GBM. While administration of Bevacizumab slows tumour growth, it 
does not affect overall survival in GBM patients (279). Indeed the limited efficacy 
observed in patients is thought to paradoxically be a result of the inability of bevacizumab 
to cross the BBB and limit angiogenesis within the tumour (280). Further, it is now 
thought that vascular normalisation, rather than anti-angiogenesis, is preferable as this 
permits the passage of chemotherapeutics to the tumour site (281, 282). 
 
While checkpoint inhibitors have been approved for the treatment of metastatic 
melanoma, there is considerable interest in utilising these therapies for glioma. The 
CheckMate phase III trial aims to study the safety and efficacy of nivolumab compared to 
bevacizumab, and of nivolumab as a lone intervention, or combined with ipilimumab 
(283). A separate phase II trial is underway and aims to investigate the effectiveness of 
pembrolizumab as a lone therapy, or combined with bevacizumab in recurrent GBM 
patients (284). Finally, a new antibody targeting the PD-L1 pathway, currently referred to 
as MEDI4736, is being investigated in a phase II trial. Similar to the aforementioned trial, 
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MEDI4736 will be examined both as a lone therapy and also in combination with 
bevacizumab (285). 
1.23 GBM vaccine immunotherapy  
Thus far, the most commonly adopted approach for immunotherapy for GBM has been 
vaccine meditated. Several studies have been completed which have utilised the 
identification of GBM-specific antigens, such as the EGFRvIII, or have adopted a multi-
antigen approach. This has typically been accomplished through the use of lysates 
generated from resected tumour tissue, or synthetic peptides which have been loaded 
onto autologous DCs isolated from patients (286). In the VICTORI phase 1 trial, 
EGFRvIII peptides were loaded onto DCs. Minimal adverse reactions were observed in 
patients and 60% of patients became sensitised to the peptides upon subsequent testing 
(287). 
 
Whole tumour cell lysate as an antigen source has the benefit of providing a broad and 
patient specific repertoire of immunological targets. Generally, lysates are generated by 
culturing resected tumours ex vivo and isolating the surface proteins associated with MHC 
molecules. These can then be combined with autologous DCs and administered to 
patients. This method has been investigated in phase I clinical trials where vaccines were 
delivered subcutaneously over several weeks and patients were followed for up to 5 years 
(288, 289). Analysis of PBMCs revealed T cell reactivity against tumour cells, indicative of 
a systemic immune response. Furthermore, intratumoural T cell infiltration was observed 
in patients who required a second operation (289). As mentioned previously, GBM has 
been classified into four subtypes based on gene expression analysis (8). Interestingly, the 
mesenchymal subgroup has been identified as the subtype most likely to respond to 
tumour lysate vaccine therapy (290). There are currently several phase II and phase III 
trials underway to assess tumour lysate vaccines. One phase II trial currently underway 
aims to compare the efficacy of lysate-pulsed DCs with the TLR agonists resiquimod or 
poly-ICLC (291). Finally, the phase III trial is aiming to compare standard radiation and 
chemotherapy combined with tumour-lysate vaccination, to standard care plus placebo, 
with the option of crossover to the vaccine group if disease progresses (292). Similarly, a 
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phase II trial is underway in Vienna aiming to compare temozolomide and radiation to 
temozolomide, radiation and tumour-lysate vaccination (293). 
 
A phase I clinical trial conducted in Wellington, NZ, aimed to assess the feasibility of 
treating patients who had previously been exposed to temozolomide chemotherapy with 
an autologous DC vaccine. While therapy was well tolerated, feasibility was marginal as 
insufficient vaccine was able to be produced in three of the fourteen patients (294). Here, 
the authors attributed the inability to generate enough vaccine to be a consequence of 
recent temozolomide exposure as previous reports have shown human monocytes are 
sensitive to temozolomide-induced apoptosis in vitro (295). 
 
Different protocols for generating DCs for cancer vaccines may account for the varying 
differences in the efficacy of inducing T cell responses and ultimate induction of clinical 
responses in patients (296). Given the specialised cell culture techniques and ex vivo 
manipulation of PBMCs required for generation of DC vaccines, new approaches are 
being investigated which target a patients DCs, without having to culture cell ex vivo. Here, 
heat shock proteins (HSPs) have been investigated as they are known to bind receptors 
expressed by DCs, resulting in the delivery of a broad array of peptides (297). HSP-96 is a 
HSP expressed in GBM which has been investigated for use as a cancer vaccine (298). In 
a phase I study, patients were administered autologous tumour-derived HSP peptide 
complex intradermally. Eleven of the twelve patients recruited had specific peripheral 
immune responses as determined by ex vivo restimulation of PBMCs with vaccine and 
examining cytokine production and proliferation (298). Seven of the twelve patients also 
had post therapy tumour biopsies which revealed increased immune cell infiltrates (298). 
Based on these results, a phase II study has been completed in which patients received 
the HSP vaccine following standard treatment with radiation and temozolomide (299, 
300). 
 
To circumvent the identification of neoepitopes, computational analysis to predict MHC 
binding, and then peptide and vaccine synthesis, vaccines can be generated simply from 
resected tumour tissue (301, 302). To facilitate DC activation, tumour cells can be 
transduced to produce granulocyte monocyte-colony stimulating factor (GM-CSF) before 
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being irradiated and transferred back to the host (303). Irradiation renders the cells non-
viable and can act to increase immunogenicity by inducing cell death (304, 305). In a 
myeloid leukaemia trial, co-injection of irradiated K562 cells, an immortalised 
myelogenous leukaemia line (306), transduced to produce GM-CSF, was observed to 
reduce tumour burden in patients on imatinib mesylate but with residual disease (307). 
Alternatively, resected tumour tissue can be fixed in paraformaldehyde to preserve 
antigen peptides and delivered in combination with an adjuvant (301). Each of these 
approaches are quick to manufacture and allow the entire epitope repertoire of a patient 
to be expressed without the need for exome sequencing. Conversely, as tumours arise 
from self-tissue and invade local and distant sites, any resected tumour will invariably 
contain a mixture of both self and transformed tissue. There is therefore the possibility 
that a vaccine generated this way may drive a response against healthy as well as 
transformed tumour tissues (308). 
 
The induction of an effective anti-tumour response is reliant on both the efficient 
licensing of DCs as well as the cytotoxic capacity of T cells. Given the rarity of a specific 
TCR for a given antigen, whole cell based approaches are now being explored. Despite 
these pitfalls mentioned above, such an approach serves two purposes. First, a polyclonal 
population of T cells is activated, therefore increasing the population of cells with anti-
tumour activity. Secondly, owing to the polyclonal T cell activation, the likelihood of 
tumour evasion of immunotherapy is decreased, compared to targeting therapy to a single 
antigen. 
1.24 A cell-based vaccine for glioma based on the APC 
licensing function of NKT cells 
Invariant NK T cells (iNKT) are innate T cells that share properties and receptors of 
both NK cells and T cells. iNKT cells develop in the thymus (309) but have a semi-
invariant TCR, typically consisting of Vα14-Jα18 Vβ8.2 configuration in mice and Vα24-
Jα18 Vβ11 in humans as opposed to the highly polymorphic αβ TCR expressed on 
conventional T cells. Whereas T cells recognise peptide antigens in the context of MHC 
class I and II, iNKT cells recognise the glycolipids presented by the MHC-like molecule 
CD1d (310). Upon administration of the glycolipid α-galactosylceramide (α-GalCer) to 
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mice, iNKT cells produce large amounts of IFN-γ and IL-4 (311). In addition to rapid 
cytokine release, iNKT cells are able to license DCs via CD40-CD40L interactions (Fig 
1.4) (312). As described earlier, licensing is critical to ensure activation and potent 
costimulation ability of DCs to T cells. Increasing evidence suggests iNKT cells are 
required for clearing certain infectious diseases, as well as having roles in anti-tumour 
responses (313) and autoimmune diseases including EAE (314) and type 1 diabetes 
mellitus (315). As these are divergent diseases, it is likely that depending on the ligand 
dose and frequency, iNKT cells can enhance or regulate T cell activity in different 
diseases, most likely as a result of the cytokine milieu generated following activation. 
 
One of the hurdles to DC based therapies has been the extensive ex vivo manipulation 
required to generate a suitable vaccine product. Additionally, patients undergoing chemo-
and radiotherapy are often immune suppressed following treatment, resulting in fewer 
DCs with which to generate a vaccine (294). Due to these difficulties, considerable 
interest is being focused on targeting APCs within a patient with cancer vaccines. 
Resected tumour tissue is an attractive source of tumour specific antigens as mutations 
give rise to neoepitopes and other novel proteins, that can be targeted by T cells (316). 
The fundamental requirement of any vaccine strategy is the generation of systemic 
immune responses, resulting from the potent activation of APCs (317). Pulsing tumour 
cells with α-GalCer before irradiation is a simple yet elegant means to generate a vaccine 
with little manipulation of cells required. Incorporation of α-GalCer into a whole vaccine 
strategy, ensures both antigen and α-GalCer are delivered to the same APC, a 
phenomenon that has previously been shown to be essential for inducing effective 
immune responses (52). 
 
This intravenous vaccine strategy has previously been shown to prevent tumour growth 
in several mouse models, including glioma (29). Vaccine efficacy is dependent on both α-
GalCer and whole tumour cell antigen as neither irradiated cells in the absence of α-
GalCer, nor free α-GalCer prevented tumour outgrowth in a subcutaneous setting (29). 
Additionally, CD1d-/- mice which lack NKT cells were unable to prevent tumour growth, 
suggesting NKT cell mediated licensing of DCs is required to induce anti-tumour 
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immune responses in this model (29). Induction of NKT cell activation could be 
observed by quantification of serum cytokines IL-4, IL-12p70 and IFN-γ following 
vaccine administration, with increased cytokine production not attributed to unpulsed 
vaccine cells, or free α-GalCer (29). Following activation, NKT cells enter a state of 
anergy and become unresponsive to further α-GalCer mediated activation, potentially 
restricting application in a prime-boost regime (318, 319). Indeed, previous exposure to 
free α-GalCer can abrogate response to a second α-GalCer-adjuvanted vaccine. 
Interestingly pre-treatment with a cell-based vaccine glioma vaccine loaded with α-GalCer 
only partially attenuated CD8+ T cell expansion, suggesting that NKT cell anergy is 
somewhat averted by this vaccine strategy (29). 
 
While considerable focus has been aimed at enhancing CD8+ T cell responses for cancer 
immunotherapy, the α-GalCer-adjuvanted glioma vaccine efficacy was CD4+ T cell 
mediated, as efficacy was lost in MHC class II-deficient mice, and also following CD4+ T 
cell depletion in a prophylactic setting. While a large population of NKT cells reside in 
the spleen, and anti-tumour responses could be detected in this organ, it was surprising 
that anti-tumour responses could be induced in splenectomised animals. When examined 
further, it was revealed that anti-tumour immune responses could also be primed in the 
lung-draining lymph nodes, as revealed by enhanced overall cellularity, increased CD11c+ 
MHC-II+ DCs and increased expression of CD44 on CD4+ T cells. Interestingly, this 
appeared to be specific to the route of administration as no difference was observed both 
in cellularity, or the expression of CD44 on CD4+ T cells within the non-draining, 
inguinal lymph nodes (29). While prophylactic vaccine administration was effective at 
preventing tumour growth following either subcutaneous or intracranial tumour challenge, 
no anti-tumour effect was observed in a therapeutic setting unless Tregs were depleted 
before vaccination. The survival benefit was not a result of Treg depletion alone, as Tregs 
depletion in the absence of vaccine revealed no survival benefit (29). 
 
To have translational relevance, this strategy requires NKT cells to be functional within 
GBM patients. Analysis of NKT cell number and function from the peripheral blood of 
histologically confirmed GBM patients revealed comparable numbers to age matched 
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healthy controls. Importantly, NKT cells could be expanded from the PBMCs of patients 
in response to α-GalCer in vitro, suggesting the NKT:DC axis is still functional in GBM 
patients. To confirm this further, patient derived primary tumour cell lines were pulsed 
with α-GalCer in vitro and were irradiated, washed and co-cultured with CFSE labelled 
PBMCs from a healthy donor. Proliferation of donor cells was measured as a loss of 
CFSE fluorescence on α-GalCer loaded CD1d tetramers, providing a proof-of-principle 
that a vaccine based on whole tumour cells and pulsed with α-GalCer can induce the 
proliferation of NKT cells in humans (29). Additionally, primary cell lines exposed to 
IFN-γ in vitro up-regulated MHC-II expression, suggesting that these cells could be 
susceptible to CD4+ T cell targeted killing in patients (29). 
 
Taken together, an α-GalCer pulsed autologous whole tumour cell vaccine generates anti-
tumour responses within both the spleen and the mediastinal lymph node (MdLN). These 
responses are dependent on NKT cell licensing of DCs and induce CD4+ T cell activation. 
Importantly, the NKT cell population appeared to be intact within the GBM patients 
sampled in this study, suggesting a vaccine approach described here could be an effective 
vaccine for humans (29). Thus far, no strategy exists to specifically deplete Tregs in 
human patients; however, checkpoint blockade is showing remarkable success in the 
clinic, albeit in a limited cohort of patients who respond to therapy. It is therefore 
conceivable that combining checkpoint blockade to unleash an underlying immune 
response could be enhanced with vaccination to induce anti-tumour immune responses. 
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Figure 1.4 Immune cell modulation by activated iNKT cells. 
(A) Ligation of CD40 on the surface of a DC by CD40L on an iNKT cell results in upregulation of 
costimulatory molecules such as CD86 and production of IL-12. This affords DCs stronger T cell 
stimulation capacity. iNKT cells also receive signals from DCs, promoting their activation. (B) Licensed 
DCs can present tumour antigenic peptides to CD4+ and CD8+ T cells. (C) Release of IFN-γ from iNKT 
cells acts to directly activate NK cells. Figure adapted from Cerundolo et al (320). 
 
1.25 Gaps in knowledge 
Given the dire outlook for GBM patients, immunotherapy represents a novel and 
promising treatment modality. While the CNS has traditionally been considered an 
immune privileged site, there is accumulating evidence that malignant tissue within the 
CNS can be targeted by T cells, giving the impetus to develop T cell-based 
immunotherapies. However, there is little consensus as to how to best achieve this. 
Research on vaccines to date have shown only limited efficacy in patients, and are often 
cumbersome to prepare. Recent clinical successes with checkpoint blockade antibodies in 
melanoma and non-small cell lung cancer (NSCLC) have shown that it is possible to 
unleashing immune responses in cancer patients. However, even in these diseases, only a 
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relatively small number of patients respond to this therapy (153). Given that checkpoint 
blockade is reliant on unleashing pre-existing immune responses, it is possible that those 
patients who fail to respond to therapy may have not induced an endogenous anti-tumour 
response in the first place. There is therefore accumulating interest in using therapeutic 
vaccines to initiate anti-tumour responses, which could be complemented with 
checkpoint blockade. Furthermore, the majority of the pre-clinical research in the 
checkpoint blockade field has focused on tumours within the periphery - little is know 
about the response to tumours behind the blood brain barrier. With this in mind, the 
work presented in this thesis aims to investigate checkpoint blockade combined with an 
autologous whole tumour cell vaccine in a mouse model of glioma. In particular, the work 
focuses on providing mechanistic insight into an effective combination therapy. 
1.26 Hypothesis + aims 
Administration of vaccines can be used to induce adaptive immune responses to tumour-
associated antigens that have the capacity to limit tumour growth. Conversely, immune 
checkpoints pathways act as brakes for the immune system. However, following 
administration of checkpoint inhibitors, the immune system can again respond 
unhindered. The hypothesis underlying this thesis is:  
 
“that the combination of vaccine-based immunotherapy and checkpoint blockade will result in improved 
immune-mediated tumour clearance.” 
 
 Addressing the following aims will challenge this hypothesis. 
1. To assess the efficacy of vaccination in combination with different checkpoint 
inhibitors  
2. To assess the impact of the combination of efficacious combination therapy on 
the immune system 
3. To determine the mechanism(s) of anti-tumour activity 
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Chapter 2 
2  Materials and Methods 
2.1 Labware 
Table 2.1 Table of plasticware used throughout this thesis 
Product Supplier/Distributor 
Acrodisc 13mm Syringe Filters with 0.2 
µM membrane 
PALL LifeSciences, Cornwall, UK 
Axygen Microtubes 1.7 mL Axygen Scientific Inc, Union City, CA, 
USA 
BD 1 mL syringes 
BD 5 mL syringes 
BD 10 mL syringes 
BD 30 mL syringes 
BD Biosciences, Bedford, MA, USA 
Falcon tissue culture plates: 
6-well plates 
24-well plates 
96-well round bottom plates 
96-well U-bottom plates 
BD Biosciences, Bedford, MA, USA 
Falcon polypropylene conical tubes: 
50 mL 
15 mL 
BD Biosciences, Bedford, MA, USA 
Falcon tissue culture flasks: 
75 cm2 
175 cm2 
BD Biosciences, Bedford, MA, USA 
Falcon nylon cell strainers 70 µM BD Biosciences, Bedford, MA, USA 
Hamilton syringe: 
31 gauge 
Hamilton Laboratory Products, Reno, NV, 
USA 
Iodine Orion Las, Balcutta, WA, Australia 
Minisart Syringe Filter Sartorius 
Precision Glide needles: 
18 gauge 
20 gauge 
25 gauge 
27 gauge 
BD Biosciences, Bedford, MA, USA 
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2.2 Reagents and Buffers 
Table 2.2 Table of reagents used throughout this thesis 
Product Supplier/Distributor 
α-galactosylceramide Produced by Ferrier Research Institute as previously 
described (321) 
2 Mercaptoethanol (2 ME) Gibco, Invitrogen, OR, USA. 
2 ME was stored at 4°C 
Bovine serum albumin (BSA) ICP Biologicals, New Zealand 
Brefeldin A Sigma-Aldrich, MO, USA 
CFSE Molecular Probes, Invitrogen, OR, USA 
Collagenase II Gibco, Invitrogen, OR, USA 
Dimethyl sulfoxide (DMSO) Cryoserv, BionichePharma 
Diphtheria Toxin Sigma-Aldrich, MO, USA. 
Powdered diphtheria toxin was reconstituted in H2O 
and stored at -20°C 
Dulbecco’s Modified Eagle 
Medium (DMEM) 
Gibco, Invitrogen, OR, USA 
DNAse Roche, IN, USA. 
DNAse was stored at -20°C 
Ultrapure 0.5 M, pH 8.0  
Ethylenediaminetetraacetic acid 
(EDTA) 
Invitrogen, Life Technologies, Auckland, New 
Zealand 
Foetal Bovine Serum (FBS) SAFC Biosciences Sigma-Aldrich, MO, USA. 
FBS was stored at -20°C 
Glutamax Gibco, Invitrogen, OR, USA 
Glycine Sigma-Aldrich, MO, USA 
Iscove’s Modified Mulbecco’s 
Medium (IMDM) 
Gibco, Invitrogen, OR, USA 
Monensin Sigma-Aldrich, MO, USA 
Percoll GE Healthcare Bioscience, Uppsala, Sweden 
PBS Gibco, Invitrogen, OR, USA 
Red Blood Cell Lysis Buffer Qiagen Sciences, MD, USA 
RBC Lysis Buffer stored at room temp 
Roswell Park Memorial Institute 
(RPMI) 1640 Medium 
Gibco, Invitrogen, OR, USA 
Trypan Blue (0.4% v/v) Gibco, Invitrogen, OR, USA 
TrypLE Gibco, Invitrogen, OR, USA 
Tween 20 Bio-Rad Laboratories, CA, USA 
Penicillin Streptomycin Gibco, Invitrogen, OR, USA 
Sodium Azide Sigma-Aldrich, MO, USA 
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2.2.1 3% Hydrogen peroxide 
PBS (40 mL), methanol (50 mL) and 30% hydrogen peroxide (10 mL) 
2.2.2 Antibody purification buffers 
Wash/Start Buffer: 1L of 20 mM di-Sodium Orthophosphate (Na2HPO4), pH 8.0 
Add 2.48g to 1L dH2O 
Use HCl to bring pH to 8.0 
 
Elution Buffer: 500 mL 0.1M glycine-HCl, pH 2.7 
Add 3.75g to 500 mL dH2O 
Use HCl to bring pH to 2.7 
 
Neutralising Buffer: 50 mL 1M Tris-HCl, pH 9.0 
Add 6.06g to 50 mL dH2O) 
Use HCl to bring pH to 9.0 
 
20% EtOH 
Add 200 mL EtOH to 800 mL dH2O 
 
dH2O 
Filter sterilise 500 mL of dH2O and leave overnight to degass 
2.2.3 Citrate buffer 
Citrate buffer was made fresh as needed by diluting 5.88g Sodium TriCitrate in 2L dH2O 
before being pH adjusted to 6.0 with HCl. Tween 20 (1 mL) was added following pH 
adjustment. 
2.2.4 Complete DMEM (cDMEM) 
DMEM was supplemented with 20% FBS, 2mM Glutamax, 100 u/mL penicillin and 100 
ug/mL streptomycin 
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2.2.5 Complete IMDM (cIMDM) 
IMDM was supplemented with 10% FBS, 2mM Glutamax, 100 u/mL penicillin, 100 
ug/mL streptomycin and 500 µL 2 ME 
2.2.6 Complete IMDM for hybridomas 
IMDM was supplemented with 5-20% FBS, 2mM Glutamax, 100 u/mL penicillin, 100 
ug/mL streptomycin and 500 µL 2 ME 
2.2.7 Complete RPMI (cRPMI) 
RPMI was supplemented with 10% FBS, 2mM Glutamax, 100 u/mL penicillin, 100 
ug/mL streptomycin and 500 µL 2 ME 
2.2.8 Flow buffer 
PBS containing 1% FBS, 0.01% NaN3 and 2 mM EDTA was used for all flow cytometry 
experiments. Buffer was filter sterilised for FACS experiments 
2.2.9 FoxP3 Fix/Perm Buffer Set 
Purchased from BD Biosciences. Buffers were diluted in PBS prior to use 
2.2.10 PBST 
Tween 20 (500 µL) added to 1L PBS 
2.2.11 PBS + EDTA 
EDTA added to PBS to give final concentration of 10 mM 
2.2.12 Percoll Diluent 
Add 135 mL 10 X PBS to 145 mL dH2O 
2.2.13 37% Percoll 
Combine 33.4% stock Percoll, 19.6% Percoll diluent and 47% 1 x PBS. Warm to room 
temperature before use 
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2.2.14 Wurzburger buffer 
FBS, DNase and EDTA were added to PBS at final concentrations of 1%, 5 mM and 
0.02 mg/mL, respectively. Buffer was stored at 4°C and used under sterile conditions. 
2.3 Purified Antibodies 
2.3.1 Antibodies 
Hybridomas were grown in cIMDM, with FBS ranging in concentration from 5-20%. 
Antibodies were isolated from supernatants by fast pressure liquid chromatography using 
Hitrap protein G affinity columns used according to manufacturers instructions. After 
isolation into neutralising buffer, antibody was dialysed for 4 hours in 2L PBS using 
10000 molecular-weight cut off cassettes. The PBS was changed and antibody was 
dialysed overnight. The next day, dialysed protein was extracted from the cassette and 
filter sterilised. Antibody concentration was determined by nanodrop absorption at 280 
nm. 
2.3.2 α-CTLA-4 
α-CTLA-4 mAb (4F10, hamster IgG2a) was purified from hybridoma supernatant by 
protein G affinity columns. Mice were injected with 1 mg of antibody the day before 
vaccine administration, unless otherwise indicated. The 4F10 hybridoma was kindly 
provided by Dr Jeff Bluestone, UCSF, CA, USA. 
2.3.3 α-LAG-3 
α-LAG-3 mAb (C9B7W, rat IgG1) was purified from hybridoma supernatant by protein 
G affinity column. Mice were injected with 500 µg of antibody on days 7 and 250 µg, 10, 
13 and 16 after vaccine administration, unless otherwise indicated. The RMPI-14 
hybridoma was kindly provided by Mr Rohit Sinha, The University of Queensland 
Diamantina Institute, Australia. 
2.3.4 α-PD-1 
α-PD-1 mAb (RMPI-14, rat IgG2a) was purified from hybridoma supernatant by protein 
G affinity column. Mice were injected with 250 µg of antibody on days 3, 6 and 9 after 
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vaccine administration, unless otherwise indicated. The RMPI-14 hybridoma was kindly 
provided by Dr Hideo Yagata, Juntendo University School of Medicine, Toyko University, 
Japan. 
2.3.5 IgG controls 
The appropriate IgG controls were purchased from BioXCell and administered to mice in 
an identical dosing and timing schedule as the checkpoint blockade antibodies. 
2.4 Cell Culture 
Cell culture was performed under PC2 conditions at the Malaghan Institute of Medical 
Research, Wellington. Cell line work was performed in Class II biological safety cabinets 
with HEPA air filters (HERAsafe, Heraeus, Germany). Cells were incubated in 
humidified incubators (HERAcell incubator, Heraeus, Germany). 
2.4.1 GL261 
The murine glioma cell line GL261 was obtained from the DCTD Tumour Repository 
(NCI, Frederick, MD). Cells were grown in cDMEM at 37°C + 5% CO2. When cells 
reached 80% confluency, they were harvested with TrypLE and passaged. 
2.4.2 LLTC 
The tissue culture adapted lewis lung carcinoma (LLTC) was kindly provided by Dr 
Graeme Finlay (Cancer Research Laboratories, Auckland, NZ). Cells were grown in 
cDMEM at 37°C + 5% CO2. When cells reached 80% confluency, they were harvested 
with TrypLE and passaged. 
2.4.3 Mycoplasma testing 
Cultured cells were tested every 3-6 months for mycoplasma contamination using the 
Intron Mycoplasma PCR detection Kit, as per the manufacturers instructions. Cells were 
also tested for mycoplasma prior to freezing to ensure stocks were mycoplasma-free. 
2.4.4 GL261 Cell Lysate 
GL261 cells were bulked over the course of a week before media was removed and cells 
were harvested with TrypLE. Cells were washed three times with PBS by centrifugation at 
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400 x g for 4 mins. Cells were adjusted to 1 x 107 cells/mL in PBS and 1.5 mL aliquots 
were made into cryovials. Cells were lysed by repeated freeze/thaw cycles in liquid 
nitrogen and a 37°C waterbath. Cell death was verified using trypan blue exclusion and 
cells were triturated ten times with a 26G needle to burst dead cells. Large particles were 
removed by centrifugation at 1000 x g for 10 mins and lysate containing supernatant was 
transferred to a new tube. Lysate was then filter sterilised through a 0.2 µM syringe filter 
and protein concentration was determined by Nanodrop. 
2.4.5 Protein Quantification 
GL261 lysate concentration was determined using a NanoDrop ND-1000 
Spectrophotometer at 280 nm, with ND-1000 v 3.8.1 Software. 
2.5 Mice 
2.5.1 Ethical Approval and Housing 
All mice were bred and housed at the Biomedical Research Unit at the Malaghan Institute 
of Medical Research. Mice were age and sex matched where possible. All experiments 
were carried out within the requirements of the Animal Welfare Act of New Zealand and 
approved by the Victoria University of Wellington Animal Ethics Committee 
(2012R15M). 
2.5.2 C57BL/6 
The C57BL/6 inbred mouse strain was obtained from Jackson Laboratories (Bar Harbour, 
ME, USA). 
 
Crossing C57BL/6 mice with SJL/J mice generated B6-Sj ptprca mice. These mice 
express the congenic marker CD45.1 (322). The B6-Sj ptprca mice were obtained from 
Jackson Laboratories (ME, USA) 
2.5.3 B6Aa0 
The B6Aa0 knockout strain was developed by targeting a mutation to the Aa gene in 
embryonic C57BL/6 stem cells. This mutation prevents the expression of MHC II, 
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preventing CD4+ T cell positive selection (323). Mice were supplied by Dr H Bluethmann 
(Hoffmann-LaRoche, Basel, Switzerland). 
2.5.4 Tap1-/- 
TAP-/- mice are defective in the stable assembly and intracellular transport of MHC class I 
molecules and are thus deficient in CD8+ T cell responses (324). These mice were 
developed by Van Kaer and colleagues  
2.5.5 Pfp-/- 
Mice lacking the perforin molecule have normal numbers of CD8+ T cells and NK cells. 
These mice are unable to lyse virus-infected or allogeneic fibroblasts in vitro (325). 
2.5.6 Ifng-/- 
Targeted disruption of the interferon-gamma gene results in mice which are normal in a 
resting state but display reduced macrophage function in response to pathogens (326). 
2.5.7 CD11b-DTR x C57Bl/6 
CD11b-DTR transgenic mice are on a BALB/c background and have a diphtheria toxin 
(DT) inducible system that transiently depletes macrophages in various tissues. The 
transgene insert contains a fusion product involving simian diphtheria toxin receptor and 
green fluorescent protein under the control of the human ITGAM (integrin alpha M) 
promoter (CD11b) (327). CD11b-DTR mice were crossed onto a C57BL/6 background 
for one generation before being used in experiments. 
2.5.8 OT-II 
A T cell hybridoma which was CD4 positive, MHC-II restricted and specific for chicken 
ovalbumin (OVA)323-339. The α- and β-chain transgenic constructs were taken form the 
hybridoma and injected into fertilised B6 mouse eggs to generate OT-II mice. These mice 
harbour peripheral T cells which express the transgene and are therefore only receptive to 
MHC-II presenting OVA323-339 peptide (328). 
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2.5.9 Cd1d-/- 
CD1d-deficient mice harbour a knock-out of the CD1d1/CD1d2 locus, resulting in a lack 
of NKT cells (329). 
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2.6 Methods 
2.6.1 Intracranial Surgery 
For intracranial tumour implantation, from here on defined as tumour challenge, 
previously frozen cell aliquots were obtained from liquid nitrogen where they were stored 
at 2.5 x 106 cells/mL in 90% cDMEM20 + 10% DMSO. Cells were thawed by gentle 
agitation into 10 mL iDMEM. Cells were centrifuged at 400 x g for 4 mins. The cell pellet 
was resuspended in 200 µL sterile PBS. A 10 µL aliquot was taken before and after 
challenge to determine tumour cell viability. Ketamine and xylazine (Phoenix 
Phamraceuticals, Auckland, NZ) were used to anaesthetise mice (100 mg/kg and 10 
mg/kg respectively). Buprenorphine (Renckitt Benckiser Pharmaceuticals, North 
Chesterfield, USA) and carprofen (Norbrook Laboratories, Corby, UK) were 
administered subcutaneously for perioperative analgesic pain management. Once under 
anaesthesia, the head was mounted onto a stereotactic frame (Harvard Apparatus, 
Holliston, MA, USA) and secured with ear bars. Lacrilube (Allergan, Parsippany, USA) 
was applied to prevent corneal desiccation and skin was prepped with povidone iodine 
solution (Betadine, Purdue Products, Stamford, CT, USA). A lateral incision was made 
from behind the eyes to the base of the neck to expose the skull. A 20 gauge needle (BD 
Biosciences) was used to make a burr hole 2 mm right of the bregma. Cells were drawn 
into a 10 µL Hamilton Syringe with a 32G needle (Hamilton Company, Reno, NV, USA). 
The needle was advanced to a depth of 4 mm from the surface of the brain then 
withdrawn 1 mm and 1 µL of cells deposited. The needle was then withdrawn another 1 
mm and 1 µL cells deposited. The needle was withdrawn a further 1 mm and left in place 
for tumour cells to settle for 5 mins. The needle was then withdrawn completely and the 
hole sealed with sterile bone wax (Amtech Medical, Auckland, NZ). The wound was 
closed with two non-continuous 7/0 nylon sutures (Amtech Medical, Auckland, NZ). 
Mice were left to recover in cages on a heat pad. 
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2.6.2 Subcutaneous Challenge 
For subcutaneous tumour challenge, GL261 cells were harvested during the logarithmic 
growth phase. The cell monolayer was washed with PBS and then cells were incubated 
with TrypLE at 37°C + 5% CO2 for 10 mins. TrypLE was quenched with the addition of 
cDMEM20 and cells were centrifuged at 400 x g for 4 mins. The cell pellet was 
resuspended in incomplete DMEM and counted before being resuspended at 1 x 107 
cell/mL. Mice received 100 µL cells (1 x 106 cells total) in the subcutaneous left flank. 
2.7 Therapy 
2.7.1 Vaccine Generation 
To generate vaccine, GL261 cells were grown in complete DMEM supplemented with 
200 ng/mL α-GalCer for 24 hours. Media was discarded and the monolayer was washed 
three times with PBS to remove unbound α-GalCer. Cells were then lifted with TrypLE 
(Gibco) and resuspended in incomplete DMEM. Cells were then γ-irradiated (150 cGy) 
on ice and washed 3 times in PBS before freezing in 10% DMSO + 90% cDMEM. 
2.7.2 Vaccine Administration 
To administer vaccine, cells were thawed by gentle agitation into serum free incomplete 
DMEM. Cells were centrifuged at 400 x g for 4 mins and resuspended in PBS. Cells were 
adjusted to 5 x 105 cells/mL in PBS. Mice received 1 x 105 cells in 200 µL PBS, injected 
intravenously via the lateral tail vein. 
2.7.3 Antibody administration 
Checkpoint blockade antibodies, or appropriate isotype controls were administered 
intraperitoneally as indicated in the figure legends. 
2.8 MRI 
Magnetic Resonance Imaging (MRI) was conducted on anaesthetised animals using a 
clinical 1.5-T MR scanner (Philips Medical Systems) equipped with a wrist solenoid coil. 
T1 weighted images were acquired with the following parameters: TE = 20 milliseconds, 
TR = 800 milliseconds, thickness = 1 mm. Contrast was enhanced by intravenous 
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administration of 100 µl/mouse of gadolinium-DTPA (Magnevist, Bayer Schering 
Pharma). Image analysis was performed using Philips DICOM Viewer R2.5 Version 1. 
2.9 Survival Studies 
In some experiments, mice were intracranially challenged and treated with vaccine, 
checkpoint blockade antibodies or both. Mice were monitored for signs of weight loss or 
neurological deficit. When weight loss exceeded 10%, or mice exhibited signs of 
discomfort including decreased activity, hunched posture, ruffled fur or eye closure, mice 
were culled by cervical dislocation and tumour presence confirmed macroscopically. 
2.10 Tissue Isolation 
2.10.1 Brain 
For analysis of infiltrates into tumours, brains were collected and dissociated with a 
scalpel before digestion in incomplete IMDM, supplemented with 4 µg/mL DNAse I 
and 2.4 mg/mL collagenase II. Samples were incubated at 37°C + 5% CO2 for 30 mins 
before digested tissue was homogenized by passage through an 18G needle and filtered 
through a 70 µM filter and washed twice with PBS. Filtered tissue was centrifuged on a 
37 % percoll gradient at 760 x g for 30 mins with no brake. Myelin and percoll was 
aspirated to allow cells to be recovered from the bottom of the gradient. Samples were 
washed with 10 mL PBS and centrifuged at 400 x g for 4 mins. Supernatant was discarded 
and cell pellets resuspended in 500 µL RBC lysis buffer and incubated at 37°C for 15 
mins. RBC lysis was quenched with 1.5 mL FACS buffer and samples were transferred to 
FACS tubes for flow cytometric analysis. 
2.10.2 Lymphocyte Isolation 
Lymph nodes were isolated from mice using blunt forceps and transferred to 24 well 
plates containing gauze and 250 µL cDMEM. Lymph nodes were mechanically 
dissociated between gauze with the soft end of a syringe plunger. Wells were then washed 
with 1 mL media and total contents excluding gauze were transferred to 15 mL conical 
tubes. 
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2.10.3 Splenocyte Isolation 
Spleens were isolated from mice using blunt forceps and transferred to 24 well plates 
containing gauze and 500 µL cDMEM. Spleens were mechanically dissociated between 
gauze with the hard end of a syringe plunger. Wells were then washed with 1 mL media 
and total contents excluding gauze were transferred to 15 mL conical tubes. Contents 
were centrifuged and supernatant discarded. The pellet was resuspended in 3mL RBC 
Lysis Buffer and incubated for 15 mins. Lysis buffer was quenched with 7 mL cDMEM 
and samples were filtered through 70 µM filter into a 50 mL conical tube. 
2.10.4 Blood 
Cardiac puncture was performed on euthanised mice and whole blood was transferred 
into a 1.5 mL eppendorf tube containing 500 µL PBS + EDTA. Samples were 
centrifuged at 700 x g for 4 mins in a Biofuge Fresco (Heraeus, ThermoFisher Scientific, 
New Zealand). Supernatant was aspirated before samples were washed with PBS. Samples 
were centrifuged again, supernatant aspirated and whole blood was resuspended in 1 mL 
RBC lysis buffer and incubated for 37°C + 5% CO2 for 30 mins. White blood cells were 
pelleted by centrifugation at 700 x g for 4 mins and resuspended in 200 µL FACS buffer 
for flow cytometric analysis. 
2.10.5 Serum 
Cardiac puncture was performed on euthanised mice and whole blood was transferred 
into a 1.5 mL eppendorf tube containing 500 µL PBS + EDTA. Samples were stored at 
4°C overnight and centrifuged at 13,250 x g for 10 min. The top serum layer within the 
tube after centrifugation was transferred into new tubes and stored at -20°C until analysis 
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2.10.6 Viable cell counts 
To determine total cell counts, a 10 µL aliquot of cells was added to 190 µL 0.4% trypan 
blue and mixed. A 10 µL aliquot of this mixture was loaded onto a haemocytometer 
(source) and cells were counted on an inverted microscope. Viable cells were identified as 
white whereas dead cells were blue. The total cell number was calculated using the 
following formula: 
Total cell number = (Average cell count) x (dultion factor) x (total volume) x 104 
2.10.7 Restimulation with tumour lysate for intracellular flow cytometry 
Splenocytes in cRPMI (2 x 106/mL) were plated into wells of a 24 well plate. GL261 cell 
(section 2.4.4) lysate was added to wells at a final concentration of 100 µg/mL. Final 
volume in cultures was brought to 2 mL. Cultures were incubated for 2 hours at 37°C + 
5% CO2. Monensin (20 µM) and brefeldin A (3 µg/mL) were added to cultures to 
prevent cytokine release and cultures were incubated for a further 4 hours. At the end of 
the culture, cells and supernatant were harvested into 5 mL FACS tubes. Wells were 
washed with 2 mL PBS + EDTA and residual cells were added to the respective FACS 
tubes. Cells were centrifuged at 400 x g for 4 mins and supernatant discarded. Samples 
were resuspended in residual volume and progressed to surface staining before staining 
for intracellular cytokines as described in section 2.12.2. 
2.10.8 Restimulation with tumour lysate for in vitro killing assay 
cRPMI10 media was supplemented with α-CD28 antibodies diluted 1/750 and GL261 
tumour cell lysate (section 2.4.4) at a concentration of 100 µg/mL and 500 µL aliquots 
were made into individual wells of 24 well plates. Splenocytes were harvested from 
treated mice and processed into single cell suspension as described in section 2.10.3. 
Splenocytes were then resuspended in cRPMI10 at a concentration of 1 x 107 cells/mL 
and 500 µL aliquots were added to individual wells of a 24 well plate with supplemented 
media described above, to give a final dilution of 1/1500 α-CD28 and 50 µg/mL GL261 
lysate. Cultures were incubated for 96 hours at 37°C + 5% CO2. 
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2.10.9 Dynabead enrichment 
Cells restimulated as described in section 2.10.8 were washed in Wurzburger buffer, 
counted and resuspended at 1 x 108 cells/mL. A Dynabead CD4 Positive Isolation Kit 
Invitrogen, Life Technologies) was then used to isolate CD4+ cells following the 
manufacturers instructions. Cells were incubated for 20 min at 4°C with 25 µL CD4+ 
Dynabeads/mL of sample and were intermittently mixed to prevent the beads from 
settling to the bottom of the tube. Sample tubes were placed in a magnetic column for 1 
min and the negative unbound cells were transferred to a negative fraction tube. Bead 
bound cells were washed with Wurzburger buffer and placed back in the column for a 
further minute to remove any remaining unbound cells. Samples were then resuspended 
in 500 µL iIMDM and 10 µL DETACHaBEAD per 25 µL Dybabeads was added. 
Samples were incubated at room temperature for 45 mins with intermittent mixing. 
Sample tubes were placed in the magnetic column for 1 min and positive cells were 
removed from the tube and transferred to a positive fraction tube. This was repeated 
twice more before isolated positive and negative fractions were counted for downstream 
applications. A 100 µL aliquot from each of the positive and negative fractions was set 
aside for purity determination by flow cytometry, with samples stained as described in 
section 2.12.1. 
2.10.10 In vitro T cell proliferation assay 
Spleens were isolated from mice 18 hours following treatment and single cell suspensions 
were created as described in section 2.10.3. Cells were incubated with 10 µM OVA323-339 
(ISQAVHAAHAEINEAGR) for 2 hours at 37°C + 5% CO2. Cells were then fixed in 
2% PFA and quenched with 0.1 mM glycine (Sigma-Aldrich). Quenched cells were 
resuspended in cIMDM and serially diluted across a 96-well plate. Cell suspensions 
created from spleens of OT-II mice were stained with 1 µM CFSE and 2 x 105 cells were 
added to the wells containing fixed splenocytes. Cultures were incubated for 6 days and 
CFSE dilution of OT-II cells, indicative of cell proliferation, was determined by flow 
cytometry. 
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2.10.11 Assessment of T cell proliferation in vivo 
Single cell suspensions from B6-Sj ptprca mice were created as described in section 2.10.3. 
Cells were stained with 1 µM CFSE and 1 x 107 cells were adoptively transferred into 
naïve hosts. Hosts were treated the following day with α-CTLA-4, vaccination, combined 
treatment, or remained naïve. One week later, host mice were culled and spleens were 
harvested and processed as described in section 2.10.3. The proliferation of CD45.1 
transferred splenocytes, indicated by CFSE dilution, was determined by flow cytometry 
following surface staining, as described in section 2.12.1. 
2.10.12 In vitro killing assay 
To assess the cytotoxic capacity of splenocytes following treatment, splenocytes were 
titrated into an in vitro killing assay. On day 3 after restimulation, 3 x 105 GL261 and 
LLTC were aliquoted into wells of a 24 well plate in cDMEM20. A final concentration of 
1.88 µCi/mL tritiated ([3H])-thymidine (PerkinElmer, MA, USA) was added to each well 
and cells were incubated overnight to allow the incorporation of [3H]-thymidine into the 
DNA of proliferating cells. On day 4, restimulated splenocytes were harvested and 
centrifuged at 400 x g for 4 mins. Cells were washed with cRMPI10 and readjusted to 5 x 
106 cells/mL and 200 µL added to the first row of wells in a 96 well plate. A 2-fold serial 
dilution was made down the plate, with no cells added the final row. Target cells were 
harvested and washed in cRPMI10 and cells readjusted to 1 x 105 cells/mL and 100 µL 
added to each well of a 96 well plate. Cultures were incubated at 37°C + 5% CO2 for 4 
hours before being harvested onto filter paper (Walla, Turku, Finland) using a cell 
harvested (TOMTEC, Germany). Betaplate scintillation fluid (PerkinElmer) was added to 
the dried filter paper and the beta radioactivity was measured using a MICROBETA 
PLUS Liquid Scintillation Counter (WALLAC, PerkinElmer Inc) and Microbeta 
Windows Workstation Software. 
 
To calculate the percentage of specific cell lysis per sample, counts per minute (CPM) the 
following formula was used: 
% specific lysis = (spontaneous lysis – experimental lysis)/(spontaneous lysis x 100) 
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2.11 Serum Analysis 
Serum samples were thawed at room temperature and cytokines IL-4, IFN-γ and IL-
12p70 was assessed by cytokine bead arrays analysed on a Bio-Plex analyser (Bio-Rad 
Laboratories, CA, USA) according to manufacturers instructions. A 96-well filter plate on 
a vacuum manifold was pre-wet with 1 x Assay Buffer. The plate was removed from the 
manifold and 25 µL of the serially diluted standards was aliquoted into the allocated wells. 
Assay Buffer was added to the designated “blank” controls wells, before 25 µL of each 
serum samples was aliquoted into the designated sample wells. A volume of 25 µL of 
1/40 Bead Mixture and 50 µL of 1/40 Biotin-Conjugate Mixture was added to each well. 
The plate was protected from light and incubated for 2 hours at room temperature on a 
plate shaker at 500 rpm. Wells were then washed twice with Assay Buffer using the 
vacuum manifold. The plate was removed from the vacuum and 100 µL Assay Buffer was 
added to each well in addition to 50 µL of 1/31.25 Streptavidin-PE solution. The plate 
was again protected from light and incubated for 1 hour at room temperature on a plate 
shaker at 500 rpm. The wells were washed twice with Assay Buffer using the vacuum 
manifold and the stained beads were resuspended in a 125 µL final volume of Assay 
Buffer before being read on the Bio-Plex analyser. 
2.12 Flow Cytometry 
2.12.1 Surface staining 
Single cell suspensions from harvested organs were washed with flow buffer and 
resuspended in 1 mL flow buffer. The cell suspension was distributed to 5 mL FACS 
tubes for staining. Samples were centrifuged at 400 x g for 4 mins, and supernatants 
discarded. Pellets were resuspended in residual volume by vortexing before 100 µL of 
flow buffer containing FC receptor blocking 2.4G2 antibody at 10 µg/mL and 
Live/Dead fixable blue (1:1000) was added. Samples were incubated on ice for 20 mins. 
Cells were washed with 500 µL flow buffer before being centrifuged again, supernatants 
discarded and cells resuspended as described above. Cells were resuspended in 100 µL 
flow buffer containing fluorescently-conjugated antibodies at pre-determined optimal 
dilutions. Samples were incubated on ice for 20 mins. Cells were washed again with 500 
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µL flow buffer. Samples were resuspended in 200 µL of 2% PFA for analysis by flow 
cytometry or were progressed to intracellular staining. 
2.12.2 Intracellular staining 
Intracellular staining was performed using the FoxP3 staining kit (BD) according to the 
manufacturers instructions. Briefly, following extracellular staining described in section 
2.12.1, cells were fixed by incubation in 500 µL Fix/Perm for 60 minutes at room 
temperature, in the dark. Samples were centrifuged at 400 x g for 4 mins and resuspended 
in 200 µL Perm buffer and incubated for 30 mins at room temp in the dark. Samples 
were washed once more and stained with the appropriate antibody diluted in 100 µL 
perm buffer for 30 mins at room temp, in the dark. Appropriate isotype control 
antibodies were used to stain extra cells or fluorescence minus one (FMO) controls were 
used to determine gating strategies. 
2.12.3 CFSE Staining 
Splenocytes isolated as described in section 2.10.3 were centrifuged at 400 x g for 4 mins 
and resuspended in PBS at 5 x 106 cells/mL. CFSE was diluted 1/100 from a stock 
concentration of 10 mM in PBS and 20 µL diluted CFSE was added per 1 mL of cells. 
Samples were vortexed immediately and incubated at 37°C + 5% CO2 for 10 mins. 
Following incubation, CFSE was quenched with 5 volumes of cold FBS and centrifuged 
at 400 x g for 4 mins. Samples were washed with cIMDM and transferred to new tubes 
before being centrifuged at 400 x g for 4 mins for a total of 3 washes. Samples were then 
counted and resuspended at the appropriate concentration for in vitro or in vivo use. 
2.13 Acquisition and Analysis 
2.13.1 BD LSR-II Special Order Product 
Samples were acquired on an LSR-II special order product (BD). 
The LSR-II was equipped with the following lasers and detectors: Ultra violet laser (355 
nm) UV740/35, UV450/50 and UV379/28.  Violet laser (405 nm) V780/60, V720/40, 
V660/20, V605/40, V560/40, V525/50 and V450/50. Blue laser (488 nm) B705/70, 
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B515/20 and B488/10. Green laser (532 nm) G780/60, G610/20 and G575/26. Red 
laser (640 nm) R780/60, R710/50 and R670/14. 
 
All fluorophores were detected using laser and detector combinations which best 
matched their excitation and emission profile. 
2.13.2 BD Influx 
Fluorescence Activated Cell Sorting (FACS) was performed using a BD Influx Cell Sorter. 
The influx was equipped with the following lasers and detectors: Ultra violet laser (355 
nm) UV730/45, UV670/30, UV460/50 and UV379/34.  Violet laser (405 nm) V780/60, 
V710/50, V660/20, V610/20, V520/35 and V425/26. Blue/Violet laser (445 nm) 
BV504/12. Blue Laser (488 nm), B692/40 and B520/35. Green laser (552 nm) G780/60, 
G710/50, G670/30, G610/20 and G575/26. Red laser (640 nm) R780/60, R720/40 and 
R670/30. 
2.13.3 FlowJo 
Flow Cytometry Standard (FCS) files were analysed using FlowJo software (Tree Star, San 
Carlos, CA, USA). Example flow plots in the results section were pre-gated on live, single 
cells based on FSC-A v FSC-H profile and negative staining for viability dye. 
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2.14 Antibodies 
Table 2.3 Table of Flow Cytometry Antibodies used throughout this thesis 
Specificity Clone Fluorophore Manufacturer 
CD3ε 17A2 BV421 Biolegend 
 145-2C11 FITC Biolegend 
 145-2C11 PeCy7 eBioscience 
CD4 RM4-5 eFluor450 eBioscience 
 RM4-5 BV711 Biolegend 
CD8α 53-6.7 Pacific Blue BD Bioscience 
 53-6.7 AlexaFluor 647 In house 
CD11b M1/70 ApcCy7 BD Bioscience 
CD1d αGal-loaded tetramer  PE NIH 
CD11c HL3 PeCy7 BD Bioscience 
MHC-II M5/114.15.1 PeCy7 Biolegend 
NK1.1 PK136 PerCpCy5.5 BD Bioscience 
B220 RA3-6B2 PerCpCy5.5 eBioscience 
CD19 eBio1D3 eFluor450 eBioscience 
 6D5 BV605 Biolegend 
CD86 GL-1 BV650 Biolegend 
 GL1 PE eBioscience 
CD44 1M7 Pacific Blue eBioscience 
 1M7 PerCpCy5.5 eBioscience 
 1M7 APC-AF750 eBioscience 
CD62L MEL-14 Pacific Blue eBioscience 
 MEL-14 PeCy7 eBioscience 
CD45 30-F11 APC eBioscience 
IFN-γ XMG1.2 PeCy7 eBioscience 
FoxP3 FJK-16S PE eBioscience 
 FJK-16S APC eBioscience 
TNF-α MP6-XT22 FITC eBioscience 
 
All antibodies were titrated before first use to ensure the optimal signal to noise ratio. 
2.15 Fluorophores 
Table 2.4 Table of Flow Cytometry Fluorophores used throughout this thesis 
Fluorophore Manufacturer 
DAPI Invitrogen 
Live Dead Fixable Blue (LDFB) Invitrogen 
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2.16 RNA Analysis 
2.16.1 RNA Extraction 
Cells for RNA extraction were FACS sorted before being washed in PBS and centrifuged 
at 400 x g for 4 mins. Supernatant was removed and RNA extraction was performed 
using the NucleoSpin RNA kit (Machery-Nagel), as per the manufacturers instructions. 
Briefly, cells were lysed in Buffer RA1 and β-mercaptoethanol and lysate filtered through 
a NucleoSpin Filter by centrifugation at 11,000 x g for 1 min. The NucleoSpin Filter was 
then discarded, 70% ethanol was added to the lysate and mixed before both the lysate and 
ethanol were loaded onto a NucleoSpin RNA Column and centrifuged at 11,000 x g for 
30 sec. The column was placed into a new tube and Membrane Desalting Buffer was 
added to the column membrane before centrifugation at 11,000 x g to dry the membrane. 
DNA was digested by the addition of DNase reaction mixture directly onto the silica 
membrane and samples were incubated at room temperature for 15 mins. Buffer RAW2 
was then added to the column to inactivate rDNase and samples were centrifuged at 
11,000 x g for 30 secs. Samples were washed twice with the addition of Buffer RA3 to the 
NucleoSpin RNA column and centrifugation at 11,000 x g for 30 secs. Finally, RNA was 
eluted from the column by addition of RNase-free water and centrifugation at 11,000 x g 
for 1 min. RNA concentration was determined using a NanoDrop ND-1000 
Spectrophotometer at 280 nm, with ND-1000 v 3.8.1 Software. 
2.16.2 Reverse Transcription PCR 
The iScript cDNA synthesis protocol (Bio-Rad Laboratories, CA, USA) was used for 
reverse transcription as per the manufacturers instructions. Combined in an RNAse-free 
tube was 10 µL of 5 x iScript Reaction Mix, 1 µL of iScript Reverse Transcriptase, 30 ng 
of RNA and DNAse/RNAse-free water to make a total of 50 µL. The samples were 
placed in an Applied Biosystems Veriti Thermal Cycler with the parameters of 5 mins at 
25°C, 30 mins at 42°C and 5 mins at 85°C for the primers to bind, the reverse 
transcriptase to transcribe RNA to cDNA and the inactivation of the reverse transcriptase 
enzyme. Samples were then held at 4°C. 
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2.16.3 Real-time quantitative PCR 
Real-time quantitative PCR was performed in a 20 µL reaction volume 10 µL SYBR 
Green Master Mix, 3 µL primer, 2 µL sterile distilled water and 6 ng cDNA. Primers to 
18s ribosomal RNA were used to normalise the amount of nuclear material. The 7500 
Real Time PCR System with 7500 Software version 2.0.6 (Applied Biosystems, Life 
Technologies) was used for real-time PCR quantification. The parameters used were 1 
cycle of 94°C for 15 mins to activate the DNA polymerase and denature the DNA; then 
40 cycles of 94°C for 15 secs to separate the DNA strands, 55°C for 30 secs to allow the 
primers to anneal, and 72°C for 35 sec to allow extension of the DNA strands. The 
amount of DNA was measured sat the end of each cycle using SYBR green as the 
fluorescent detector. 
2.16.4 Real-time quantitative PCR analysis 
Microsoft Excel software was used to analyse the real-time quantitative PCR data. Cycle 
threshold (Ct) values were normalised by calculating the difference between the sample Ct 
value and the corresponding 18s CT value to give the ΔCT value. The difference in 
normalised ΔCT between the treated and untreated cell RNA was calculated, termed the 
ΔΔCT, and the fold change of the transcript determined using the equation: 
Fold change = 2ΔΔCT 
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Table 2.5 Table of real-time quantitative PCR primers used throughout this thesis. 
All primers were purchased from Qiagen 
Gene Name Number Reference 
sequence 
accession number 
18s 18S ribosomal RNA QT02448075 NR_003278 
IL-1β Interleukin 1 beta QT01048355 NM_008361 
 
CXCL2 Chemokine (C-X-C motif) ligand 
3 
QT00113253 NM_009140 
 
CXCL5 Chemokine (C-X-C motif) ligand 
5 
QT01658146 NM_009141 
 
CCL3 Chemokine (C-C motif) ligand 3 QT00248199 NM_013025 
 
Arg1 Arginase QT00134288 NM_007482 
 
Relmα Resistin like alpha QT00254359 NM_020509 
 
Ym1 Similar to Chitinase 3-like QT02241722 XR_034276 
CD206 Mannose receptor, C type 1 QT00103012 NM_008625 
 
TNFα Tumour Necrosis Factor QT00104006 NM_013693 
 
IL-6 Interleukin 6 QT00098875 NM_031168 
iNOS Inducible nitric oxide synthase QT01547980 XM_001004823 
 
2.17 IHC 
Mice were tumour challenged intracranially and treated with α-CTLA-4, vaccination or a 
combination of both. On day 20 after challenge (13 days post therapy), mice were 
sacrificed by anaesthetic overdose and were perfused via the left ventricle with 10 mL ice 
cold PBS. Brains were harvested into 4% PFA (Sigma-Aldrich) for 72 hours before being 
transferred to 70% ethanol. Brains were processed into 10 µM sections using standard 
histological techniques by Jane Anderson of the Wellington School of Medicine. 
2.17.1 Haemotoxylin and Eosin Staining 
Was performed by Jane Anderson at the Wellington School of Medicine 
2.17.2 CD3 staining 
Slides were incubated at 60°C for 30 mins to melt wax and affix tissue to slides. Samples 
were then passaged through xylene and an ethanol rehydration gradient to remove 
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paraffin. Antigen retrieval was performed in citrate buffer for 10 mins at 90°C, with 
samples left for a further 30 mins to cool before being washed in PBS. Slides were 
permeabilised in 3% hydrogen peroxide buffer for 20 mins and washed in PBS, then 
PBST for 5 mins. Non-specific binding was prevented by incubation in serum (Vector 
Laboratories, USA) in a humidified chamber for 20 mins. Primary antibody (Abcam, New 
Zealand) was applied in PBS + 1% BSA and incubated for 1 hour at room temp before 
being washed three times in PBST. Secondary antibody (Vector Laboratories, USA) was 
applied for 10 mins at room temp. Samples were again washed in PBST for 5 mins before 
streptavidin-peroxidase complex (Vector Laboratories, USA) was added. Samples were 
incubated for 5 mins at room temp then washed in PBS. Two components of 3,3' 
Diaminobenzidine (DAB) substrate (Abcam, New Zealand) was mixed, applied to 
samples and left to develop for a minimum of 2 minutes. DAB was quenched with tap 
water for 3 mins before samples were counterstained with haematoxylin. Tissue was 
dehydrated by passage through an ethanol dehydration gradient before DPX glue 
(Scharlab, Sentmenat, Spain) and a coverslip were applied and left to dry. 
2.18 Microscopy 
Gross pathology photomicrographs were acquired using an Olympus SZX16 microscope 
with a 2 x objective lens equipped with an Olympus XC50 digital camera and CellF 
software. 
 
IHC and microscopic photomicrographs were acquired using an Olympus BX51 
microscope with a 40 x objective lens equipped with an Olympus DP70 digital camera 
and CellF software. 
2.19 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism version 5.0 software (CA, USA). 
Between 3 or more groups, a one-way analysis of variance (ANOVA) with Bonferroni’s 
post-test was used. When using two parameters with multiple groups, a two-way 
ANOVA with Bonferroni’s post-test was used. P values of P < 0.05 were considered 
significant. 
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Chapter 3 
3  Establishing an intracranial model of 
glioma and identifying a successful 
treatment regime 
3.1 General Introduction 
Historically, the CNS has been considered an immune privileged site owing to 
experiments conducted by Goldmann, showing compartmentalisation of the CNS from 
the circulatory system following trypan blue injection (330, 331). However, there is 
accumulating evidence that malignant tissue within the CNS can be targeted by T cells 
(332), giving impetus to develop vaccines for diseases like high-grade glioma for which 
current treatments are generally ineffective (5). However, the development of effective 
cancer vaccines faces numerous challenges, including a high level of tumour heterogeneity 
and a paucity of defined glioma-associated antigens (333). With surgical resection being a 
mainstay of glioma treatment, it is possible to use resected tumour material as a 
“personalized” source of antigens. Indeed intact irradiated tumour cells can act as a 
vehicle for the delivery of these antigens to APCs within the host. However, to best elicit 
an effective T cell response it is critical that these APCs also receive strong licensing 
signals. My colleagues have previously described a simple vaccine composed of irradiated 
autologous tumour cells pulsed with α-GalCer, an adjuvant that stimulates iNKT cells, 
which was shown to be an effective treatment against tumours in an orthotopic murine 
glioma model (29). The vaccine depends on the reciprocal activation of iNKT cells and 
APCs and elicits an adaptive immune response dominated by CD4+ T cells that is 
tumour-specific and long lasting. Although evidence of cellular activation was observed in 
the spleen, the mediastinal lymph node (MdLN) was shown to be an important 
anatomical site of T-cell priming. Importantly, the principal effectors necessary for the 
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success of such a vaccine are present and functional in patients with high-grade glioma 
(29). 
 
Significantly, it was found that the α-GalCer-adjuvanted vaccine could only prevent the 
development of tumours in a therapeutic setting if suppression mediated by Tregs was 
overcome (29). This is consistent with general observations in patients, where vaccine-
mediated cancer treatment is generally insufficient to bestow long-term survival; most 
attribute this to a variety of different suppressive mechanisms driven by the tumour. In 
addition to tumour driven suppression, T cells are regulated by inhibitory signals from 
both APCs and peripheral tissues, which result in suppression of T cell responses. These 
signals are known as checkpoint molecules as they maintain self-tolerance and prevent the 
activation of autoreactive T cells. (136). Recent studies have shown that overriding these 
immune checkpoints with antibody blockade can result in sustained T cell responses, 
which induce clinical responses in patients (153, 162). While these treatments have 
validated the concept of enhancing T cell-mediated immune responses for clinical impact, 
it is clear that not all patients respond. There is therefore considerable interest in using 
vaccines to initiate anti-tumour responses (or boost weak ones), which could then 
potentially be enhanced through checkpoint blockade. 
 
In order to develop treatments for glioma, it is important that relevant in vivo models are 
utilised. Tumours injected into mice subcutaneously form solid tumour masses with 
relative ease of injection and analysis, but fail to recapitulate many of the key features of 
tumours in the brain. Additionally, tissue specific cells and physiological barriers can 
affect both tumour growth, and the ability of a tumour to respond to therapies. Microglia, 
the brain-resident macrophages, are known to take on both pro- and anti-tumourigenic 
capacities depending on their activation status (334, 335). As these cells are present in the 
natural site of tumour development, it is likely that they will play a role in therapies aimed 
at activating the immune system (336, 337). Additionally, the BBB was thought to inhibit 
the trafficking of immune cells into the brain and CNS (104, 330, 331, 338). The recent 
discovery of lymphatic vessels within the dura mater and meninges of the brain has 
revealed a previously undocumented route of lymphatic drainage from the brain. 
Previously, antigen within the brain was observed to drain within the cerebrospinal fluid 
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(CSF), via the olfactory bulbs, along the cribriform palate and terminating in the 
superficial cervical lymph nodes. However, the identification of lymphatic vessels within 
the dura mater has revealed lymphatic drainage directly to the deep cervical lymph nodes, 
independent of the CSF (339, 340). It is now clear that there is a direct link between the 
immune system and the CNS, facilitating both a means for antigenic drainage as well as a 
conduit to permit lymphocyte entry to the brain. 
 
In order to best test novel immunotherapeutic approaches, utilisation of an orthotopic 
model of glioma permits the best representation of the clinical manifestation of disease. 
The three main murine tumour models currently utilised for the examination of GBM 
involve the transplantation of murine glioma cells into syngeneic mice, transplantation of 
human glioma cells into immune-compromised mice and transgenic spontaneous models 
(341). Transplantable models are advantageous for testing therapeutic regimes as they are 
highly reproducible and have a predictable growth rate and are easily monitored as they 
are injected into a known location. Further, syngeneic models permit interactions between 
the immune system and the tumour which is prohibited in immune-compromised 
xenograft models. Additionally, transplantable models are best used for immunotherapy, 
as they are likely to have accumulated the neoantigens that are required for T cell 
recognition. Transgenic models have been developed whereby genetic mutations are 
generated, recapitulating those known to occur during tumour development (342-344). 
While recapitulating tumour development from the initial mutations through to full 
presentation of disease, spontaneous formation of tumours in these models can be 
unpredictable. The tumours which do form can range from low to high grade tumours 
and penetrance can be low, sometimes with only half of the mice developing tumours 
which resemble GBM (345). Additionally, the latency period taken for tumour 
development can take months, making these models more costly and time intensive to 
examine. While useful for studying the underlying determinants of disease and tumour 
progression, spontaneous models are less practical for the development and testing of 
novel treatment regimes. 
 
Several syngeneic transgenic models exist which are either chemically induced, or were 
developed from spontaneously arising tumours. The GL261 cell line was created by the 
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injection of MCA pellets into the brains of immune-competent mice and maintained by 
serial passage of pieces of tumour tissue into the brains of recipient mice (346, 347). 
Another MCA induced model is the CT-2A brain tumour (348). CT-2A has been 
characterised and proposed as suitable for preclinical studies (349). Other transplant 
models utilised were derived from spontaneously derived glioma-like tumours. The 4C8 
tumour arose in a transgenic mouse was transplanted into an F1 cross of C57BL/6 x 
DBA/2 mice and has been used for preclinical studies (350). Finally, the spontaneous 
murine astrocytoma (SMA) arose in the VM/Dk mouse strain (351). From here, the 
SMA-560 cell line was cloned from this tumour and has been used in preclinical studies 
(352, 353). Of these aforementioned models, GL261 is the most frequently used for 
preclinical studies and has been demonstrated to replicate human GBM both 
histopathologically and biologically (354, 355). To this end, intracranial injections of the 
murine cell line GL261 have been adopted for in vivo tumour challenge experiments in 
this thesis.  
 
With the development of checkpoint blockade and other drugs aimed at targeting 
tumours to induce immunological cell death, it is imperative that these drugs are able to 
access the correct physiological site to exert their function. The BBB is a highly selective, 
permeable physical barrier, which serves to separate circulating blood from the brain 
extracellular fluid within the central nervous system (356). Formed by endothelial cells 
and maintained by astrocytes, the BBB permits the passage of water and lipid soluble 
molecules by passive diffusion, as well as the selective transport of molecules such as 
glucose and amino acids that are critical to neural function (357). In contrast to endothelia 
in the rest of the body, the endothelial cells of the BBB are devoid of fenestrations but 
have more extensive tight junctions to limit the paracellular flux of hydrophilic molecules. 
In addition to endothelial cells, the BBB is composed of the capillary basement 
membrane and pericytes with astrocytes ensheathing the vessels. Pericytes provide a key 
role in angiogenesis, structural integrity and differentiation of the barrier, as well as 
formation of the tight junctions (358). In serving its function, the BBB allows the passage 
of lipophilic substances such as oxygen and carbon dioxide (359) whereas nutrients 
including glucose and amino acids enter via transporters (357). Receptor mediated 
endocytosis is required for the uptake of larger molecules such as leptin and iron 
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transferrin (360). In maintaining its integrity, this highly selective barrier can also prevent 
the entry of antibodies as well as chemotherapeutics aimed at minimising tumour growth 
(361). 
 
Antibodies to CTLA-4 and PD-1 were recently FDA approved (153, 162, 361) and are 
currently used for the treatment of metastatic melanoma. In addition to utility for 
melanoma, both human α-CTLA-4 (ipilimumab) and α-PD-1 (nivolumab and 
pembrolizumab) are being investigated for efficacy in other malignancies. Briefly, phase II 
trials have been conducted with ipilimumab for prostate and lung cancer (362, 363) in 
addition to trials underway in NSCLC, small-cell lung cancer (SCLC) (364), bladder 
cancer (365) and hormone-refractory prostate cancer (366). Importantly, ipilimumab, in 
combination with nivolumab is being investigated in GBM patients (283). As ipilimumab 
acts by unleashing immune responses, it is likely that patients who respond best will have 
cancers with high mutational loads (367). 
 
As nivolumab acts via blockade of PD-1, antibody binding to T cells reverses the 
“exhausted” phenotype exhibited by intratumoural T cells. Again, while approved for the 
treatment of metastatic melanoma, nivolumab is also being investigated for cancers 
including lung cancer and Hodgkin’s lymphoma. Similar to CTLA-4 blockade, PD-1 
blockade is likely to be most efficacious in tumours with a high mutation load. As the 
ligand for PD-1, PD-L1, can be expressed on tumour tissue, tumour biopsies can be 
taken for histological identification of patients who are likely to respond to therapy (368). 
Nivolumab is currently in phase III clinical investigation, in combination with ipilimumab, 
for GBM (283). Also, pembrolizumab, a second FDA approved PD-1 monoclonal 
antibody is under phase II investigation for GBM both as a monotherapy, and in 
combination with bevacizumab, an antibody against VEGF-A (284). Antibodies to the 
ligand for PD-1, PD-L1, are in advanced clinical development and are also being explored 
for use in GBM (285). 
 
In addition to these molecules, many more are under preclinical development. LAG-3 is a 
potential checkpoint, which could also be targeted for antibody mediated blockade (166, 
167, 176). LAG-3 was recently discovered and is a CD4+ T cell homologue, which binds 
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to MHC-II (176). While CTLA-4 and PD-1 are primarily limited to expression on T cells, 
LAG-3 has a broader expression profile, with expression detected on T cells, B cells, NK 
cells and DCs (172-175). Thus far, LAG-3 blockade has been examined in self- and 
tumour-tolerance systems in vivo, with enhanced accumulation of CD8+ effector T cells 
(171). In this study, antibody mediated blockade of LAG-3, or genetic ablation of the Lag-
3 gene resulted in increased accumulation and effector function of CD8+ T cells within 
tissues expressing the cognate antigen (171). In addition, the effects observed were CD4+ 
T cell independent, which is intriguing as LAG-3 is a CD4 homologue (171). In another 
study, combination therapy of α-CTLA-4, α-PD-L1, α-GITR and α-LAG-3 was found 
to be ineffective as a therapy in an intracranial model of melanoma. However, the B16-
F10 model is notoriously aggressive and this may have contributed towards the failure of 
therapy in this study (369). 
 
Even if checkpoint blockade proves useful in glioma, it is likely that it will fail in many 
patients. Similarly vaccination alone is not likely to be efficacious, despite evidence that T 
cell responses can be generated. It is therefore possible that vaccination and checkpoint 
blockade will be useful to induce anti-tumour immune responses that can be further 
augmented by blocking negative regulation of T cell inhibitory pathways. Successful 
therapy assumes T cells can enter the brain and infiltrate the tumour, and may also require 
the checkpoint inhibitor to can also cross the blood brain barrier. 
3.2 Aims 
The experiments in this chapter were designed to evaluate the efficacy of vaccination 
combined with different checkpoint blockade antibodies in an intracranial glioma 
challenge model. 
 
The specific aims were: 
1. To develop a reproducible orthotopic GL261 challenge model 
2. To evaluate the anti-tumour efficacy of combining the vaccine with checkpoint 
antibodies in a therapeutic setting 
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3.3 Results 
3.3.1 Cryopreserved tumour cells implanted intracranially into immune-
competent mice are lethal within 4 weeks 
The GL261 tumour model used in this thesis were received from the National Cancer 
Institute (Frederick, MD) and subsequently authenticated genotypically (IDEXX 13512-
2014). However, there have been previous reports of rapid phenotypic changes with 
passage with this model (370), which has been observed by colleagues in my laboratory. 
Therefore, in order to conduct reproducible glioma growth experiments for this thesis, it 
was decided to bulk up a large number of cells and cryopreserve them for use in multiple 
experiments. Initial experiments were conducted to determine the dose of frozen tumour 
cells to be delivered in an intracranial setting. Previous reports used 5,000 live cells, 
harvested during exponential growth, with untreated mice typically succumbing to 
tumour burden 3 weeks post challenge (29). Using this as a reference, tumours were 
thawed from storage in liquid nitrogen and resuspended in PBS at titrated doses. Cells 
were administered under general anaesthesia and mice were left to recover before being 
monitored for signs of weight loss or neurological deficit. When weight loss exceeded 
10%, or mice exhibited signs of discomfort including decreased activity, hunched posture, 
ruffled fur or eye closure, mice were culled and presence of tumour confirmed 
macroscopically (Fig 3.1 A, B). To examine the gross tumour pathology, one mouse from 
each group was excluded from survival analysis on day 18 and the brain was harvested 
and fixed in 4% paraformaldehyde (PFA). Coronal sections were taken through the centre 
of the tumour mass for inspection. Challenge doses of 10,000 and 25,000 cells resulted in 
tumours that were still contained within the brain, however, an initial challenge dose of 
50,000 cells the tumour mass breached the surface of the brain (Fig 3.1 C). Based on this 
experiment, a dose of 25,000 frozen cells typically lead to mice succumbing to tumour 
burden 3 weeks post challenge, and this dose was used in all future experiments as it 
allowed maximal vials of cells to be frozen, without resorting to the lowest dose. To 
assess the histopathological features associated with tumour growth, a brain was 
harvested from a tumour-bearing mouse on day 20 and fixed in PFA before being H&E 
stained. Histopathology revealed a dense tumour mass with a high mitotic rate and 
infiltration into local brain tissue (Fig 3.1 D).  
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Figure 3.1 Intracranial implantation of cryopreserved tumour cells reproducibly results in tumour 
engraftment and growth. 
(A) Individual percentage weight loss for mice with titrated doses of intracranial tumours. Mice were 
injected with indicated doses GL261 glioma cells from a cryopreserved source that were thawed 
immediately before injection. Cells were injected into the right striatum at a point 2 mm lateral to the 
bregma and at a depth of 3 mm using a stereotactic frame. Mice were monitored for weight loss as a 
symptom of tumour development. (B) Symptom-free survival curves for mice with titrated doses of 
intracranial tumours. Mice were euthanised when they lost weight loss reached >10% or showed signs of 
overt behavioural changes such as hunching or reduced activity (n = 5-6). (C) Mice were challenged with 
titrated tumour doses and were sacrificed on D18 for gross-pathological assessment. Tumour development 
was confirmed by visual inspection of coronal sections through the centre of the tumour mass. Tumour 
border is outlined in black. (D) Haematoxylin and eosin analysis of a formalin-fixed, paraffin-embedded 
tumour bearing brain 20 days following challenge with 25,000 cells. Tumour mass is indicated by an arrow. 
Arrowheads on the right image indicate the tumour infiltrative border. 
 
3.3.2 Prophylactic administration of a cryopreserved vaccine prevents 
tumour growth 
By using a tumour cell line, it is possible to generate vaccines on an as-required basis. 
However, given the same considerations as above, a frozen vaccine approach was devised. 
To generate the vaccine, GL261 cells were pulsed with α-GalCer overnight, before being 
irradiated. Cells were then frozen in 10% DMSO + 90% cDMEM until use. To test the 
efficacy of this frozen vaccine approach, mice were administered a vaccine which was 
cryopreserved, or the equivalent dose of a freshly made, but not frozen vaccine, in a 
prophylactic setting. One week later, mice were challenged intracranially and monitored 
for weight loss and neurological deficit. Both the fresh and frozen vaccines protected 
mice from intracranial challenge (Fig 3.2). From here on, the term vaccine will be used to 
describe the frozen vaccine unless otherwise stated. 
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Figure 3.2 Prophylactic vaccination with cryopreserved vaccines impairs tumour development in 
an intracranial model of glioma. 
Symptom-free survival curves for mice challenged with intracranial glioma one week following intravenous 
administration of vaccines consisting of 100,000 α-GalCer-pulsed and irradiated GL261 cells (n = 10). 
Vaccines were either prepared fresh, or had been cryopreserved and thawed immediately before use. 
Controls were challenged with tumour cells only (n = 5) **** P < 0.001 (Log-Rank (Mantel Cox) test). 
Results represent two combined experiments. 
 
3.3.3 Therapeutic administration of cryopreserved vaccine does not 
prevent tumour growth 
Having determined the α-GalCer pulsed, irradiated vaccine prevent mice succumbing to 
tumour burden, experiments were performed in a therapeutic setting to examine if 
vaccine administration was sufficient to induce rejection of intracranial glioma. In this 
setting, mice were challenged intracranially before receiving either the vaccine on day 7, 
or remaining as tumour only controls. Mice were monitored for weight loss and signs of 
neurological deficit. While vaccination provided a modest but statistically significant 
survival advantage, all mice eventually yielded to tumour burden and had to be sacrificed 
(Fig 3.3). The ability of the vaccine to prevent tumour growth in the prophylactic setting, 
yet prove relatively ineffective at controlling tumour growth in a therapeutic setting 
suggests that an immune response can be induced, but in the presence of a tumour, this 
immune response is suppressed. This is in keeping with an earlier report on this type of 
vaccine where suppression was overcome to a large extent by antibody-mediated 
depletion of Tregs, which improved vaccine responses significantly, with 40-60% of mice 
surviving past day 60 (29). 
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Figure 3.3 Therapeutic vaccination is ineffective at limiting intracranial tumour growth. 
Symptom-free survival curves for mice (n = 9-14) with intracranial tumours treated with vaccine only on 
day 7 * P < 0.05 (Log-Rank (Mantel Cox) test). Results represent two combined experiments. 
 
3.3.4 PD-1 blockade combined with therapeutic vaccination is an 
ineffective therapy for orthotopic glioma 
It is now known that tumours subvert the immune system via manipulation of immune 
checkpoint molecules. For example, IFN-γ released from tumour infiltrating lymphocytes 
is known to induce the ligands for PD-1 in the tumour environment, preventing tumour 
rejection (158, 161). To test whether vaccination can be combined effectively with 
inhibiting PD-1, experiments were first conducted on established tumours that were 
implanted subcutaneously, thereby avoiding any confounding effects associated with 
accessing the brain. Thus, mice were challenged subcutaneously and allowed to form 
tumours before being treated with vaccine on day 7. The α-PD-1 antibodies were 
administered on days 10, 13 and 16 after challenge (representing days 3, 6 and 9 following 
vaccination). This dosing regime was adopted based on typical schedules from the 
literature (371, 372). In this setting, vaccination failed to eliminate established tumours. 
Interestingly, administration of α-PD-1 as a monotherapy on days 10, 13 and 16 was a 
very effective treatment for established subcutaneous tumours, and this could not be 
improved by combining with the vaccine (Fig 3.4 A). To determine if the therapeutic 
vaccination and α-PD-1 strategy could be applied to the orthotopic setting, mice were 
challenged intracranially before being treated with either vaccine immunotherapy alone 
one week later, α-PD-1 antibodies alone, or a combination of both as described for the 
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subcutaneous setting. Blockade of PD-1 both as a monotherapy and in combination with 
vaccination had no discernible effect on overall survival (Fig 3.4 B). 
 
 
Figure 3.4 PD-1 blockade combined with vaccination is an ineffective therapy for intracranial 
glioma. 
(A) Mean tumour size (± SEM) in groups of mice (n = 5) subcutaneously challenged with 106 GL261 cells 
and treated with vaccine on day 7, α-PD-1 on days 10, 13 and 16, or a combination of both **** P < 0.001 
(Two-way ANOVA with Bonferroni post-test). Results are representative of three independent 
experiments. (B) Symptom-free survival curves for mice (n = 4) with intracranial tumours treated with 
vaccine alone on day 7, α-PD-1 on days 10, 13 and 16, or a combination of both. Results are representative 
of three independent experiments. 
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3.3.5 LAG-3 blockade combined with therapeutic vaccination is an 
ineffective therapy for subcutaneous and orthotopic glioma 
Blocking antibodies to LAG-3 are currently in clinical trials for haematological 
malignancies (373) and combination therapy with PD-1 and LAG-3 blockade has shown 
preclinical efficacy (374-376) and are in clinical trials for solid tumours (190). Given this 
level of clinical development, checkpoint blockade with anti-murine LAG3 antibodies (α-
LAG-3) was evaluated here. Initial experiments were performed on mice challenged 
subcutaneously. Therapy started on day 7 and consisted of vaccination, α-LAG-3 
antibody administration, or combination therapy. For antibody treatment, mice received a 
0.5 mg bolus dose of α-LAG-3 on day 7 after challenge, with 3 doses of 0.25 mg each 
administered every three days thereafter. In contrast to PD-1 blockade, no effect on 
subcutaneous tumour growth was observed (Fig 3.5 A). To test for efficacy in the 
orthotopic setting, mice were challenged intracranially and received the same treatment 
schedule as for subcutaneous tumours. Similar to PD-1 blockade, no survival advantage 
was observed when LAG-3 blockade was combined with therapeutic vaccination (Fig 3.5 
B). 
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Figure 3.5 LAG-3 blockade combined with vaccination is an ineffective therapy for intracranial 
glioma. 
(A) Mean tumour size (± SEM) in groups of mice (n = 5) subcutaneously challenged with 106 GL261 cells 
and treated with vaccine on day 7, α-LAG-3 on days 6, 9, 12 and 15, or a combination of both. Results are 
representative of two independent experiments. (B) Symptom-free survival curves for mice (n = 4-5) with 
intracranial tumours treated with vaccine alone on day 7, α-LAG-3 on days 6, 9, 12 and 15 or a 
combination of both. Results are representative of two independent experiments. 
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3.3.6 CTLA-4 blockade combined with therapeutic vaccination confers 
long-term survival in mice with subcutaneous and orthotopic 
glioma 
In addition to PD-1, antibodies targeting the CTLA-4 pathway have received recent FDA 
approval. Again, initial experiments were performed in the subcutaneous setting. Mice 
were challenged subcutaneously and received a single dose of α-CTLA-4 administered by 
intraperitoneal injection one day prior to vaccination (day 6 after tumour challenge), or 
three days after vaccination (day 10 following challenge). This dosing schedule was based 
on a report showing increased accumulation and activation of adoptively transferred 
antigen specific T cells in the lymph nodes of mice immunised with peptide loaded DCs 
(377). Each of these treatment schedules induced complete tumour regression after an 
initial period of tumour growth (Figure 3.6 A), although reduced tumour growth, both in 
the overall size of the tumour, as well as the growth kinetic, was observed to a greater 
extent when α-CTLA-4 was delivered prior to vaccination. To examine how CTLA-4 
blockade affects survival in the orthotopic setting, mice were challenged intracranially and 
treated with α-CTLA-4 antibody administration on day 6, vaccine immunotherapy on day 
7, or received combination treatment. While no monotherapy was effective as a sole agent, 
the combination of CTLA-4 blockade and vaccine immunotherapy conferred a long-term 
survival advantage, with 80% of mice surviving past day 60 (Fig 3.6 B). Importantly, 
antibody administration was most effective when administered close to vaccination as 
delaying administration until 3 or 7 days post vaccination (day 10 or day 14 following 
challenge) significantly impaired survival, suggesting CTLA-4 blockade was most relevant 
when delivered close to immune priming (Fig 3.6 C). 
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Figure 3.6 CTLA-4 blockade combined with vaccination is an effective therapy for intracranial 
glioma. 
(A) Mean tumour size (± SEM) in groups of mice (n = 5) subcutaneously challenged with 106 GL261 cells 
and treated with vaccine on day 7, α-CTLA-4 on days 6 or 10, or received α-CTLA-4 on day 6 and vaccine 
on day 7 * P < 0.05, ** P < 0.01, **** P < 0.001 (Two-way ANOVA with Bonferroni post-test). Results are 
representative of three independent experiments. (B) Symptom-free survival curves for mice with 
intracranial tumours treated with either vaccine alone on day 7, α-CTLA-4 alone on day 6, or both ** P < 
0.01 (Log-Rank (Mantel Cox) test. Results are representative of three independent experiments. (C) Survival 
curves for mice (n = 10) with intracranial tumours treated with vaccine on day 7 together with α-CTLA-4 
on either day 6, day 10 or day 14 **** P < 0.0001. Results represent combined data from two experiments. 
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3.3.7 Blocking CTLA-4 signalling before vaccination can induce 
radiological regression 
To determine how CTLA-4 blockade and immunotherapeutic vaccination affects tumour 
progression, radiological analyses were performed. Mice were intracranially challenged 
and treated with α-CTLA-4 on day 6, vaccination on day 7, or combined therapy. Initial 
analysis by MRI on day 20-post implantation revealed gadolinium enhanced regions in all 
mice regardless of treatment (Fig 3.7 A). In agreement with previous experiments, all 
untreated mice, and those receiving monotherapy developed glioma-associated symptoms 
and were culled within days of this analysis. In contrast, four of the five mice receiving 
combination treatment remained symptom free and could be re-imaged on day 41. Of 
these, two now showed complete loss of enhanced regions, another was markedly 
decreased in size while the last increased in size only slightly (Fig 3.7 B). 
 
 
Figure 3.7 Combining vaccination with α-CTLA-4 induces radiologic regression of established 
intracranial tumours. 
(A) Mice with intracranial tumours (n = 5) were treated with either vaccine alone on day 7, α-CTLA-4 on 
day 6, or received combination treatment. T1 weighted MR images of brains of mice were taken under 
general anaesthesia. Gadolinium was administered prior to imaging to enhance contrast and enhanced 
regions are revealed in white (B) Surviving mice underwent further MRI scans to assess tumour 
progression. Results are representative of one experiment. 
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3.3.8 Histolopathological analysis of tumours following immunotherapy 
MRI analysis on day 20 revealed large enhanced regions within the brains of mice that 
received vaccination, both in the presence and absence of CTLA-4 blockade. To 
determine if the enhanced regions observed correlated with increased tumour burden at 
this time point, a separate experiment was performed where brains were harvested for 
histopathological analysis, 20 days following challenge (Fig 3.8 A). Here, mice receiving 
combination treatment had a significantly reduced tumour size compared to untreated 
animals (Fig 3.8 B). Mice treated with vaccine or α-CTLA-4 alone had hypercellular 
tumours with a high mitotic rate, whereas mice treated with both vaccination and α-
CTLA-4 had relatively hypocellular tumours with low mitotic activity (Fig 3.8 C). 
Therefore, tumours had engrafted in all groups, but the combination treatment already 
showed some anti-tumour effect by day 20. The discrepancy in the combination 
treatment group between tumours appearing larger on MRI than the corresponding 
histology may be analogous to the phenomenon of pseudo-progression observed in 
human patients undergoing treatment for glioma as well as patients receiving checkpoint 
blockade therapy (378). 
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Figure 3.8 Histopathological characteristics of intracranial GL261 tumours following α-CTLA-4 
and vaccine immunotherapy. 
Mice with intracranial tumours (n = 5) were treated with α-CTLA-4 on day 6, vaccine on day 7, or both. 
Brains were harvested on day 20 following tumour challenge for histological analysis. (A) 
Photomicrographs of formalin-fixed paraffin-embedded coronal brain sections. Arrowheads indicate 
tumours. (B) Mean tumour area ± SEM (n = 5) was calculated per treatment group by transcribing the 
tumour perimeter for analysis by Cell^F software * P < 0.05 (One-way ANOVA with Bonferroni post-test). 
(C) Mean number of mitotic events per high power field ± SEM (n = 5) was calculated per treatment group 
by a histopathologist blinded to sample groups **** P < 0.0001 (One-way ANOVA with Bonferroni post-
test). Results are representative of one experiment. 
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3.4 Discussion 
In order to explore new therapeutic strategies for cancer, appropriate models must first 
be developed that allow the consistent growth of tumours while also properly 
recapitulating the natural site of development. Adoption of the GL261 cell line as an 
orthotopic model permits each of these parameters to be adhered to. Furthermore, the 
use of a cell line has additional advantages over spontaneous models, where mice have 
pre-disposing mutations (343), or inducible models where animals with pre-disposing 
mutations will characteristically develop a specific tumour after exposure to a given 
carcinogen, or cancer-causing agent (379, 380). Both spontaneous and inducible models 
typically rely on mutations in key tumour suppressor proteins (or are driven by transgenic 
oncogenes), resulting in tumours which develop much faster than a naturally occurring 
tumour would. Owing to this increased growth rate, tumour cells already have the 
required proliferative capacity required to outgrow the immune system. This rapid growth 
also limits the accumulation of mutations that can give rise to the neo-antigens typically 
targeted by the immune system. Transplantable models like the GL261 cell line used here 
are likely to have accumulated several neoantigens over the course of in vitro development. 
Indeed several transplantable tumours that have now been sequenced, including B16 
melanoma, 4T1 breast cancer, and CT26 colon cancer, with each showing existence of 
neoantigens that could be targeted by T cells (381). 
 
One of the goals of this chapter was to develop an intracranial tumour model that 
recapitulated much of the tumour biology seen in patients (382), but within a regular and 
reproducible timeframe. This was achieved by using a defined dose of frozen GL261 cells 
that were immediately thawed before injection. In contrast, spontaneous or inducible 
tumour models in the intracranial setting generally require a longer timeframes (several 
weeks to months), making confirmation of tumour development more difficult, and often 
requiring a luciferase reporter system or small animal MRI imaging systems for detection. 
Here, untreated GL261 tumours developed within 3 to 4 weeks, and became apparent as 
>10 % weight-loss, or overt behavioural including decreased activity, hunched posture, 
ruffled fur or eye closure. The presence of tumours was confirmed by histologic 
examination, and could easily be observed by visual inspection at necropsy. 
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Checkpoint blockade with monoclonal antibodies has ushered a new era in cancer therapy. 
Targeting the immune system and not the tumour directly has opened new avenues for 
therapeutic regimes, as well as new defined end points for treatment. While so far only 
approved for melanoma, both α-CTLA-4 and α-PD-1 are showing promise in other 
malignancies including NSCLC and SCLC (364), bladder cancer (365), metastatic 
hormone-refractory prostate cancer (366). Thus far, the only cerebral malignancies tested 
have been melanoma lesions which have metastasised to the brain. In general, therapy 
was well tolerated and some activity of ipilimumab was observed when melanoma 
metastases were small and asymptomatic (383-385). Given the dire prognosis for patients 
diagnosed with high grade glioma such as GBM, and the evidence (albeit limited) that 
immune therapy can alter the course of disease (386), it is promising that clinical trials are 
now underway to evaluate checkpoint blockade immunotherapy in combination with 
currently approved interventions (284, 285, 366). 
 
However, while checkpoint blockade is showing remarkable success in metastatic 
melanoma compared to other treatments, overall response rates still remain low. As these 
antibodies are designed to amplify de novo immune responses that have developed in 
patients before treatment, the lack of responders may be a consequence of ineffective 
induction of T cell responses in the first place. There is therefore considerable interest in 
combining checkpoint blockade antibodies with vaccines to either initiate immune 
responses, or to boost weak responses. While a gp100 peptide vaccine was included in the 
clinical trial preceding FDA approval of ipilimumab, no increased efficacy was observed 
when the two therapies were combined. This highlights the necessity of integrating the 
most appropriate antigens into a vaccine strategy. The gp100 vaccine is based on 
generating responses to a commonly shared tumour-associated antigen. However, studies 
of patients who have responded to checkpoint blockade suggest that such shared antigens 
are not the predominant targets of T cell activity, and it is likely that patient-specific 
neoantigens are more relevant targets (316). Therefore, the field is currently focused on 
sequencing tumour samples to identify neoepitopes. As these neoepitopes are unique to a 
tumour specimen, they provide a patient-specific source of antigens, which must be 
considered for a vaccine strategy. Generation of patient-specific neoepitope vaccines is 
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being investigated using an RNA based vaccination approach (387, 388), and it is 
conceivable that a peptide-based approaches could be used in the future. 
 
Conversely, whole tumour cells acquired from a patient can be used, circumventing the 
time intensive DNA sequencing and epitope binding predictions required for the 
aforementioned approaches. While there is some concern a tumour sample is not a 
homologous sample of cells but rather a heterologous sample, containing immune cells 
and tumour associated stroma in addition to a heterogeneous population of tumour cells, 
whole tumour cell vaccines have been combined with BCG in a phase III trials in stage 
II/III colon cancer patients (389, 390). In these studies, delayed type hypersensitivity 
(DTH) was used as a read out of tumour specific immunity and positive responses 
(>5mm) were observed in 97% of the 254 patients enrolled. In an intent to treat analysis, 
irradiated autologous tumour cell vaccination combined with BCG reduced the rate of 
disease recurrence by 44% but overall survival was not significantly affected (390). 
Additionally, irradiated autologous whole cell vaccines combined with BCG have been 
investigated in melanoma patients with stage III/IV disease (391). In patients with 
evidence of disease during the vaccination period, no clinical responses occurred. 
However, in patients with no detectable disease, the 5-year overall survival rate was 
superior compared to historical controls (391). Interestingly, the size of the DTH-reaction 
was observed to wane with repeated non-BCG-containing vaccines, suggesting booster 
vaccines require adjuvants for effective immune induction (391). 
 
The vaccine generation protocol described in this chapter allows the rapid production of 
vaccine from the syngeneic cell line used to challenge mice. However, owing to its ease, it 
is possible that a similar approach could be adopted for the generation of a patient 
specific autologous, irradiated, whole cell vaccine from resected tumour material in a 
short timeframe, requiring only 24 hours of time in a good manufacturing practice (GMP) 
facility. Additionally, by cryopreserving the cells, the vaccine can remain frozen until 
required for administration. Current therapy for high grade glioma typically relies on 
traditional interventions consisting of surgical resection, followed by chemotherapy and 
radiotherapy to eliminate as much of the residual tumour as possible. Following this, 
vaccine immunotherapy could be applied to clear any residual cells which are either radio-
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resistant or chemo-resistant. Of course, there is no guarantee that the sample obtained 
during resection will harbour the same antigens as those remaining following 
chemotherapy and radiotherapy however this is a caveat which exists for all forms of 
vaccine immunotherapy. For this reason, implementation of multivalent vaccine 
approaches will be an effective means to limit antigenic loss following therapy. 
 
However, vaccination alone is unlikely to provide the therapeutic efficacy needed to 
eliminate significant residual tumour burden. In addition, while checkpoint blockade 
alone has resulted in remarkable success in rejuvenating the field of immunotherapy, 
overall response rates as a monotherapy are still modest. The meek response rates could 
be a result of inefficient or absent immune priming of the de novo immune responses that 
could otherwise be unleashed by checkpoint blockade. To this end, combination therapy, 
consisting of a vaccine strategy combined with checkpoint blockade represents an 
attractive means to achieve larger response rates, with the potential for application to a 
variety of different cancers. Here, data is presented showing that therapeutic vaccination 
can act to induce an immune response, which can be further improved by administration 
of α-CTLA-4 antibodies immune priming. Conversely, neither α-PD-1 nor α-LAG-3 
were able to synergise with vaccination and increase survival in an intracranial challenge 
setting. 
 
Survival benefit was not observed when α-CTLA-4 or α-PD-1 were used as 
monotherapies against established tumours in the intracranial setting. In agreement, a 
previous report showed that α-CTLA-4 as a monotherapy could not provide protection 
against intracranial GL261 tumours once established, but could induce limited protection 
when multiple treatments were started only three days after implantation. Effective 
treatment of established tumours could be achieved when α-CTLA-4 was combined with 
a vaccine comprised of GM-CSF-transfected glioma cells (392). Conversely, another 
study showed that α-CTLA alone could be used to treat SMA-560 glioma in VM/Dk 
mice (393). The authors attributed the activity of α-CTLA-4 in this model to 
enhancement of T cell-proliferative capacity, which was otherwise severely reduced in the 
presence of this tumour. While these reports adopted two distinct models, a common 
 98 
feature of these studies is that α-CTLA-4 appears to mediate its effects on glioma 
through augmentation of immune cells in the secondary lymphoid organs. In contrast, α-
PD-1 is generally thought to mediate its anti-tumour effect through preventing inhibition 
of T cells within the tumour (160, 394, 395). It is therefore likely that efficacy could be 
improved by enhancing access of blocking antibodies or other PD-1 inhibitors to effector 
cells in the brain, although strategies to improve penetrance of drugs and antibodies still 
remain in the early stages of development (396). 
 
This is a highly relevant issue, as the clinical failure of bevacizumab, an antibody to 
VEGF-A, in glioma patients may also have been due to minimal antibody penetrance 
(280, 397, 398). It may be possible that the timing of antibody delivery with radiotherapy 
could improve access to brain tumour tissue. One study has demonstrated successful 
treatment of murine glioma when administration of α-PD-1 was delivered with 
stereotactic radiation (371). In agreement with this concept, increased uptake of 
gadolinium DPTA has been observed by MRI in glioma patients following radiotherapy, 
indicating increased permeability of the blood brain barrier (399). 
 
For combination therapy to be effective, it is paramount that checkpoint blockade 
antibodies are able to bind their respective targets. CTLA-4 is expressed on T cells within 
secondary lymphoid organs following immune priming, thus systemic antibody 
administration has relatively unhindered access to bind. Conversely, while α-PD-1 and α-
LAG-3 monoclonal antibodies are showing clinical and pre-clinical efficacy respectively, 
they were unable to promote a survival advantage in the intracranial model. As both 
membrane bound and soluble forms of LAG-3 exist, it is possible that administered 
antibodies bind soluble LAG-3, impeding APC activation (400), rather than enhancing T 
cell activation (400). If this is the case, a combination of soluble LAG-3 could be 
combined with CTLA-4 blockade, theoretically enhancing both APC activation and T cell 
effector function. Whether this has merit is yet to be investigated. Additionally, this could 
be due to both the dosing regime i.e, not enough antibody to drive tumour regression, or 
limited antibody penetrance due to physical barriers, such as the blood brain barrier. In 
the absence of further improvements to penetrating the blood brain barrier, inhibitors of 
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immune checkpoints that regulate immune priming in peripheral lymphoid organs, such 
as CTLA-4 and VISTA, will likely be of more therapeutic benefit in glioma than 
inhibitors that target immune checkpoints on intratumoural effector T cells such as PD-1 
or TIM-3, unless these are combined with blood brain barrier disrupting therapies (191). 
Due to the failure of α-PD-1 and α-LAG-3 antibodies to exert efficacy when combined 
with vaccination, the combination of α-CTLA-4 with vaccination was taken further for 
characterisation. 
3.5 Conclusions 
An orthotopic GL261 model was developed as a reproducible model for intracranial 
glioma. Using this model, it was shown that an α-GalCer loaded, irradiated, whole cell 
vaccine was unable to prevent the growth of intracranially implanted GL261 unless 
combined with blocking antibodies to the immune checkpoint molecule CTLA-4. 
Blockade of CTLA-4 was ineffective as a monotherapy, suggesting that the combined 
activities of the two immunotherapies were required for tumour eradication. In contrast, 
blockade of the immune checkpoint molecules PD-1 or LAG-3 was ineffective, alone or 
in combination with vaccination. Efficacy with PD-1 blockade was observed in a 
subcutaneous model, both as a monotherapy and in combination with vaccination, 
suggesting antibody penetrance into the tumour site may be impaired by the blood brain 
barrier. 
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Chapter 4 
4  Characterising the immune response 
induced by vaccination and CTLA-4 
blockade 
4.1 General Introduction 
Cells of the innate immune system play an important role during in recognising malignant 
cells during the initial stages of transformation, and also play an essential role in 
transactivating cells of the adaptive immune system. Importantly though, the cancer 
immune-editing hypothesis states tumour clearance is critically dependent on T cells (401, 
402). Indeed, it is now apparent that the extent of T cell infiltration into a tumour is 
indicative of how a patient is likely to respond to therapy (79). Thus, to generate an 
effective anti-tumour response, vaccination must induce a T cell response. Previous 
studies have shown α-GalCer loaded, irradiated whole tumour cell vaccines in a variety of 
different tumours can activate T cells (29, 403-406). Interestingly, in the GL261 glioma 
model anti-tumour efficacy was dependent on activation of CD4+ T cells, provided that 
Tregs were depleted (29, 403). In the previous chapter, combination of this vaccine 
therapy with CTLA-4 blockade was also seen to provide therapeutic efficacy. In this 
chapter, the character of the immune responses elicited in this efficacious response is 
investigated. 
 
While CTLA-4 functions to maintain immune homeostasis and attenuate T cell 
costimulation following antigen recognition, there is some controversy as to the 
mechanism of action of antibody-mediated blockade in an immunotherapeutic setting. 
Initial studies identified CTLA-4 as part of the family of costimulatory receptors on T 
cells, and it was thought to permit an additional activatory T cell signal (138, 407). 
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However, genetic ablation studies in mice revealed a fatal lymphoproliferative phenotype 
driven by CD4+ T cells, resulting in multi-organ tissue destruction (136, 408). Indeed, a 
similar phenotype is observed with humans whereby mutations in the CTLA-4 gene 
present as a disease referred to as common variable immunodeficiency (CVID) with 
symptoms including autoimmunity, granulatomous disease and other malignancies (409). 
Later studies revealed that CTLA-4 serves to compete for binding to CD80 and CD86, 
inhibiting the costimulatory signal afforded to T cells (139). As CTLA-4 binds with higher 
affinity to CD80 and CD86 than CD28, ligation of the CTLA-4 receptor activates an 
intracellular cascade, resulting in inhibition of IL-2 secretion and reduced T cell activation 
resulting in cell cycle arrest (147). 
 
While the initial premise was that CTLA-4 blockade functioned via an effector cell 
intrinsic mechanism, with antibody mediated blockade of inhibitory signals resulting in 
enhanced effector T cell function, the demonstration that Tregs express high levels of 
CTLA-4 raised the suggestion that α-CTLA-4 antibodies could also have effector T cell 
extrinsic mechanisms (151). A principal feature of Tregs is the constitutive expression of 
CTLA-4 and thus, they remain a prime target for antibody binding, therefore, it is likely 
that α-CTLA-4 antibodies bind not only primed effector T cells but Tregs also.  
 
Other suppressive mechanisms of CTLA-4 that are extrinsic to the activated T cell itself 
have been previously described. Dominant protection against fatal lymphoproliferation 
was observed by WT mixed chimerism following bone marrow transfer using CTLA-4-/- 
and WT donors, suggesting that the proliferative phenotype of T cells without CTLA-4 
can be controlled by external factors from wild-type cells (410). It has also been shown 
that CTLA-4 blockade negates the protection afforded by Tregs in a colitis model where 
adoptive transfer of CD4+ CD45RBhigh (naïve, wild-type) cells into immune-deficient 
hosts results in severe colitis (411, 412), indicating that Tregs are required for 
maintenance of T cell homeostasis and this is dependent on the expression of CTLA-4. 
 
Each of these models is confounded by the inability to differentiate between the 
independent effects CTLA-4 blockade has on effector T cells and Tregs. To overcome 
this, a model system was developed whereby the extracellular domain of human CTLA-4 
 103 
was combined with the mouse transmembrane and intracellular signalling domain (151). 
Human CTLA-4 is capable of interacting with mouse CD80/86 molecules, however 
antibody administration affects either mouse or human CTLA-4 independently, 
permitting uni-compartmental blockade of CTLA-4 on effector T cells or Tregs 
individually. When applying this system to a melanoma tumour model, it was shown that 
blockade of CTLA-4 on both effector T cells and Tregs, combined with therapeutic 
vaccination was required for effective anti-tumour activity (151). Indeed, earlier studies 
have shown ligation of CTLA-4 on Tregs results in TGF-β production, dampening 
effector CD4+ T cell responses (411).  
 
In addition to the effects on T cells, CTLA-4:CD86 binding also drives a signal within the 
APC, resulting in upregulation of IDO (413, 414). As a catabolic enzyme, IDO converts 
the essential amino acid tryptophan to N-formylkynurine, limiting immune responses in 2 
distinct approaches (415). Firstly, in catabolising tryptophan, activated T cells are starved 
of an essential amino acid, required for rapid proliferation (415). Secondly, the 
accumulation of kynurenines within the local microenvironment acts to be directly 
immunosuppressive via apoptosis of T cells. Interestingly, apoptosis was unique to Th1 
cells, as Th2 cells subjected to the same assay remained unaffected (416). 
 
Further cell extrinsic mechanims relating to APC function include the trans-endocytosis 
of costimulatory molecules. Trans-endocytosis is the biological process whereby material 
from one cell undergoes endocytosis and enters another cell. In a resting state, activation 
of APCs is limited via trans-endocytosis of surface CD80 and CD86 from APCs into 
intracellular compartments within CTLA-4-expressing Tregs where they are degraded, 
preventing immune activation (417). Importantly, this phenomenon was observed in both 
murine and human systems. In accordance with the upregulation of CTLA-4 following T 
cell activation, TCR stimulated CD4+ T cell blasts promoted trans-endocytosis of CD86 
in this in vitro system (417). Finally, CD86 capture was observed in vivo using adoptive 
transfer of CD86-GFP transduced BALB/c RAG2-/- bone marrow into BALB/c RAG2-/- 
recipients, permitting the development of CD86-GFP APCs. CD4+ T cells from CTLA-
4+/+ or CTLA-4-/- mice, specific for the H-2d binding domain of OVA protein (DO11.10 
cells) were then transferred and hosts were subsequently challenged with OVA protein. 
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Here, internalisation of CD86-GFP was only observed in mice harbouring CTLA-4+/+ 
CD4+ T cells which had been challenged with OVA peptide (417). Further studies have 
expanded on this concept, suggesting that for a T cell to become activated, the amount of 
ligand on the APC relative to the amount of CTLA-4 on T cells should dictate whether 
the threshold for CD28 costimulation is achieved (418). 
 
Clinically, there is some evidence to suggest that melanoma patients receiving ipilimumab 
have a broadened T cell response. That is, the increased numbers of peripheral blood 
effector T cells are a result of a increased melanoma reactive T cell responses, with a 
varied TCR diversity, as opposed to an increase in the magnitude of a single TCR clone, 
suggesting that patients receiving ipilimumab have a lower threshold for T cell activation 
(154). By using tetramer technology to analyse specific T cell responses in patients pre- 
and post-therapy, Kvistborg and colleagues identified α-CTLA-4 therapy to selectively 
induce novel CD8+ T cell responses (154). Importantly, the newly detected T cell 
responses were shown to have anti-tumour activity when co-cultured with tumour lines 
known to express the TCR relevant antigen (154). 
 
A common observation between studies is the increase in the ratio of effector T cells to 
Treg cells within tumours, or within the peripheral blood of patients during clinical 
studies, with this expansion thought to be a result of preferential proliferation of effector 
T cells over Tregs (419-421). While the primary targets of blocking antibodies remain to 
be the surface receptors they are targeted against, receptor-mediated recognition of the 
fragment crystallisable region (Fc region) of the antibody can also occur. Macrophages 
express high levels of Fc receptors, facilitating antibody-dependent cell-mediated 
cytotoxicity (ADCC). Studies investigating the interplay between α-CTLA-4 antibodies 
and T cells within the tumour microenvironment have identified macrophage dependent 
depletion of Tregs (152). Here, effective depletion was reliant on the expression of 
FcγRIV on macrophages, with the clone and isotype of α-CTLA-4 antibody used 
important in mediating this effect (152). 
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Given the critical role of NKT cells in the mode of activity of the vaccines used in this 
thesis, it also important to note that NKT cells utilise, and are functionally constrained by, 
the same checkpoint receptors that regulate conventional T cells (311, 319, 422, 423). It is 
therefore possible that the efficacy of combining vaccines with checkpoint blockade may 
be through enhanced activity of iNKT cells. Furthermore, in addition to playing a role in 
initiating immune responses, iNKT cells also play a role in the regulation of host 
immunity (313, 424, 425). Following activation with α-GalCer, human iNKT cells 
produce IL-2, which, in the presence of allogeneic DCs has been observed to promote 
Treg proliferation (426). In this study, Tregs maintained immunosuppressive capacity and 
expressed high levels of intracellular CTLA-4 (426). Interestingly, the influence of 
activated NKT cells was limited to the proliferation, but not suppressive capacity of Tregs, 
as Tregs stimulated by DCs in the presence or absence of NKT cells demonstrated 
comparable levels of suppression (426). Further evidence of NKT:Treg interactions have 
been examined in a murine model of experimental autoimmune myasthenia gravis 
(EAMG) (427). Immunisation of C57BL/6 mice with the self-antigen acetylcholine 
receptor (AchR) induces EAMG (428) and development of disease is not impacted in the 
absence of NKT cells (429, 430). However, in vivo activation of NKT cells with α-GalCer 
protected mice from EAMG and this correlated with the expansion of peripheral Tregs 
(427). These Tregs expressed high levels of FoxP3 and Bcl-2 and suppressed proliferation 
and IFN-γ production of auto-reactive CD4+ T cells (427). Further, Treg mediated 
control of disease following α-GalCer administration was demonstrated using α-CD25 
depleting antibodies (427). It is therefore possible that vaccines incorporating α-GalCer 
induce Tregs as well as anti-tumour T cells, and that by combining with checkpoint 
blockade this regulatory pathway is blocked, leading to superior anti-tumour responses.  
 
There is also a body of evidence describing Treg mediated regulation of NKT cell 
activation. While Vα14 iNKT cells have been shown to promote tumour surveillance in 
some models (431), one study has shown prophylactic immunisation of mice with 
plasmids encoding auto-antigens resulted in enhanced tumour growth, which was 
attributed to the induction of Tregs that suppressed the number and activity of NKT cells 
(432). In this scenario, it is possible that vaccines incorporating α-GalCer do not 
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maximally induce iNKT cell activation, and hence observe full adjuvant activity, unless 
Treg suppression is alleviated, which may be achieved by checkpoint blockade. 
 
Altogether, combining blockade of CTLA-4 with an α-GalCer-adjuvanted vaccine could 
result in a multifaceted array of consequences, including modulating the activity of NKT 
cells, which are responsible for licensing APCs, or cell intrinsic and extrinsic mechanisms 
contributing to improved T cell function. To address this, the cellular responses induced 
following antibody-mediated CTLA-4 blockade combined with vaccination were 
examined in the murine model of glioma used in the previous chapter. 
4.2 Aims 
The experiments in this chapter were to designed to investigate the mechanism of anti-
tumour activity of combination therapy with vaccination and CTLA-4 blockade, including 
adjuvant function of NKT cells and effector functions of T cells. 
 
The specific aims were: 
1. To characterise the iNKT cell response following vaccination and CTLA-4 
blockade 
2. To assess APC activation and stimulatory capacity as a T cell-extrinsic mechanism 
contributing to the efficacy of the combined treatment  
3. To characterise the T cell response induced with vaccination combined with 
CTLA-4 blockade 
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4.3 Results 
4.3.1 Vaccine induced activation of NKT cells is not affected by CTLA-4 
blockade 
Although previous studies with the α-GalCer-adjuvanted glioma vaccine showed 
complete dependence on NKT cell function, which was attributed a requirement for the 
NKT cells to licence vaccine-bearing APCs (29), it was possible that combination with α-
CTLA-4 induced some activity that was independent of this function. To determine if 
iNKT cells were required for treatment efficacy, CD1d-/- mice were challenged and 
treated with α-CTLA-4 and vaccine combination therapy. Untreated C57BL/6 hosts 
served as tumour only controls, and treated C57BL/6 hosts served as positive controls 
for treatment efficacy. The combined therapy failed to avert tumour growth in CD1d-/- 
mice, suggesting that even in the presence of CTLA-4 blockade, the mechanism of 
activity of the vaccine was still reliant on iNKT cells, likely reflecting their capacity to 
license APCs (Fig 4.1 A). 
 
It has previously been reported that activation of iNKT cells with free α-GalCer can 
induce anti-tumour immune responses in some models (433). To assess whether cell-
associated α-GalCer can inhibit glioma growth, an α-GalCer pulsed, irradiated vaccine 
was generated using the irrelevant tumour line, Lewis lung carcinoma adapted for tissue 
culture (LLTC) which was cryopreserved in an identical fashion to the frozen vaccine 
described earlier. Mice were challenged intracranially and treated with CTLA-4 blockade 
on day 6. On day 7, they received either α-GalCer loaded and irradiated GL261 cells, or 
α-GalCer loaded and irradiated LLTC cells. Untreated mice served as tumour only 
controls. The LLTC vaccine failed to prevent tumour growth in this setting, suggesting 
that responses observed with the GL261 vaccine were not attributable to α-GalCer alone, 
but required antigen specific anti-tumour responses (Fig 4.1 B) 
 
It was possible that α-CTLA-4 targeted CTLA-4 molecules on NKT cells and enhanced 
NKT cell activation by preventing signalling through this immune checkpoint. This in 
turn may have improved the capacity of NKT cells to license APCs, and thereby improve 
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the anti-tumour responses mediated by conventional T cells. To address this, the 
proportion, number and function of iNKT cells within the spleen was assessed at various 
times following vaccination and α-CTLA-4 administration. A large population of iNKT 
cells reside within the spleen, and are therefore exposed to α-GalCer following 
intravenous vaccine administration. Blockade of CTLA-4 had no impact on either the 
proportion of iNKT cells within in the spleen, nor their number when assessed 
throughout the course of one week (Fig 4.2 A, B). 
 
As a read out of iNKT activation following therapy, IFN-γ production was assessed by 
intracellular cytokine staining and flow cytometry at various times following vaccination 
and CTLA-4 blockade. Again, no discernable difference was observed between the 
vaccine and combination treatment groups (Fig 4.3 A, B). Finally, previous reports have 
shown the α-GalCer adjuvanted whole cell vaccine can trigger NKT cell dependent 
release of IL-4 and IFN-γ into the serum, in addition to IL-12p70 which is likely derived 
from licensed APCs (29). Here, IL-4 is produced early and is derived directly from the 
activated NKT cells. While NKT cells also produce IFN-γ after activation, the bulk of the 
IFN-γ detected in the serum is derived from NK cells activated in a cytokine dependent 
manner (434, 435). No difference in the quantity or kinetics of cytokine accumulation in 
the serum were observed when α-CTLA-4 was combined with vaccination, further 
suggesting NKT cell activation was no further enhanced by blocking CTLA-4 signalling 
(Fig 4.3 C). 
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Figure 4.1 NKT cells and specific tumour antigens are required for effective combination therapy. 
Mice were intracranially challenged with GL261 and monitored for symptoms of tumour development, 
including > 10% weight loss and overt behavioural changes such as hunching or reduced activity. (A) 
Symptom-free survival curves for C57BL/6 and CD1d-/- mice (n = 6) with intracranial tumours treated with 
α-CTLA-4 on day 6 and vaccine on day 7. Untreated C57BL/6 mice (n = 5) served as tumour only 
controls. Results are representative of two independent experiments ** P < 0.01 (Log-Rank (Mantel Cox) 
test). (B) Symptom-free survival curves for C57BL/6 mice either untreated (n = 4) or treated with α-CTLA-
4 and the GL261 vaccine or α-CTLA-4 and a lung carcinoma (LLTC) vaccine (n = 5 per group) * P < 0.05 
(Log-Rank (Mantel Cox) test). 
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Figure 4.2 NKT cell numbers are not further increased following vaccine administration and 
CTLA-4 blockade. 
Mice were treated with α-CTLA-4, vaccine or combination treatment and spleens were harvested at 
indicated times following therapy. (A) Gating strategy used to enumerate NKT cells in the spleen after 
treatment with α-CTLA-4 and vaccine. (B) Mean percentage and number (± SEM) of NKT cells per 
treatment group (n = 5) at indicated times **** P < 0.001 (Two-way ANOVA with Bonferroni post-test 
Vaccine cf. α-CTLA-4) ^^^^ P < 0.001 (Two-way ANOVA with Bonferroni post-test α-CTLA-4 + 
Vaccine cf. α-CTLA-4). Results are representative of two independent experiments. 
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Figure 4.3 NKT cell activity is not enhanced following α-CTLA-4 and vaccine therapy. 
Mice were treated with either α-CTLA-4, vaccination, or both and spleens were harvested at indicated times 
following therapy. (A) Gating strategy used to enumerate NKT cells and examine IFN-γ expression in the 
spleen following therapy. (B) Mean percentage and number (± SEM) of IFN-γ producing NKT cells per 
treatment group at indicated times (n = 5) **** P < 0.001 (Two-way ANOVA with Bonferroni post-test 
Vaccine cf. α-CTLA-4) ^^^^ P < 0.001 (Two-way ANOVA with Bonferroni post-test α-CTLA-4 + 
Vaccine cf. α-CTLA-4). Results are representative of two independent experiments. (C) Mice subjected to 
the same treatment were bled at the indicated times to determine the levels of cytokines IL-4, IL-12p70 and 
IFN-γ in the serum. Mean values per group (± SEM) are shown (n = 5) ** P < 0.01 (Two-way ANOVA 
with Bonferroni post-test Vaccine cf. α-CTLA-4) **** P < 0.001 (Two-way ANOVA with Bonferroni post-
test Vaccine cf. α-CTLA-4) ^^ P < 0.01 (Two-way ANOVA with Bonferroni post-test α-CTLA-4 + 
Vaccine cf. α-CTLA-4) ^^^ P < 0.005 (Two-way ANOVA with Bonferroni post-test α-CTLA-4 + Vaccine 
cf. α-CTLA-4) ^^^^ P < 0.001 (Two-way ANOVA with Bonferroni post-test α-CTLA-4 + Vaccine cf. α-
CTLA-4). Results representative of two independent experiments. 
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4.3.2 Blockade of CTLA-4 does not enhance expression of costimulatory 
molecules on APCs in vitro 
Trans-endocytosis of costimulatory molecules CD80 and CD86 by CTLA-4 expressing 
cells has been reported to maintain low activation status of APCs during immune 
quiescence. It was therefore possible that inhibition of CTLA-4 during immune priming 
compromised this process, enhancing the costimulatory ability of APCs involved in 
activation of T cells. To explore this, an in vitro experiment was conducted in which 
expression of CD86 was examined on splenocytes from animals with or with out prior α-
CTLA-4 treatment, in co-cultures with titrated doses of the vaccine. While cultures 
containing the vaccine showed increased expression of CD86 on CD11c+ MHC-II+ DCs, 
reflecting the adjuvant activity afforded by iNKT cells within the culture, this was not 
increased when mice were pre-treated with α-CTLA-4 (Fig 4.4 A, B). Furthermore, no 
impact of combination with α-CTLA-4 was observed on other APC subsets including 
B220+ cells in a dose dependent manner (Fig 4.4 C, D). 
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Figure 4.4 CTLA-4 blockade does not enhance costimulatory molecule expression on APCs in  
v i t ro . 
Splenocytes from mice treated 24 hours earlier with α-CTLA-4 were incubated with titrated doses of 
vaccine in vitro or free α-GalCer. Expression of the activation marker CD86 was assessed 16 hours later on 
DCs, defined as B220- CD11c+ MHC-II+ cells. (A) Gating strategy used to identify DCs. (B) Mean 
Fluorescence Intensity (MFI) of CD86 (± SEM) at each vaccine dose (n = 5). Triangle indicates increasing 
dose of vaccine cells from left to right (1 x 105, 3.3 x 105, 1 x 106). (B) Gating strategy used to identify B 
Cells. (D) Mean Fluorescence Intensity (MFI) of CD86 (± SEM) at each vaccine dose (n = 5). Triangle 
indicates increasing dose of vaccine cells from left to right (1 x 105, 3.3 x 105, 1 x 106). Results are 
representative of three independent experiments.  
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4.3.3 Blockade of CTLA-4 does not enhance expression of costimulatory 
molecules on APCs in vivo 
To accompany the previous in vitro results, activation of splenic APCs was assessed in vivo 
at various times following vaccination and α-CTLA-4 administration, or following α-
CTLA-4 administration alone. Peak expression of CD80 and CD86 was observed on 
CD11c+ DCs within the spleen 24 hours following vaccination, with the highest 
expression observed in vaccinated mice which did not receive α-CTLA-4 (Fig 4.5 A-B). 
Therefore, if anything, CTLA-4 blockade was actually detrimental to DC activation in this 
setting. Although it is not clear what role activated B cells play in the priming of T cell 
responses to α-GalCer adjuvanted vaccines, it was notable that CD86 expression was 
increased on these cells with vaccination as well, and α-CTLA-4 treatment did not alter 
this. Peak expression of CD86 was observed on B cells 24 hours following vaccination 
but no difference was seen when vaccination was combined with CTLA-4 blockade (Fig 
4.5 C). 
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Figure 4.5 CTLA-4 blockade does not enhance costimulatory molecule expression on APCs in  
v ivo .  
Mice were treated with either α-CTLA-4, vaccination, or both and spleens were harvested at indicated times 
following therapy. Expression of the activation markers CD80 and CD86 was assessed on B cells, defined 
as B220+ and DCs, defined as B220-, CD11c+ (A). Gating strategy used to identify DCs and assess CD80 
and CD86 MFI. (B) Mean Fluorescence Intensity (MFI) of CD80 and CD86 (± SEM) (n = 3) at indicated 
times **** P < 0.001 (Two-way ANOVA with Bonferroni post-test Vaccine cf. α-CTLA-4) #### P < 
0.001 (Two-way ANOVA with Bonferroni post-test Vaccine cf. α-CTLA-4 + Vaccine) ^^^^ P < 0.001 
(Two-way ANOVA with Bonferroni post-test α-CTLA-4 + Vaccine cf. α-CTLA-4). (C) Gating strategy 
used to identify B cells and assess CD80 and CD86 MFI. (D) Mean Fluorescence Intensity (MFI) of CD80 
and CD86 (± SEM) (n = 3) ** P < 0.01 (Two-way ANOVA with Bonferroni post-test Vaccine cf. α-CTLA-
4) **** P < 0.001 (Two-way ANOVA with Bonferroni post-test Vaccine cf. α-CTLA-4) ^^^^ P < 0.001 
(Two-way ANOVA with Bonferroni post-test α-CTLA-4 + Vaccine cf. α-CTLA-4). Results representative 
of two independent experiments. 
 
4.3.4 Blockade of CTLA-4 does not enhance the stimulatory function of 
APCs in vitro 
While no enhanced expression of costimulatory molecules was observed following 
vaccination with CTLA-4 blockade, further experiments were conducted to elucidate if α-
CTLA-4 bestowed functional differences within the APC compartment. To this end, 
splenocytes were harvested from mice 18 hours following vaccination, α-CTLA-4 
administration, or both, and pulsed with peptide corresponding to the I-Ab-binding 
epitope of chicken ovalbumin (ISQ peptide). They were then used as APCs to stimulate 
CFSE-labelled CD4+ T cells from OT-II mice, which express a transgenic TCR specific 
for the ISQ epitope. The induction of T cell proliferation was determined by assessing 
CFSE fluorescence on the T cells by flow cytometry. As cells divide, the fluorescent 
signal is halved as CFSE is passed on to daughter cells, thus a reduction in fluorescence is 
indicative of proliferating cells. To define proliferating T cells, CFSE dilution was 
assessed relative to T cells plated in the absence of stimulator APCs (Fig 4.6A). While 
splenocytes from vaccinated mice induced increased proliferation of antigen specific T 
cells compared to splenocytes from untreated mice, or those treated with α-CTLA-4 
alone, the proportion of proliferating T cells was not affected by in vivo administration of 
α-CTLA-4 (Fig 4.6 B). This data suggests that treatment with α-CTLA-4 prior to 
vaccination does not augment the stimulatory function of APCs in this in vitro setting. 
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Figure 4.6 CTLA-4 blockade does not enhance APC function ex v ivo . 
Splenocytes from mice treated 24 hours earlier with α-CTLA-4, vaccine, or both, were pulsed with OVA323-
329 peptide for 2 hours and used to stimulate CFSE-labelled OT-II cells in vitro for 6 days. (A) The extent of 
proliferation induced was determined by examining CFSE dilution of T cells cultured with splenocytes 
(black line) relative to T cells cultured alone (shaded grey). (B) Mean percentage of proliferated cells (± 
SEM) treatment group (n = 3) are shown * P < 0.05 (One-way ANOVA with Bonferroni post-test). Results 
representative of two independent experiments. 
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4.3.5 Enhanced proliferation and accumulation of T cells with CTLA-4 
blockade and vaccination 
The expression of CTLA-4 is up-regulated early after T cell stimulation and signalling 
through this molecule is known to negatively impact on T cell proliferation in an effector 
T cell intrinsic manner. To examine if the blockade of CTLA-4 signalling affected the 
proliferation of vaccine stimulated T cells in vivo, CFSE labelled CD45.1+ congenic 
splenocytes were adoptively transferred into CD45.2+ hosts the day before treatment. 
Spleens were harvested from hosts one week later and the proliferation of transferred 
cells was assessed by flow cytometry. While vaccination alone resulted in a modest trend 
towards increased proliferation, the greatest response was observed in mice receiving 
both vaccination and α-CTLA-4 (Fig 4.7 A-D). Interestingly, significant proliferation was 
observed in both CD4+ and CD8+ T cells from mice receiving α-CTLA-4 as a 
monotherapy, suggesting inhibition of CTLA-4 is capable of releasing T cell proliferation 
in the absence of an obvious priming signal in this in vivo setting.  
 
To determine if enhanced proliferation corresponded with amplified accumulation of T 
cells in the lymphoid organs of mice receiving vaccine and CTLA-4 blockade therapy, the 
number and proportion of T cells in the spleen were assessed on different days following 
therapy. Cellularity was significantly increased after three days in mice receiving vaccine 
alone compared to untreated controls and this was reduced to normal levels by day 7. The 
most pronounced increase was observed in mice receiving α-CTLA-4 combined with 
vaccine, with splenic cellularity remaining increased at day 7 (Fig 4.8 A). Within the T cell 
compartment, both CD4+ and CD8+ T cells were increased in the spleen following 
combination treatment, whereas no increase was observed in the number of Tregs 
(defined as CD4+ FoxP3+ cells) (Fig 4.8 B). Intriguingly, the increased in cellularity 
involved all cell types examined but was most pronounced within the B cell compartment 
(Fig 4.8 C). While the previous adoptive transfer experiments revealed significant 
proliferation of CFSE labelled cells in mice receiving CTLA-4 as a monotherapy, this 
observation was not reflected in an increased T cell accumulation in the spleen. Therefore, 
vaccine induced stimulation was required to drive the significant lymphocyte trapping 
observed with the combined treatment group, leading to increased cellularity.  
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Figure 4.7 Combining vaccination with CTLA-4 blockade enhances T cell proliferation. 
CFSE labelled, CD45.1+ congenic splenocytes were adoptively transferred into CD45.2+ hosts which were 
subsequently treated with α-CTLA-4 on day 6, vaccine on day 7, both or remained untreated. Proliferation 
was determined by examining CFSE dilution 7 days later. (A) Representative histograms of CFSE dilution 
in transferred CD4+ T cells 7 days after vaccination. (B) Mean percentage (± SEM) of divided CD4+ T cells 
on day 7 (n = 4 per treatment group) ** P < 0.01, *** P < 0.005 (One-way ANOVA with Bonferroni post-
test). (C). Representative histograms of CFSE dilution in transferred CD8+ T cells 7 days after vaccination. 
(D) Mean percentage (± SEM) of divided CD8+ T cells on day 7 (n = 4 per treatment group). * P < 0.05, 
*** P < 0.005 (One-way ANOVA with Bonferroni post-test). Results are representative of two independent 
experiments. 
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Figure 4.8 Combining vaccination with CTLA-4 blockade enhances leukocyte accumulation in the 
spleen. 
Mice were treated with vaccine, α-CTLA-4, or both and spleens were harvested at indicated times. (A) 
Total cell count of splenocytes per treatment group (± SEM) (n = 5) * P < 0.05 (Two-way ANOVA with 
Bonferroni post-test Vaccine cf. α-CTLA-4) ^^ P < 0.01 (Two-way ANOVA with Bonferroni post-test α-
CTLA-4 + Vaccine cf. α-CTLA-4) ^^^^ P < 0.001 (Two-way ANOVA with Bonferroni post-test α-CTLA-
4 + Vaccine cf. α-CTLA-4) #### P < 0.001 (Two-way ANOVA with Bonferroni post-test Vaccine cf. α-
CTLA-4 + Vaccine) Data are representative of two independent experiments. (B) Total cell count per 
treatment group (± SEM) of FoxP3+ CD4+ T cells, CD4+ T cells and CD8+ T cells were determined on day 
7 in groups treated as in A, together with untreated controls. * P < 0.05, ** P < 0.01 (One-way ANOVA 
with Bonferroni post-test). (C) Total number of B cells, T cells and Non B and T cells (± SEM) in each 
treatment group (n = 5). Results are representative of two independent experiments. 
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4.3.6 Increased T cell effector phenotype following vaccination and 
CTLA-4 blockade 
In order to elicit an effective immune response, T cells must not only proliferate, but also 
differentiate into useful effector T cells. As T cells were highly represented in the 
increased cellularity of the lymphoid organs observed in vaccinated mice, and their 
accumulation was further enhanced with CTLA-4 blockade, additional studies were 
performed to examine their effector phenotype. Mice were culled at various times 
following vaccine, α-CTLA-4 administration, or combination treatment and effector T 
cells were assessed based on the expression of CD44 and CD62L. The CD44 antigen is a 
glycoprotein involved in cell-cell interactions, cell adhesion and migration while CD62L is 
a “homing receptor” for lymphocytes to enter secondary lymphoid tissues. These markers 
were used because their expression can be used to discriminate naïve CD44lo CD62Lhi 
cells from effector CD44hi CD62Llo T cells. A greater than 5 fold increase in effector 
CD4+ T cells (CD44hi CD62Llo) was observed in the spleens of mice treated with 
combination treatment compared to vaccine only or α-CTLA-4 monotherapy, with 
overall numbers continuing to increase until day 7 (Fig 4.9 A, B). The number of CD8+ 
effector T cells were also increased in α-CTLA-4 and vaccine treated mice compared to 
monotherapy groups, with increased cell numbers occurring at day 3 and remaining 
sustained until day 7 (Fig 4.9 C, D). Notably, the number of effector CD8+ T cells was 
lower than CD4+ T cells. 
 
While the glioma vaccine used is known to induce immune responses in the spleen (29), 
prophylactic vaccination in splenectomised mice still resulted in effective anti-tumour 
responses which was attributed to immune priming occurring in the lung draining lymph 
nodes (29). To explore whether such priming was occurring in combination with CTLA-4 
blockade, the mediastinal lymph nodes were assessed 7 days following vaccination, α-
CTLA-4, or combination therapy. Overall cellularity was increased in vaccinated mice in 
the presence and absence of α-CTLA-4 administration (Fig 4.10 A). Similarly to the 
spleen, the number of Tregs was comparable between treatment groups (Fig 4.10 B). To 
quantify effector T cells, the expression of CD44 on CD4+ FoxP3- and CD8+ T cells was 
used. Vaccination resulted in increased effector CD4+ and CD8+ T cells compared to 
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naïve mice, with vaccine only treated mice also having an increased effector CD8+ T cells 
compared to α-CTLA-4 only mice. The most profound increase was observed in both 
CD4+ and CD8+ T cells in mice that received the combined treatemnt (Fig 4.10 B). As 
increased numbers of effector T cells could not account for the overall increase in 
cellularity within the MdLN, the remaining cells were quantified. As observed in the 
spleen, an increase was observed in all cell types examined, possibly reflecting trapping 
due to reduced egress (Fig 4.10). 
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Figure 4.9 Vaccine and α-CTLA-4 therapy increases the accumulation of effector T cells in the 
spleen. 
Mice were treated with vaccine, α-CTLA-4, or both and spleens were harvested at indicated times. Effector 
phenotype of T cells was assessed based on the expression of CD44 and CD62L. Effector T cells were 
defined as CD44+ CD62L-. (A) Gating strategy used to define and enumerate effector T cells on day 7 
following therapy. Examples are pregated on CD4+ T cells. (B) Total number (± SEM) of effector CD4+ T 
cells per group (n = 5) at indicated times following therapy. Significance between vaccinated mice and mice 
treated with vaccine and α-CTLA-4 is shown * P < 0.05 (Two-way ANOVA with Bonferroni post-test 
Vaccine cf. α-CTLA-4) #### P < 0.001 (Two-way ANOVA with Bonferroni post-test Vaccine cf. α-
CTLA-4 + Vaccine) ^^^^ P < 0.001 (Two-way ANOVA with Bonferroni post-test α-CTLA-4 + Vaccine 
cf. α-CTLA-4). (C) Gating strategy used to define and enumerate effector T cells on day 7 following 
therapy. Examples are pregated on CD8+ T cells. (D) Total number (± SEM) of effector CD8+ T cells per 
group (n = 5) at indicated times following therapy # P < 0.05 (Two-way ANOVA with Bonferroni post-test 
Vaccine cf. α-CTLA-4 + Vaccine) #### P < 0.001 (Two-way ANOVA with Bonferroni post-test Vaccine 
cf. α-CTLA-4 + Vaccine) ^^ P < 0.01 (Two-way ANOVA with Bonferroni post-test α-CTLA-4 + Vaccine 
cf. α-CTLA-4) ^^^^ P < 0.001 (Two-way ANOVA with Bonferroni post-test α-CTLA-4 + Vaccine cf. α-
CTLA-4) Results representative of two independent experiments. 
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Figure 4.10 Vaccine-induced immune priming within the mediastinal lymph node is enhanced 
with CTLA-4 blockade 
Mice were treated with vaccine, α-CTLA-4, combination treatment or remained untreated. Mediastinal 
lymph nodes were harvested one week following therapy and immune cells were assessed. (A) Total cell 
count (± SEM) within the MdLN (n = 5) ** P < 0.01 (One-way ANOVA with Bonferroni post-test). (B) 
Gating strategy used to identify effector CD4 and CD8 cells as well as NK cells. (C) Total cell count (± 
SEM) of CD4+ FoxP3+ T cells, CD44+ effector CD4+ T cells and CD44+ effector CD8+ T cells within the 
MdLN (n = 5) * P < 0.05, ** P < 0.01, *** P < 0.005, **** P < 0.001 (One-way ANOVA with Bonferroni 
post-test). (D) Total cell count (± SEM) of NK cells and all remaining cells within the MdLN (n = 5) * P < 
0.05 (One-way ANOVA with Bonferroni post-test). Results representative of two independent 
experiments. 
 
4.3.7 Enhanced T cell cytokine production following α-CTLA-4 and 
vaccination 
To examine whether anti-tumour effector T cells were elicited following vaccination, and 
enhanced through combination with CTLA-4 blockade, splenocytes were restimulated 
with GL261 tumour cell lysate one week following therapy and assessed for cytokine 
production. In concert with the increased effector T cells induced within the spleen 
following α-CTLA-4 and vaccine therapy, both CD4+ and CD8+ T cells proportionally 
produced higher levels of IFN-γ and TNF-α compared to each intervention alone (Fig 
4.11 A-D). While no defined tumour antigen could be evaluated using this system, the 
high proportion of T cells responding to tumour cell lysate suggests tumour-specific T 
cells were highly represented within the expanded population. 
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Figure 4.11 Combining vaccination with α-CTLA-4 enhances T cell cytokine production in the 
spleen. 
Splenocytes were harvested from mice 7 days following vaccine, α-CTLA-4, combination treament, or 
untreated controls and restimulated ex vivo with tumour lysate for 6 hours in the presence of monensin to 
prevent cytokine release. Cytokines IFN-γ and TNF-α were assessed by intracellular cytokine staining. (A) 
Gating strategy used to determine cytokine production in restimulated CD4+ T cells. Examples are pregated 
on CD4+ T cells. (B) Proportion of CD4+ T cells (± SEM) producing IFN-γ or TNF-α are shown (n = 5) * 
P < 0.05, ** P < 0.01, *** P < 0.005 (One-way ANOVA with Bonferroni post-test). (B) Gating strategy 
used to determine cytokine production in restimulated CD8+ T cells. Examples are pregated on CD8+ T 
cells. (D) Proportion of CD8+ T cells (± SEM)  producing IFN-γ or TNF-α are shown (n = 5) * P < 0.05, 
** P < 0.01 (One-way ANOVA with Bonferroni post-test). Results are representative of two independent 
experiments.  
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4.4 Discussion 
Targeting of CTLA-4 with blocking monoclonal antibodies has resulted in unprecedented 
durable clinical responses in cancer patients, most notably in advanced melanoma (436). 
In contrast, the induction of anti-tumour T cells through vaccination has been met with 
less clinical success, potentially because the induced responses are not potent or broad 
enough to generate a clinical response, or the T cells ultimately come under regulation, 
including through the same checkpoint pathways. Having observed synergy between 
CTLA-4 blockade and vaccination in a therapeutic model of glioma in the previous 
chapter, whereby 80% of mice consistently survived long term, studies were performed 
here to characterise the immune response induced following therapy. 
 
Therapeutic efficacy was lost in CD1d-/- mice suggesting that even when combined with 
α-CTLA-4, therapy was still dependent on the ability of iNKT cells to license APCs. 
Through examination of the early immune cascade involved in APC activation and T cell 
priming, therapeutic benefit of vaccination with α-CTLA-4 could not be attributed to 
improved responses to the adjuvant used. Focusing on iNKT cells, no further increase in 
cell number or activation was observed when α-CTLA-4 was combined with vaccination, 
compared to vaccine only, with comparable levels of IFN-γ production observed both in 
the presence and absence of CTLA-4 blockade. Additionally, serum cytokines IL-4, IL-
12p70 and IFN-γ, indicative of iNKT cell activation, were increased with vaccine 
administration (29), but α-CTLA-4 did not increase these further. 
 
In contrast to other studies showing anti-tumour effects mediated by α-GalCer induced 
activation of iNKT cells (433), no therapeutic efficacy was observed here when an α-
GalCer loaded, unrelated tumour cell line was used as a vaccine. This suggests that the 
anti-tumour effect was not a consequence of delivery of cell-associated α-GalCer driving 
NKT cells with direct anti-tumour activity. Rather it was an indirect effect, with NKT cell 
activation enhancing an antigen specific anti-tumour response.  
 
Following intravenous vaccination, antigens will travel via the heart to the lungs where 
antigen can be transported to the MdLN (437, 438). In the lymph node, NKT cells 
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primarily reside within the paracortex, similar to CD4+ T cells (439). Large antigens are 
retained by cells lining the subcapsular sinus and are therefore restricted from direct 
interactions with cells within the paracortex (440, 441). Within the subcapsular sinus, 
CD169+ macrophages have been shown to mediate the retention of antigen (442) and to 
also induce NKT cell localisation (439). Intriguingly, depletion of CD169+ macrophages 
by administration of clodronate liposomes abolished NKT cell proliferation and 
activation (439). In addition to inducing NKT cell arrest, CD169+ macrophages within 
the subcapsular sinus were shown to present antigen to NKT cells to an extent similar to 
that of DCs in vitro (439). Importantly, when the ability of CD169+ macrophages to 
present antigen was tested in vivo, it was found that the CD169+ macrophages, but not 
DCs or B cells, permitted activation of iNKT cells as early as 2 hours following antigen 
administration (439). In this situation, it is conceivable that macrophages within the 
subcapsular sinus induce NKT cell activation at the initiation of an immune response 
providing an inflammatory environment whereby later DC:T cell interactions favour the 
development of a Th1 immune response. Additionally, targeting vaccines to the 
subcapsular macrophages may further enhance early immune cell activation. 
 
The priming of immune responses within the lung draining lymph node is fascinating as 
recent evidence suggests T cells undergo gene-expression reprogramming within the lung. 
This was characterised as down-regulation of proliferation- and activation-associated 
genes and up-regulation of migration-associated molecules as well as chemokine and 
adhesion receptors including sphingosine 1-phosphate (S1P), integrin α4 and ninjurin 1 
(103). With the recent discovery of lymphatic vessels within the meninges, draining to the 
cervical lymph nodes (340, 443), it is conceivable that an aerosol-based vaccine could be 
adopted for malignancies of the CNS. An aerosol vaccine could potentially target both 
the cervical lymph nodes via the nasal lymphatics, as well as migratory DCs within the 
lung parenchyma which could transport antigen to the mediastinal lymph node. 
 
Vaccine antigens which are not trapped within the MdLN will continue to recirculate 
where they can accumulate in both the spleen and liver (444, 445). Arterial branches 
within the spleen terminate at he marginal sinus, allowing blood to pass through the 
marginal zone and into the red pulp (446). Such organisation allows the spleen to screen 
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blood borne antigens. Within the spleen, NKT cells are compartmentalised at the 
marginal zone and within the red pulp, where they are ideally positioned to respond to 
lipid antigen (447). Whereas NKT cells have been observed to arrest at the subcapsular 
sinus, splenic NKT cells arrest at the marginal zone 2 hours following antigen 
administration, suggesting rapid processing and presentation of antigen by APCs within 
the marginal zone permits the rapid induction of immune responses. Indeed, disruption 
of the marginal zone abrogated NKT cell responses to lipid antigen (447). Further 
interrogation of this phenomenon revealed SIGN-R1+ macrophages were able to activate 
NKT cells ex vivo, however, activation was further enhanced when DCs were used to 
stimulate NKT cell hybridomas ex vivo (447). In the current study many of the 
downstream effector activities that were observed following vaccination in the MdLN 
were also seen in the spleen, including increased overall cellularity and increased numbers 
of activated T cells. Importantly, increases in anti-tumour T cells could be more readily 
examined in this organ, as well as changes in APC function.  
 
The function of DCs can be manipulated with CTLA-4-Ig fusion proteins, where CTLA-
4 binding to CD80 and CD86 has been show to limit the ability of DCs to stimulate T 
cells, an effect that has been attributed to induction of IDO production (148). 
Additionally, aggregation of Tregs, which express CTLA-4 constitutively, around DCs 
following TCR stimulation can occur in an LFA-1 dependent but CTLA-4 independent 
manner, leading to down-regulation of CD80 and CD86 expression on DCs. This down-
regulation is dependent on CTLA-4 expression (448), with some suggesting a mechanism 
involving trans-endocytosis of surface CD80 and CD86 from APCs into intracellular 
compartments within Treg cells. Activation of both DCs and B cells in vitro was 
comparable, whether mice had been previously treated with α-CTLA-4 or not. Similarly, 
APC responses in vivo were not enhanced with the addition of α-CTLA-4. Taken together, 
these results suggest that improved APC licensing or function do not contribute towards 
the anti-tumour responses observed following α-CTLA-4 and vaccine immunotherapy. 
Perhaps this is unsurprising, as while blocking Treg:APC interactions is a plausible 
mechanism, supporting experimental evidence only exists in extremely artificial model 
systems (417, 418). 
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Having been unable to identify a role for increased APC licensing or APC function to 
contribute towards effective anti-tumour responses in mice receiving the combined 
treatment, attention was focused on the T cell response. A notable feature of the 
combined treatment was accumulation of lymphocytes in the spleen and MdLN, likely 
reflecting reduced cellular egress leading to accumulation of circulating cells within the 
secondary lymphoid organs. It is possible that the enhanced lymphocyte trapping that was 
a feature of the increased cellularity may improve responses to the vaccine by increasing 
the probability of APC:T cell contacts. The enlargement of secondary lymphoid organs in 
mice is a typical feature of antigen administration and is thought to occur through 
interactions between APCs and T cells recognising cognate antigen (449-451). In a murine 
model of herpes simplex virus (HSV) infection, CD4+ T cells were found to be critical for 
controlling lymph node input (452). In this study, CD4+ T cells were required for 
remodelling the LN afferent arteriole to a larger diameter. Additionally, draining lymph 
node enlargement following DC vaccination was dependent on MHC-II and CD40 
signalling (452). While no difference in NKT cell activation was found when comparing 
vaccinated mice to mice receiving α-CTLA-4 and vaccination, the requirement for CD40 
signalling for DC licensing and subsequent lymphocyte trapping could be a coordinated 
effort between both CD4+ T cells and NKT cells in mice receiving α-CTLA-4 and 
vaccination. 
 
The enlargement of lymphoid organs during an immune response has been attributed to 
vascular endothelial growth factor-C (VEGF-C) by activated APCs, which is required for 
lymphangiogenesis (453, 454). Increased lymphangiogenesis serves to build new 
lymphatic vessels, however lymphoid remodelling is also regulated by the fibroblast 
reticular cells (FRCs) which are found within the secondary lymphoid organs (455). The 
reticular network formed by FRCs acts to simultaneously provide strength to the tissue 
and space for movement while acting as a barrier for compartmentalisation of T and B 
cells (456). Additionally, the production of IL-7 by FRCs may provide survival signals to 
T, B and NKT cells while lymphocyte trapping is underway (457, 458). While CD4+ T 
cells and FRCs have been shown to modulate cellular ingress into secondary lymphoid 
organs, expression of the S1P within efferent lymphatic vessels influences cellular egress. 
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As S1P induces transient desensitisation of the S1P receptor 1 (S1PR1) on lymphocytes; 
recent migrants that enter secondary lymphoid organs are relatively insensitive to the S1P 
gradient (459, 460). Taken together, it is conceivable that CTLA-4 blockade could have an 
effect on enhanced cellular ingress in a DC and CD4+ T cell dependent manner and, 
reduced cellular egress as a result of continued insensitivity to S1P. 
 
Some of the increased cellularity may be explained as a result of increased cellular 
proliferation following T cell priming. To address this, adoptive T cell transfer 
experiments were conducted which showed increased proliferation of donor cells 
following α-CTLA-4 administration, or α-CTLA-4 combined with vaccination. 
Interestingly, α-CTLA-4 treatment alone showed some activity in these assays, suggesting 
that the efficacy of the combined treatment may be the result of two activities; priming of 
anti-tumour T cells by the vaccine, and removal of CTLA-4-mediated checks on the 
proliferation of anti-tumour T cells. It remains to be established whether the same T cells 
were affected in each case. In agreement with previous studies, the CD4+ T cell 
compartment was most affected with increased proliferation observed highlighting the 
role of CTLA-4 as an immune checkpoint (139, 461). Importantly, when phenotyped, the 
increased CD4+ T cells were not FoxP3+ Tregs. 
 
Further characterisation of the T cells revealed an expansion of effector T cells, based on 
the expression of CD44 and CD62L, with these cells producing effector cytokines IFN-γ 
and TNF-α following ex vivo restimulation with tumour lysate. Due to the lack of a 
defined antigen in this system, it cannot be determined if the increased effector T cell 
pool within the spleens of α-CTLA-4 and vaccine treated mice is due to antigen specific 
expansion, however, the increased proportion of cells producing IFN-γ and TNF-α 
suggests that T cells recognise antigens within the tumour lysate. 
4.5 Conclusions 
Treatment with CTLA-4 blockade combined with vaccination induces a profound 
increase in cellularity in the lymphoid organs that is not achieved with either treatment 
alone. Within this response, there is clear evidence of an enhanced T cell response. This 
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may have resulted from two activities; priming of anti-tumour T cells by the vaccine, and 
removal of CTLA-4-mediated checks on the proliferation of anti-tumour T cells. Without 
knowing the antigens targeted, it is hard to determine whether the same T cells are 
affected in each case. 
 135 
Chapter 5 
5  Mechanisms underlying successful 
therapy with CTLA-4 blockade and 
vaccine immunotherapy 
5.1 General Introduction 
The results in the previous chapter had indicated an important role for T cells in the 
effective combination of vaccine and α-CTLA-4 to treat glioma. The ability of T cells to 
kill tumour cells is dependent on their intrinsic ability to perform effector functions that 
have a direct effect on tumour growth, or to recruit or activate additional cells, which are 
in turn capable of performing anti-tumour effector functions.  
 
Activated T cells migrate towards effector sites by following chemokine gradients, with 
chemokine recognition driven by the expression of surface receptors on the cell surface 
(462). The expression of particular cell surface receptors facilitate the entry of T cells into 
specific tissues, and the site of immune priming can influence this receptor expression 
(463). The expression of VLA-4 (464) and LFA-1 (105) by T cells has previously been 
shown to be required for T cell adhesion and migration into the brain parenchyma. 
Alternatively, cells can undergo genetic reprogramming within the secondary lymphoid 
organs. For example, it has been shown that encephalitogenic T cells require passage 
through the lung draining lymph nodes, resulting in the upregulation of receptors to allow 
entry into the CNS (103). 
 
Following migration to the effector site, T cells will encounter cognate antigen presented 
on MHC-I and MHC-II within the local environment, in the context of tumour cells 
themselves, or on the tumour stroma. If the cell has been appropriately activated within 
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the lymphoid organs, recognition of MHC-peptide complexes within the tissue results in 
the specific effector function (465). T cells induce contact dependent apoptosis, resulting 
in nuclear blebbing, altered cellular morphology and eventual DNA fragmentation. The 
target cell will shed its membrane as vesicles, and continue to degrade itself from within. 
Killing can be mediated by the interaction of FasL on an effector T cell with Fas on a 
target cell, which induces apoptosis, resulting in the induction of an intracellular caspase 
cascade that ultimately leads to the activation of nucleases responsible for DNA 
fragmentation (109). In addition, cytotoxic T cells carry intracellular stores of perforins 
and granzymes that can trigger apoptosis (110, 111). The formation of a cytolytic synapse 
ensures both perforin and granzymes are delivered to a specific target cell, and acts to 
limit collateral damage to bystander cells. Following the formation of a cytotoxic synapse 
between an effector and target cell and the release of perforin, granzymes are released 
into the cytosol of the target cell, resulting in caspase-3 cleavage and activation of the 
apoptosis pathway (112).  
 
Furthermore, cytokines released by both effector T cells and other immune cells can 
induce cell death. Many cell types including T cells; NK cells, macrophages and neurons 
produce TNF-α. (114-116). Secreted TNF-α binds to the TNF receptors resulting in an 
intracellular signalling cascade, finally concluding in the recruitment of caspase-8, leading 
to caspase-mediated apoptosis (117). As well as inducing apoptosis, TNF-α release 
creates a pro-inflammatory environment; activating innate immune cells and also induces 
vascular permeability, easing immune cell extravasation (118, 119). TRAIL is a member of 
the tumour necrosis factor superfamily and is produced by most cells. Similarly to TNF-α, 
caspase-8 mediated apoptosis is induced when TRAIL binds receptors DR4 and DR5 
(120). Similarly, IFN-γ is expressed by a diverse array of cell types and inhibits tumour 
angiogenesis and has immunomodulatory functions, including inducing the upregulation 
of MHC-I and MHC-II expression on tumour cells, thereby enhancing tumour cell 
susceptibility to T cell mediated cytotoxicity (73, 121). 
 
While CD8+ T cells have been studied for their tumouricidal abilities, it is thought CD4+ 
T cells can also perform cytotoxic functions. The identification of a population of CD4+ 
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cytotoxic T cells was described using murine lymphocyte cultures in an in vitro MLR. Cells 
were observed to lyse both Fas+ and Fas- target cells and were seen to develop in Fas 
deficient mice. Conversely, CD4+ T cells derived from perforin deficient mice had 
decreased lytic capacity, indicating a primarily perforin-dependent mechanism (466). In 
agreement, CD4+ T cells with cytotoxic capacity have been isolated from human patients 
and have been observed to display a Th1 cytokine profile. Neutralising antibodies to Fas 
had no bearing on decreasing target cell lysis in an in vitro 51Cr-release assay (467). Further 
analysis of Fas-deficient families revealed granule exocytosis, but not Fas-FasL 
interactions to be the main pathway of cytotoxicity by alloantigen-specific CD4+ T cells 
(468). Intriguingly, CD4+ T cells have been shown to readily infiltrate the CNS (469), and 
are therefore likely to be required for eliciting anti-tumour immune responses. 
 
While T cells play a vital role in provoking anti-tumour immunity, successful tumour 
clearance relies on the dynamic coordination of both adaptive and innate immune cells. 
Th1 cells activate innate immune cells including macrophages recruited from the blood 
and microglia, a brain resident macrophage population, through MHC-II and CD40-
CD40L interactions (89, 90). This is thought to be a reciprocal interaction, as microglia 
have been shown to present antigen to stimulate T cell responses, albeit weakly compared 
to thymocytes (470). In addition to lymphocytes, histological analysis of human glioma 
tissue samples has revealed infiltration of both macrophages and microglia (471-473). 
Tumour associated macrophages are associated with high tumour grade and commonly 
infiltrate glioma and while the numbers and distribution of these cells vary with treatment 
and tumour severity, both macrophages and microglia have been identified in 85-100% of 
glioma tumour samples (474). Recruitment of macrophages can occur via the chemokines 
CXCL2 and CXCL5, which are produced by monocytes and macrophages and act as a 
chemotactic signal for granulocytes (475-478). The production of CXCL5 can be 
increased in the presence of IL-1 or TNF-α (478). Further, CCL3 is also known as 
macrophage inflammatory protein 1α (MIP1α) and is involved in acute inflammation and 
the recruitment of polymorphonuclear leukocytes (475). The cytokine IL-1β is an 
important mediator inflammation and is involved in an array of cellular processes 
including proliferation, differentiation and apoptosis (479, 480). 
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Macrophages are recognised as playing a role in tumour regression or progression based 
on their phenotypic and functional characteristics. A functional spectrum of macrophages 
exists, with the populations at either pole described as “M1” and “M2”. Classically 
activated macrophages, or M1 skewed macrophages arise following interactions with Th1 
CD4+ T cells, and exposure to TNF-α and IFN-γ in a pro-inflammatory environment 
(122-124) and can play an anti-tumour role. M1 macrophages also produce high levels of 
pro-inflammatory cytokines including TNF-α, IL-1, IL-6 and IL-12 and increase 
intracellular concentrations of nitrogen and oxygen radicals. As previously mentioned, 
TNF-α is an important mediator of apoptosis and vascular permeability (481, 482). 
Secretion of IL-6 by macrophages following trauma or tissue damage leads to 
inflammation (483) and induces the differentiation of monocytes from DCs to 
macrophages (484). In cancer, IL-6 has been shown to have pro-inflammatory and anti-
inflammatory roles (485). Furthermore, M1 macrophages can elicit effector function 
through the production of nitric oxide (NO) from L-arginine and increase expression of 
MHC-I and MHC-II to further activate T cells (127). 
 
Certainly, in the presence of a tumour, both macrophages and microglia can adopt an M2, 
or pro-tumourigenic phenotype and function, which limits the ability of T cells to exert 
anti-tumour responses. Similarly, the recruitment of macrophages from the blood into the 
tumour can play a role in shaping the immune response. Additionally, M2 skewed 
macrophages can play a pro-tumourigenic role, limiting inflammation by secretion of 
chemokines and cytokines including TGF-β as well as inducing immune cell death via 
secretion of oxygen free radicals (486). Arginase inhibits NO production and allows the 
production of ornithine, a precursor of hydroxyproline and polyamines. Consequently, 
arginase-producing macrophages have been associated with wound-healing (487, 488).  
 
Furthermore, M2 macrophages express the mannose receptor and IL-10, which result in 
M2 macrophages playing a role in tissue remodelling, immune modulation and tumour 
progression (127, 128). The mannose receptor CD206 is a c-type lectin primarily found 
on the surface of macrophages. Depletion of CD206 expressing macrophages has been 
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shown to exacerbate endotoxemic lung injury in mice, suggesting CD206 expression 
defined a population of anti-inflammatory macrophages (489). The lectin Ym1 is 
expressed in an IL-13 dependent manner and has been shown to promote Th2 cytokine 
expression from CD4+ T cells (488, 490). RELM-α expressing macrophages have been 
implicated in playing an immunoregulatory role within the lungs of mice treated with 
Schistosoma, with RELM-α deficient mice displaying exacerbated disease (491). 
 
In creating an inflammatory environment, macrophages promote angiogenesis, facilitating 
both tumour growth and metastatic potential (131, 132). Indeed, inhibition of the 
macrophage colony-stimulating factor (CSF-1) receptor (CSF-1R) has been shown to 
block tumour growth and regress glioma in a spontaneous murine glioma model (492). 
Differentiation of bone marrow-derived macrophages (BMDMs) in the presence of 
glioma-conditioned media stimulates the expression of M2-associated genes and this 
expression is diminished when the CSF-1R is blocked (492). 
 
Macrophages are also involved in phagocytosing blood borne antigens within the 
secondary lymphoid organs and inducing immune responses. It is therefore conceivable 
that macrophages play a role in both inducing adaptive immune responses, as well as co-
ordinating immune response at effector sites. As innate cells, macrophages respond 
rapidly to insult or injury. Accordingly, recent evidence has suggested a role for 
macrophages in facilitating the entry of T cells into the brain (493, 494). 
 
Following recruitment of T cells to the brain, T cells must transverse the BBB to enter 
the brain. The final physical barrier before complete cerebral penetrance is the glia 
limitans, which is biochemically distinct from the endothelial basement membrane. Here, 
the laminins α1 and α2 are expressed, in contrast to the α4 and α5 laminins of the 
endothelial cells (495). As previously mentioned, primary cell cultures from GBM patients 
can actively degrade tight junctions in vitro, potentiating the ability of T cells to enter the 
brain (107). Intriguingly, encepalitogenic T cells are unable to interact with laminins α1 
and α2 (495), however penetration of these the brain by these cells during EAE correlates 
with sites of focal activity of matrix metalloproteinases (MMPs). During EAE disease 
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progression, MMP-2 and MMP-9 cleave β-dystroglycan, a cell surface receptor which 
anchors astrocytes to the basement membrane, compromising the integrity of the BBB 
(494). In support, overexpression of CCL2 within the CNS parenchyma induces immune 
cell recruitment across the BBB into the perivascular space, but induction of MMP-2 and 
MMP-9 is required to liberate lymphocytes from the perivascular space and into the CNS 
parenchyma (496, 497). Altogether, macrophages within the lymphoid organs may 
contribute to the induction of adaptive immune response, with perivascular macrophages 
ensuring effective migration of T cells into the brain parenchyma, permitting tumour 
clearance. 
 
The role of T cells in anti-tumour immunity is therefore complex, and may involve direct 
tumour killing, or the coordination of killing function in other effector cells. To assess 
how T cells were involved in the effective combination of vaccine and α-CTLA-4 in the 
previous chapter, here the type of immune response induced following treatment was 
examined in some detail, including within the brain of tumour bearing mice. 
5.2 Aims 
The experiments in this chapter were designed to delineate the mechanism of action 
behind successful therapy with α-CTLA-4 and vaccine immunotherapy. 
 
The specific aims were: 
1. To examine the immune cells infiltrating intracranial tumours 
2. To analyse the effector cells responsible for tumour clearance following α-CTLA-
4 and vaccination 
3. To determine the killing mechanism utilised by the effector cells 
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5.3 Results 
5.3.1 Enhanced immune infiltrate featuring T cells in tumours of animals 
subject to vaccination with CTLA-4 blockade. 
Characterisation of peripheral immune responses in non tumour-burdened mice revealed 
the induction of potent CD4+ T cell responses. To explore the induction of adaptive 
immune responses in tumour burdened mice, an experiment was conducted to analyse 
the gross pathology of tumours in response to vaccine therapy, α-CTLA-4 administration, 
or combination therapy. Mice were intracranially challenged and treated with α-CTLA-4, 
vaccination, or combined therapy one week later. Brains were harvested one week 
following therapy and fixed in formalin before being subjected to immunohistological 
staining. Staining for CD3 revealed T cell infiltration throughout the tumour and 
surrounding stroma in all groups (Fig 5.1 A). Quantification of CD3+ cells was then 
conducted and compared to mean tumour size to calculate T cell density. Here, α-CTLA-
4 combined with vaccine therapy resulted in a significantly higher density of T cells per 
tumour compared to tumour only controls, as well as α-CTLA-4 and vaccination as 
monotherapies (Fig 5.1 B). 
5.3.2 Increased macrophages, microglia and CD4+ T cells within the 
brain of α-CTLA-4 and vaccine treated mice 
To further explore the phenotype of infiltrating immune cells, the whole brain was 
assessed by flow cytometry seven days after therapy. No obvious increase in immune 
infiltration was observed following α-CTLA-4 treatment as a monotherapy, and a trend 
towards an increased number of CD45+ immune cells was observed in brains of mice 
receiving vaccine treatment compared to tumour only controls. However statistically 
significant increases of CD45+ immune cells were observed when α-CTLA-4 was 
combined with vaccine therapy. The immune infiltrate was predominantly comprised of 
macrophages (CD45+CD11b+), microglia (CD45mid, CD11b+) and lymphocytes 
(CD45+CD11b-) (Fig 5.2 A, B). Within the T cell compartment, CD4+ T cells were mostly 
highly represented, accounting for 60-75% of all T cells within the brain (Fig 5.2 C). In 
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contrast, no differences in the numbers of CD8+ T cells or Tregs was observed within any 
of the treatment regimes (Fig 5.2 C). 
 
 
Figure 5.1 Increased intratumoural T cell infiltration following CTLA-4 blockade and vaccination. 
Mice were intracranially challenged with GL261 and treated with α-CLTA-4 on day 6, vaccine on day 7, or 
received combination treatment. On day 20, mice were culled and brains were harvested and fixed in 4% 
paraformaldehyde before being paraffin embedded for histological analysis. (A) Photomicrographs of 
formalin-fixed paraffin-embedded coronal brain sections. Arrowheads indicate CD3+ cells. (B) Mean 
density of CD3+ cells within the tumour ± SEM (n = 3-5) was calculated per treatment group * P < 0.05, ** 
P < 0.01 (One-way ANOVA with Bonferroni post-test). Results are representative of one experiment. 
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Figure 5.2 Therapeutic success of combining vaccination with CTLA-4 blockade is associated with 
accumulation of CD4+ T cells in brain. 
Mice were intracranially challenged with GL261 and treated with α-CLTA-4 on day 6, vaccine on day 7, or 
received combination treatment. On day 14, mice were culled and brains were harvested for flow cytometry. 
(A) Gating strategy used to quantify brain-infiltrating lymphocytes. (B) Mean number ± SEM of CD45+ 
immune cells, CD45+ CD11b+ macrophages and CD45mid CD11b+ microglia (n = 5) was calculated per 
treatment group * P < 0.05 (One-way ANOVA with Bonferroni post-test). Results are representative of 
two independent experiments. (C) Mean number ± SEM of CD3+ T cells, CD4+ FoxP3+ Tregs, CD4+ and 
CD8+ T cells (n = 5) was calculated per treatment group * P < 0.05, ** P < 0.01, *** P < 0.005 (One-way 
ANOVA with Bonferroni post-test). Results are representative of two independent experiments. 
 
5.3.3 Therapeutic efficacy of vaccine and α-CTLA-4 is CD4+ T cell 
dependent 
Given the robust infiltration of T cells within the brain, the dependency on T cells for 
tumours clearance was next examined. Survival experiments were conducted in mice 
deficient in MHC-II or TAP, which are unable to mount CD4+ or CD8+ T cell responses 
respectively. Mice were challenged intracranially and treated one week later with α-
CTLA-4 or α-CTLA-4 combined with vaccination. In the absence of CD4+ T cells, 
therapeutic efficacy was lost, with mice treated with the combined therapy succumbing to 
disease at a rate similar to tumour only controls (Fig 5.3 A). Strikingly, in the absence of 
CD8+ T cells, mice were able to mount an effective anti-tumour response (Fig 5.3 B). 
Taken together, these results suggest that, vaccination can be improved with CTLA-4 
blockade, resulting in effective CD4+ T cell mediated responses that are critical for the 
elimination of intracranial glioma. 
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Figure 5.3 Successful therapeutic efficacy is dependent on CD4+ T cells. 
Mice were intracranially challenged with GL261 and monitored for symptoms of tumour development, 
including > 10% weight loss and overt behavioural changes such as hunching or reduced activity. (A) 
Symptom-free survival curves for MHC-II-/- (n = 10 per group) with intracranial tumours treated with α-
CTLA-4 on day 6, or α-CTLA-4 on day 6 and vaccine on day 7. Untreated MHC-II-/- (n = 10) served as 
tumour only controls. Results represent two combined experiments. (B) Symptom-free survival curves for 
TAP-/- mice (n = 10 per group) with intracranial tumours treated with α-CTLA-4 on day 6, or α-CTLA-4 
on day 6 and vaccine on day 7. Untreated TAP -/- (n = 10) served as tumour only controls *** P < 0.005 
(Log-Rank (Mantel Cox) test). Results represent two combined experiments. 
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5.3.4 IFN-γ and perforin are required for effective α-CTLA-4 and 
vaccination therapy 
The ability of T cells to kill tumour cells is dependent on their intrinsic ability to perform 
effector functions, or to recruit or activate additional cells, which are in turn capable of 
performing effector functions. To assess the contribution of the effector molecules IFN-γ 
and perforin to α-CTLA-4 and vaccine therapeutic efficacy, C57BL/6 wild-type mice, or 
mice deficient for IFN-γ (IFN-γ KO) and perforin (Perforin KO) mice on a C57BL/6 
background were challenged intracranially and treated with α-CTLA-4 on day 6 and 
vaccination on day 7. Additionally, some mice remained untreated to assess tumour 
development in the absence of IFN-γ or perforin. Mice which were challenged but 
remained untreated succumbed to disease at a similar rate to wild-type C57BL/6 mice 
(Fig 5.4 A). In the absence of either IFN-γ or perforin, the efficacy of combined vaccine 
and checkpoint blockade was less effective, with some animals succumbing to tumour 
growth early after treatment; only 40 and 44% of mice survived past day 60 in IFN-γ or 
perforin knockouts respectively, whereas, 90% of WT mice survived past day 60 (Fig 5.4 
B). This suggests there is an additive effect between IFN-γ and perforin, with each 
effector mechanism responsible for the clearance of intracranial tumours, with the 
absence of either IFN-γ or perforin unable to completely eliminate the survival afforded 
by α-CTLA-4 and vaccination in C57BL/6 mice. 
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Figure 5.4 Therapeutic efficacy is partially dependent on IFN-γ  and perforin. 
Mice were intracranially challenged with GL261 and monitored for symptoms of tumour development, 
including > 10% weight loss and overt behavioural changes such as hunching or reduced activity. (A) 
Symptom-free survival curves for C57BL/6, IFN-γ-/- and Pfp-/- mice (n = 5 per group) with intracranial 
tumours. Results are representative of two independent experiments. (B) Symptom-free survival curves for 
C57BL/6, IFN-γ-/- and Pfp-/- mice (n = 10 per group) with intracranial tumours treated with α-CTLA-4 on 
day 6 and vaccine on day 7. Results are representative of two independent experiments * P < 0.05 (Log-
Rank (Mantel Cox) test). 
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5.3.5 Infiltration of T cells into brain in response to combined treatment 
is reduced in IFN-γ but not Perforin deficient mice 
As therapeutic efficacy was hindered in the absence of either IFN-γ or perforin, the 
induction of immune responses in response to the combined therapy was examined in 
each strain of mice and compared to WT control mice. Mice were challenged 
intracranially as described previously and received α-CTLA-4 and vaccine therapy on day 
6 and 7 respectively. The splenocytes, as well as the tumour infiltrating lymphocytes, were 
examined one week following therapy. Reduced numbers of splenocytes were observed in 
Pfp-/- mice, compared to WT, while the number of splenocytes was trending towards a 
decrease in IFN-γ-/- mice (Fig 5.5 B). In addition, a reduction in the overall numbers of 
CD4+ T cells was observed in IFN-γ-/- and Pfp-/- mice, compared to WT controls, with a 
similar trend observed within the CD8+ compartment (Fig 5.5 B, C). Despite the overall 
reduction in CD4+ T cell numbers, the number of Tregs was comparable between all 
groups. Conversely, the number of CD44+ effector CD4+ T cells was trending towards a 
decrease in the absence of IFN-γ or perforin, with a significant reduction of CD8+ 
effector T cells observed in the absence of perforin (Fig 5.5 B, C). These results suggest 
immune priming was potentially compromised in the absence of IFN-γ or perforin 
following CTLA-4 blockade and vaccination, resulting the induction of a tolerogenic 
phenotype. 
 
Within the brain, no obvious difference in the recruitment of immune cells to the brain 
could be observed, as the proportions and total number of live CD45+ leukocytes was 
comparable between all groups (Fig 5.6 A, B). However, in the absence of IFN-γ, a 
reduced proportion of CD45+ CD11b- lymphocytes was observed relative to WT, with a 
concurrent increase in the proportion of CD45+ CD11b+ macrophages. Despite this shift 
in the proportions of cells infiltrating the brain, no significant differences could be 
observed in the overall cellularity of these populations within the brain (Fig 5.6 A, B). 
 
Within the lymphocyte population, proportionally fewer CD4+ T cells were observed in 
the absence of IFN-γ, with trends towards a reduction in both Tregs and CD8+ T cells, 
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suggestive of a failure to recruit T cells to the brain. No differences in the total number of 
CD4+, Tregs nor CD8+ T cells was observed however, nor were significant differences 
were seen in Pfp KO mice relative to WT. (Fig 5.7 A, B). These results, together with the 
results observed in the spleen suggest ineffective immune priming and subsequent 
induction of effector function may underlie the inability of IFN-γ-/- and Pfp-/- mice to 
clear tumours. 
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Figure 5.5 Assessment of immune priming within the spleen of tumour bearing mice treated with 
CTLA-4 blockade and vaccination. 
C57BL/6, IFN-γ-/- and Pfp-/- mice were intracranially challenged with GL261 and treated with α-CLTA-4 
on day 6 and vaccine on day 7. On day 14, spleens were harvested and cell populations analysed by flow 
cytometry. (A) Gating strategy used to quantify Tregs and effector T cells (B) Mean proportion ± SEM of 
CD4+ T cells, CD4+ FoxP3+ Tregs, and CD4+ CD44+T cells (n = 5) was calculated per treatment group ** 
P < 0.01 (One-way ANOVA with Bonferroni post-test). Results are representative of two independent 
experiments. (C) Mean proportion ± SEM of CD8+ T cells and CD8+ CD44+T cells (n = 5) was calculated 
per treatment group * P < 0.05 (One-way ANOVA with Bonferroni post-test). Results are representative of 
two independent experiments. 
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Figure 5.6 Assessment of brain infiltrating lymphocytes in IFN-γ  and perforin deficient mice 
treated with vaccination and CTLA-4 blockade. 
C57BL/6, IFN-γ-/- and Pfp-/- mice were intracranially challenged with GL261 and treated with α-CLTA-4 
on day 6 and vaccine on day 7. On day 14, mice were culled and brains were harvested for flow cytometry. 
(A) Gating strategy used to quantify brain-infiltrating lymphocytes. (B) Mean proportion ± SEM of CD45+ 
immune cells, CD45+ CD11b+ macrophages and CD45mid CD11b+ microglia (n = 5) was calculated per 
treatment group *** P < 0.005 (One-way ANOVA with Bonferroni post-test). Results are representative of 
two independent experiments.   
 153 
 
Figure 5.7 Assessment of brain infiltrating lymphocytes in IFN-γ  and perforin deficient mice 
treated with vaccination and CTLA-4 blockade. 
C57BL/6, IFN-γ-/- and Pfp-/- mice were intracranially challenged with GL261 and treated with α-CLTA-4 
on day 6 and vaccine on day 7. On day 14, mice were culled and brains were harvested for flow cytometry. 
(A) Gating strategy used to quantify brain-infiltrating lymphocytes. Examples are pregated on CD45+ 
CD11b- lymphocytes. (B) Mean proportion ± SEM of CD4+ T cells, CD4+ FoxP3+ Tregs, and CD8+ T 
cells (n = 5) was calculated per treatment group ** P < 0.01, *** P < 0.005 (One-way ANOVA with 
Bonferroni post-test). Results are representative of two independent experiments. 
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5.3.6 Phenotype of the CD11b+ cells within the brain shows both M1 
and M2 skewed responses 
Tumour infiltrating macrophages and microglia were increased significantly in mice that 
had the combined treatment. It is known that these cells can be skewed towards a M2 
phenotype, which is regarded as pro-tumourigenic, or perhaps in the presence of pro-
inflammatory stimuli can acquire an anti-tumourigenic M1 phenotype. To assess the 
phenotypic changes associated with the macrophages and microglia, mice were challenged 
and treated with α-CTLA-4 and vaccination as previously described, or remained 
untreated. Brains were harvested 7 days following therapy and pooled before 
macrophages and microglia were sorted via fluorescence activated cell sorting (FACS) 
based on the expression of CD11b and CD45, allowing the discrimination between 
CD45hi macrophages and CD45mid microglia (498, 499). Purified cells were then subjected 
to RNA isolation and subsequent cDNA generation before genes associated with 
chemotaxis, M1 skewing or M2 skewing were assessed by quantitative-PCR. The relative 
expression of each gene was assessed relative to 18S control levels and then assessed as 
fold change over sham-challenged mice. 
 
Macrophages isolated from tumour-bearing mice treated with α-CTLA-4 and vaccine had 
higher relative expression of the cytokine IL-1β, and the chemokines CXCL2 and CCL3, 
compared to tumour only mice, with a similar pattern of gene expression observed in 
tumour bearing mice treated with vaccine only. Additionally, vaccine only mice also had 
higher expression of CXCL5 compared to both tumour only and α-CTLA-4 and vaccine 
treated mice (Fig 5.8 A). The relative expression of the M2 markers Arg1, RELM-α, Ym1 
and CD206 were decreased in α-CTLA-4 and vaccine treated mice compared to tumour 
only mice and mice treated with vaccine only. (Fig 5.8 B). Accordingly the relative 
expression of the M1 markers TNF-α, IL-6 and iNOS was increased in mice that 
received CTLA-4 blockade and vaccine therapy, or vaccine only over tumour only (Fig 
5.8 C). Therefore, macrophage gene expression generally reflected a bias towards an M1 
phenotype following therapy.  
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Interrogation of gene expression within the CD45mid microglia revealed increased levels of 
IL-1β, CXCL2, CXCL5 and CCL3 in α-CTLA-4 and vaccine treated mice, compared to 
vaccine only mice (Fig 5.9 A). Similarly, the relative expression of both Arg1 and RELM-
α were decreased in α-CTLA-4 and vaccine treated mice compared to tumour only and 
vaccine only mice. Conversely, the relative expression of Ym1 and CD206 was increased, 
suggesting heterogeneity between M1 and M2 populations within the microglia of these 
mice. (Fig 5.9 B). Expression of TNF-α and IL-6 was increased in combination treated 
mice compared to vaccine only and tumour only mice, however, iNOS was only increased 
in α-CTLA-4 and vaccine compared to vaccine only mice (Fig 5.9 C). The distinct gene 
expression profiles of macrophages and microglia in this setting may be a reflection of the 
role each cell is playing throughout the course of anti-tumour immunity. While M1 
macrophages are associated with tumour clearance, the heterogeneous gene expression 
revealed within microglia, consistent with M2 bias, could mean these cells act in parallel 
to limit overt local inflammation and to promote tissue repair (500, 501). 
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Figure 5.8 Increased M1 polarised macrophages within the brain following vaccine and CTLA-4 
blockade. 
Mice were intracranially challenged with GL261 and treated with vaccination on day 7, vaccination on day 7 
combined with α-CTLA-4 on day 6, or remained untreated. On day 14, mice were culled and brains were 
harvested and samples were combined for FACS. As controls, sham injected mice received PBS in place of 
tumour challenge. RNA was isolated from CD45+ CD11b+ purified cells and analysed by q-PCR. (A) 
Relative expression of cytokines and chemokines from CD45+ CD11b+ macrophages. (B). Relative 
expression of markers associated with an M2 phenotype from CD45+ CD11b+ macrophages. (C). Relative 
expression of markers associated with an M1 phenotype from CD45+ CD11b+ macrophages. 
  
 157 
 
Figure 5.9 Increased M2 polarised microglia within the brain following α-CTLA-4 and vaccine. 
Mice were intracranially challenged with GL261 and treated with vaccination on day 7, vaccination on day 7 
combined with α-CTLA-4 on day 6, or remained untreated. On day 14, mice were culled and brains were 
harvested and samples were combined for FACS. As controls, sham injected mice received PBS in place of 
tumour challenge. RNA was isolated from CD45mid CD11b+ purified cells and analysed by q-PCR. (A) 
Relative expression of cytokines and chemokines from CD45 mid CD11b+ microglia. (B). Relative expression 
of markers associated with an M2 phenotype from CD45 mid CD11b+ microglia. (C). Relative expression of 
markers associated with an M1 phenotype from CD45 mid CD11b+ microglia. 
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5.3.7 CD11b+ cells are required for α-CTLA-4 and vaccine therapeutic 
efficacy 
Macrophages and microglia have both been implicated in the pathogenesis of GBM. As 
both cell populations express CD11b, the contribution of CD11b+ cells towards 
therapeutic efficacy was assessed. Mice expressing the human diphtheria toxin receptor 
under control of the CD11b promoter were crossed to a C57BL/6 background to 
generate CD11b-DTRxC57 mice. These mice were challenged intracranially and treated 
with α-CTLA-4 on day 6 and vaccine on day 7 as previously described. In addition to 
receiving combination therapy, one group of CD11b-DTRxC57 mice also received 750 
ng diphtheria toxin (DT) every second day from day 8 to day 14 to deplete CD11b cells. 
Some CD11b-DTRxC57 mice were challenged intracranially and received no treatment, 
but received DT as above. As controls, C57BL/6 mice were challenged intracranially and 
treated with α-CTLA-4 and vaccine therapy in addition to DT as above, or remained 
untreated. Initial experiments confirmed the DT-mediated depletion of CD11b positive 
cells in the spleen and brain, with tissue samples taken on day 14 following tumour 
challenge (the day of the final DT treatment) (Fig 5.10 A). Interestingly, whereas CD11b-
DTRxC57 mice without DT could mount effective responses, in animals that were 
treated with DT to remove CD11b+ cells, this efficacy was lost. This was not an off-target 
effect of DT, as tumour growth was not affected by DT in untreated CD11b-DTRxC57 
hosts, and C57BL/6 mice receiving combination therapy and DT exhibited the expected 
tumour clearance, with long-term survival past day 60 observed (Fig 5.10 B). These 
results suggest CD11b+ cells are required for α-CTLA-4 and vaccine efficacy. 
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Figure 5.10 Successful therapy is CD11b dependent. 
C57BL/6 and CD11b-DTRxC57 mice were intracranially challenged with GL261 and monitored for 
symptoms of tumour development, including > 10% weight loss and overt behavioural changes such as 
hunching or reduced activity. (A) Gating strategy used to check CD11b+ cell depletion in CD11b-
DTRxC57 mice (n = 1-2 per group) with intracranial tumours either untreated, treated with α-CTLA-4 on 
day 6 and vaccine on day 7 or treated with α-CTLA-4 on day 6, vaccine on day 7 and 750 ng DT 
administered on days 8, 10, 12, 14. Results represent one experiment. (B) Symptom-free survival curves for 
C57BL/6 and CD11b-DTRxC57 mice (n = 5-6 per group) with intracranial tumours either untreated, 
treated with α-CTLA-4 on day 6 and vaccine on day 7 or treated with α-CTLA-4 on day 6, vaccine on day 
7 and 750 ng DT administered on days 8, 10, 12, 14. Black denotes C57BL/6 mice while green denotes 
CD11b-DTRxC57 mice * P < 0.05, ** P < 0.01, *** P < 0.005, (Log-Rank (Mantel Cox) test). Results 
represent three independent experiments. 
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5.3.8 Splenocytes from α-CTLA-4 and vaccine treated mice are cytotoxic 
in vitro 
Results from the previous chapter showed vaccination and α-CTLA-4 combination 
therapy induces a CD4+ T cell response, with CD4+ T cells capable of producing effector 
cytokines IFN-γ and TNF-α. In tumour-burdened mice, CD4+ T cells are required for 
therapeutic efficacy. Also, IFN-γ and perforin are partially required for complete vaccine 
efficacy. To examine whether T cells with cytotoxic activity were generated, splenocytes 
were harvested from mice one week following treatment and were restimulated with 
GL261 tumour cell lysate and soluble α-CD28 antibody for 4 days before tumour specific 
killing was analysed using the JAM test. Here, [3H]-thymidine-pulsed target cells were co-
cultured with titrated doses of effector cells for 4 hours, and specific killing was measured 
as a loss of [3H]-thymidine signal, reflecting DNA fragmentation in apoptotic target cells. 
 
Splenocytes from α-CTLA-4 and vaccine treated mice induced specific lysis of GL261 
target cells whereas LLTC target cells were not lysed (Fig 5.11 A). Tumour cell lysis was 
dependent on the combination treatment, as restimulated splenocytes from vaccine 
monotherapy treated mice were unable to lyse target cells. Furthermore, when the assay 
was performed with the addition of blocking antibodies to MHC-II, splenocytes from α-
CTLA-4 and vaccine treated mice were unable to perform effector function, suggesting 
the lytic activity was mediated by CD4+ T cells. Additionally, restimulated splenocytes 
from Pfp-/- mice were unable to lyse target cells (Fig 5.11 B). To further explore the role 
of CD4+ T cells in killing tumour cells, whole splenocytes from α-CTLA-4 and vaccine 
treated mice were restimulated as above, and then CD4+ T cells were purified from the 
culture and their killing ability was compared to the CD4 negative fraction. In the absence 
of CD4+ T cells, splenocytes were unable to induce tumour cell lysis. Conversely, purified 
CD4+ T cells were seen to induce tumour specific lysis, indicating a role for cytotoxic 
CD4+ T cells in this model (Fig 5.11 C). 
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Figure 5.11 CD4+ T cells are cytotoxic ex v ivo . 
C57BL/6 and Pfp-/- mice were administered α-CTLA-4 and vaccine, or received vaccine only. Splenocytes 
were harvested one week later and restimulated with GL261 lysate and soluble α-CD28 antibody for 4 days. 
Cells were co-incubated with [3H]-thymidine pulsed target cells for 4 hours and cytotoxicity was measured 
as a loss of radioactivity. (A) Mean specific lysis (± SEM) of α-CTLA-4 and vaccine treated C57BL/6 mice 
(n = 5) co-incubated with GL261 or LLTC target cells. (B) Mean specific lysis (± SEM) of α-CTLA-4 and 
vaccine treated C57BL/6 or Pfp-/- mice (n = 5) co-incubated with GL261 target cells. MHC-II signalling 
was blocked within the assay by addition of α-MHC-II. (C) Following ex vivo restimulation, CD4+ cells were 
positively selected by magnetic Dynabead selection and purity checked by flow cytometry. Mean specific 
lysis (± SEM) of CD4+ positive fraction and CD4+ negative fraction (n = 5). 
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5.4 Discussion 
Successful tumour clearance requires the intricate relationship between both the innate 
and adaptive arms of the immune system. This relationship not only exists during the 
initial stages of antigen acquisition and priming, but also during the effector phase to 
incite antigen clearance.  
 
In the previous chapter, T cell responses were shown to be involved in successful therapy 
with vaccination and checkpoint blockade, with both CD4+ and CD8+ T cell responses 
induced in the lymphoid tissues. Here it was shown that CD4+ T cells were highly 
represented within the brain infiltrating lymphocytes, suggesting they preferentially play a 
critical role in tumour clearance. Furthermore, the combined therapy was ineffective in 
MHC-II-deficient mice, further reinforcing the necessity for CD4+ T cells in eliciting an 
anti-tumour response in this model. While these cells may play a role in co-ordinating 
effector functions in MHC-II positive cells in the tumour stroma, which may explain the 
loss of treatment efficacy in the absence of CD11b+ cells, the data presented in Figure 
5.12 point to a mechanism in which the CD4+ T cells have direct anti-tumour activity 
through a cytotoxic mechanism. It remains possible that several mechanisms are involved, 
as indicated by only partial loss of activity when experiments were conducted in hosts 
deficient in perforin or IFN-γ. 
 
While CD4+ T cells were beneficial in this study, the results observed within the brain 
oppose findings in human samples whereby high CD4+ T cell infiltration is associated 
with poor prognosis (502). Typically, human GBM is highly infiltrated with CD4+ FoxP3+ 
Tregs (503), consequently the ratio of intra-tumoural CD8+ T cells to Tregs can be used 
as a predictor of clinical outcome (502). Intriguingly, enhanced IFN-γ and TNF-α 
production by CD4+ T cells, compared to CD8+ T cells, was observed in a case study of a 
patient who received a peptide vaccine in combination with temozolomide (504). Despite 
this finding, the levels of CD8+ and Tregs within the blood of the patient were monitored 
during the course of treatment. As a case study, this was performed with n = 1 and 
therefore further studies are required before concrete conclusions can be formed. 
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The failure of vaccine alone to mediate anti-tumour activity may have several causes. 
Within the tumour microenvironment, the competition for energy substrates is high, and 
tumour cells have been shown to secrete IDO to deplete T cells of tryptophan (505, 506). 
Aerobic glycolysis has been shown to be required for optimal T cell effector function 
(507), but not for activation, proliferation or survival (508). Glioma is highly dependent 
on glycolysis for energy production (509, 510), thus, tumour infiltrating cells could 
experience a loss of function as a result of glucose restriction. Using a mouse model of 
regressing and progressing sarcoma, glucose uptake by tumour cells was observed to act 
as a metabolic checkpoint, dampening the ability of T cells to respond and elicit an 
effective anti-tumour immune response (511). Importantly in relation to the current study, 
glycolysis was regained in T cells of mice bearing progressor tumours when these mice 
were treated with α-CTLA-4, α-PD-1 or α-PD-L1 (316, 511). Given the brain is a highly 
metabolic organ, and this metabolic burden is likely to be enhanced in the presence of a 
tumour, it is possible that anti-tumour immunity is blunted in tumour bearing mice 
following vaccination as a monotherapy. However, when combined with CTLA-4 
blockade, T cells have enhanced glycolysis and effector function, resulting in effective 
tumour clearance in immune-competent mice (316, 511). 
 
While previous reports in various tumour models have demonstrated an indispensible 
role for IFN-γ in mediating tumour clearance (253), tumour clearance in the setting 
presented here is not solely dependent on IFN-γ. Rather, mice deficient for IFN-γ were 
able to induce an anti-tumour response, as evidenced by prevention of tumour growth in 
some animals, and some evidence of activation of T cells within the spleen with the 
combined treatment. However, overall the anti-tumour response was significantly weaker 
than that seen WT hosts. The most striking finding here was a proportional decrease in T 
cells in the brain, suggesting IFN-γ is required for trafficking of the T cells to the 
intracranial tumour. 
 
While IFN-γ and TNF-α have direct cytotoxic effects, evidence suggests they may play a 
role in altering the BBB to enhance leukocyte migration. Endothelial cells of the BBB 
express TNFR1 (512, 513) and IFN-γ receptor (IFN-γR) (512, 514), with TNF-α 
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reported to increase IFN-γR expression (515). Both TNF-α and IFN-γ modulate the 
expression and secretion of chemokines from the BBB endothelial cells including CCL2, 
CCL3, CCL5, CXCL1, CXCL8, CXCL9, CXCL10 and CX3CL1 (513, 516, 517). These 
chemokines both augment adhesion of leukocytes to endothelial cells and permit the 
migration of leukocytes across the BBB (518-520). Stimulation of endothelia with both 
TNF-α and IFN-γ increases the expression of ICAM-1 (521) and VCAM-1 (522) as well 
as E- and P-selectins (523, 524). The interaction between VCAM-1 and ICAM-1 with 
VLA-4 and LFA-1 respectively on T cells is associated with the adhesion of CD4+ T cells 
to the BBB, and crawling, polarisation and extravasation of T cells across the BBB (469). 
Thus, the expression of TNF-α and IFN-γ permit interactions between activated 
lymphocytes and the BBB under inflammatory conditions. 
 
The requirement for CD11b+ cells for effective therapy is multifactorial. As previously 
discussed, macrophages and CD11b+ DCs within the lung can acquire glycolipid antigens 
and activate iNKT cells. Given the DT administration schedule, it is possible that 
depletion of CD11b+ cells starting on one day after priming may have compromised the 
induction of effective anti-tumour immunity. Conversely, microglia express CD11b and 
are therefore able to be depleted following DT administration, as demonstrated in Fig 
5.10. Microglia play a vital role in managing neuro-inflammation, and it is possible that in 
the absence of these cells, overt inflammation within the brain was ultimately fatal (500, 
501). In other studies, the role of macrophages in glioma pathogenesis is somewhat 
discordant. One study demonstrated increased glioma growth in mice following 
macrophage depletion. Within syngeneic mice expressing the herpes simplex virus 
thymidine kinase (HSV-TK) under control of the CD11b promoter, macrophages could 
be depleted following administration of ganciclovir. When applied to the intracranial 
GL261 model, ganciclovir administration resulted in a 45% reduction in the number of 
macrophages within the tumour, subsequently leading to a 33% increase in glioma 
volume (525). Macrophage depletion also resulted in reduced TNF-α mRNA within the 
tumour and reduced numbers of T cells (525). 
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In a separate study, macrophage ablation reduced M2-skewed macrophage populations, 
limiting glioma growth in a macrophage Fas-induced apoptosis (MAFIA) model. In this 
model, the murine CSF-1R promoter induces the expression of enhanced green 
fluorescent protein (EGFP) and a suicide fusion gene (526). Administration of AP20187, 
a synthetic cell-permeable ligand, dimerizes the suicide protein, inducing Fas mediated 
apoptosis of CSF-1R expressing cells. (527). Within the brains of these mice, 60-80% of 
GFP+ cells were Arg1+, as examined by confocal microscopy, with few iNOS+ cells 
detected (528). Depletion of CSF-1R expressing cells, from days 1-5 or days 6-10 
following intracranial challenge resulted in decreased tumour volumes and this was 
attributed to depletion of M2-like macrophages, hindering tumour progression (528). In 
accordance with this study, inhibition of CSF-1R was seen to improve overall survival and 
decrease glioma malignancy in a PDG transgenic model of glioma (492). Rather than 
depleting macrophages, administration of a specific CSF-1R inhibitor was seen to “re-
educate” macrophages, resulting in the reduction of genes associated with an M2 
phenotype (492). Clinically, macrophage infiltration has been associated with tumour 
progression, with tumour-associated macrophages M2 polarised (529, 530). Proliferation 
of the human GBM cell line T98G has been shown to increase in vitro when co-cultured 
with M2 skewed monocyte-derived macrophages (531). Enhanced proliferation was 
dependent on direct cell contact and was due to enhanced tumour cell STAT-3 signalling 
(531). 
 
It is yet to be determined if the observed phenotype of macrophages and microglia is a 
cause or consequence of T cell infiltration into the brain following CTLA-4 blockade and 
vaccine immunotherapy. Clearance of tumour tissue by infiltrating T cells could liberate 
antigen, which is phagocytosed by macrophages within the local microenvironment, with 
macrophages acting as APCs to further activate T cells and promote tumour clearance 
(532). Alternatively, CD4+ T cells could be interacting with macrophages via MHC-II, 
imparting a M1 phenotype required for tumour clearance (533). The results above suggest 
CD11b+ cells are required for vaccine and α-CTLA-4 therapeutic efficacy. Given that DT 
administration to deplete CD11b+ cells was initiated a day after vaccination, it may have 
impeded immune priming, resulting in a decreased T cell response rather than depleting 
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CD11b+ cells during the effector phase. A lack of availability of sufficient CD11b-
DTRxC57 mice precluded further analysis. 
 
The ability of CD4+ T cells to have direct cytotoxicity may suggest that treatment failure 
in mice depleted of CD11b+ cells was simply due to impaired immune priming. However 
given the abundance of evidence showing the importance of macrophages within the 
tumour microenvironment, and the loss of therapeutic efficacy following CTLA-4 
blockade and vaccination, when CD11b+ cells were depleted, the role of macrophages in 
this model cannot be completely excluded. With these considerations, targeting 
macrophages within the tumour microenvironment with drugs to modify the phenotype 
and function, or to transiently deplete cell populations may be a promising clinical 
approach, on conjunction with vaccines and checkpoint blockade antibodies to stimulate 
T cell responses. It is important that such inhibitors are tested in orthotopic models to 
determine the appropriate bioavailability behind the BBB (396). 
 
In the absence of perforin, survival benefit was again blunted, suggesting direct 
cytotoxicity mediated by the perforin and granzyme pathway is important for mediating 
tumour clearance. In fact, the weakened anti-tumour activity in IFN-γ-/- hosts may also 
reflect a limited ability of these important cytotoxic effectors to access the brain and 
eliminate tumour tissue, given evidence of failure of T cells to migrate in these animals 
(Fig 5.8). The role of cytotoxic cells was further examined using the JAM test to detect 
antigen specific killing. Whereas WT CD4+ T cells were capable of killing GL261 targets 
in vitro, this ability was lost in the absence of perforin. 
 
Taken together, this suggests a prominent role for cytotoxic CD4+ T cells in mediating 
tumour clearance in this model. Given the gene expression profile changes in 
macrophages and microglia seen in this model, it remains possible that a bias away from 
the M2-like macrophages contributes to the anti-tumour effect, while microglia polarised 
towards an M2-like phenotype may contribute to induce tissue repair and remodelling 
following tumour clearance. 
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5.5 Conclusions 
CTLA-4 blockade combined with vaccination induces increased T cell infiltration into the 
tumour of mice bearing intracranial glioma. Within the infiltrating T cell population, 
CD4+ T cells were seen to be the predominant population, with no increase in the 
number of Tregs. Macrophages were seen to be M1 skewed following combination 
treatment, and transient depletion of CD11b+ cells impaired therapeutic efficacy, however 
the relative contributions of macrophages and microglia to tumour-clearance could not be 
determined in this setting and loss of efficacy may have arisen through impaired immune 
priming. Rather, therapeutic efficacy was observed to be dependent on the presence of 
CD4+ T cells as well as the production of IFN-γ and perforin. Furthermore, CD4+ T cells 
were shown to be capable of killing tumour cells in vitro, suggesting that anti-tumour 
efficacy of combined vaccination and checkpoint blockade may be through the direct 
killing of glioma cells by CD4+ T cells. 
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Chapter 6 
6  Discussion 
Glioblastoma Multiforme is a rapidly fatal brain tumour with limited treatment options. 
While the inclusion of radiotherapy and temozoloimde chemotherapy following 
debulking surgery has extended overall survival to 12-15 months from diagnosis, patients 
ultimately succumb to disease. Given this dire prognosis, new treatment modalities are 
required. Immunotherapy is now recognised as a legitimate treatment option for 
melanoma, and is gaining traction as a therapy for many other cancers. The studies within 
this thesis challenged the principal hypothesis that the combination of vaccine-based 
immunotherapy and checkpoint blockade will result in improved immune-mediated 
tumour clearance. 
 
Using a vaccine comprised of α-GalCer loaded, irradiated whole tumour cells, it has 
previously been shown that prophylactic vaccine administration prevents tumour growth 
in both GL261 subcutaneous and intracranial challenge settings. Therapeutic efficacy 
however, required the depletion of Tregs, thus vaccine efficacy in a therapeutic setting 
required immunosuppressive mechanisms to be overcome. In the intracranial challenge 
setting, combining vaccination with blockade of CTLA-4 provided robust long-term 
protection in 80-90% of mice and was not dependent on either intervention as a 
monotherapy. The timing of antibody administration was important for successful 
treatment as delaying antibody delivery until 3 or 7 days post-vaccine significantly 
impaired long-term survival. 
 
The combination of α-CTLA-4 and vaccination induced an antigen specific anti-tumour 
response, which was dependent on the adjuvant activity of NKT cells. No enhancement 
in the phenotype or function of APCs could be ascertained with combination treatment, 
nor were Tregs depleted following antibody administration. Rather, CTLA-4 blockade 
combined with vaccination resulted in enhancement of effector cell intrinsic proliferation 
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and effector phenotype and function within the secondary lymphoid organs. In 
agreement with this, T cell infiltration into tumours was markedly increased following 
successful therapy. Within the brain, CD4+ T cells the predominant cell within the 
infiltrating lymphoid population, and were also found to be indispensible for treatment. 
Additionally, CD4+ T cells were found to be cytotoxic in vitro.  
 
While many immunotherapies largely focus on activating cytotoxic CD8+ T cells, there is 
growing acceptance of the cytotoxic capacity of CD4+ T cells. CD4+ T cell dependent 
anti-tumour responses have been described in both GL261 (534), as well as melanoma 
models (73, 535, 536). Transfer of CD4+ T cells, specific for the melanoma antigen TRP1, 
into tumour-bearing, lympho-depleted hosts induced tumour regression, which was 
further enhanced with CTLA-4 blockade. In this study, adoptive transfer of TRP1 
specific CD4+ T cells and treatment with α-CTLA-4 resulted in an increased proportion 
of TRP1+ CD4+ T cells within the blood, with a decrease percentage of TRP1+ FoxP3+ 
cells. Additionally, concentrations of IFN-γ and TNF-α were increased in the serum of 
α-CTLA-4 treated mice, with secretion attributed to CD4+ T cells (73). 
 
In addition to creating a pro-inflammatory environment, IFN-γ is known to induce the 
upregulation of MHC-II on tumour cells. Cell surface expression of MHC-II on GL261 is 
absent in vitro but can be induced in the presence of IFN-γ. Similarly, resected GL261 
cells that were implanted subcutaneously, express MHC-II ex vivo. Indeed, IFN-γ-
dependent upregulation of MHC-II on tumour cells has been shown to prepare tumour 
cells for killing in vivo (73). While previous reports in various tumour models have 
demonstrated an indispensible role for IFN-γ in mediating tumour clearance (253), 
tumour clearance in this setting is not solely dependent on IFN-γ. The altered immune 
response induced in IFN-γ-/- mice is curious. Both IFN-γ and perforin were required for 
complete tumour clearance and analysis of the induction of anti-tumour immunity, as 
evidenced by the activation of T cells within the spleen of tumour bearing animals 
revealed relatively comparable responses, suggesting immune priming is intact in these 
mice, but effector function is impeded. The most striking finding here was a proportional 
decrease of lymphocytes, particularly CD4+ T cells, and the reciprocal increase of CD45hi 
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CD11b+ macrophages within the brains of tumour bearing IFN-γ-/- mice treated with 
vaccination and CTLA-4 blockade. 
 
While IFN-γ and TNF-α have direct cytotoxic effects, the expression of TNF-α and 
IFN-γ permit interactions between activated lymphocytes and the BBB under 
inflammatory conditions. Therefore, decreased T cell infiltration into the brains of IFN-γ-
/- mice may be a consequence of reduced T cell trafficking and extravasation across the 
blood brain barrier (537). Using a gene-therapy approach to treat mice bearing intracranial 
GL26 tumours, administration of adenoviral vectors containing INF-γ or TNF-α directly 
to the tumour site offered improved overall survival over empty vector controls (538). 
Decreased tumour size correlated with increased CD4+ and CD8+ T cell infiltration, as 
well as increased MHC-I and MHC-II expression on tumour cells in vivo (538). 
Additionally, decreased FasL expression was observed on endothelial cells within tumours, 
bot not normal brain tissue (538), suggesting IFN-γ and TNF-α may facilitate immune 
cell penetration by allowing glioma-induced barriers to be overcome. Clinically, IFN-γ 
treatment, combined with low-dose cyclophosphamide has been examined in children 
bearing high-grade glioma (539). Following radiotherapy and chemotherapy, patients were 
treated daily with increasing doses of IFN-γ, with cyclophosphamide administered every 3 
weeks. While acceptable toxicities were observed in patients, combination treatment of 
IFN-γ and cyclophosphamide offered no beneficial effect in terms of overall survival in 
these patients (539). 
 
The exact role of CD11b+ cells in therapy is yet to be determined and warrants further 
investigation. Indeed, this result may suggest the CD11b+ DCs are an important subset 
for the induction of anti-tumour T cell responses in this model, which is in agreement 
with other studies showing the role of lung CD11b+ APCs for the induction of anti-
tumour immunity (439, 540, 541). To address the involvement of macrophages using 
these mice, alternate DT administration schedules, starting 3 or more days following 
immune priming may alleviate this problem. Otherwise, alternate approaches to 
specifically deplete macrophages, such as the administration of clodronate liposomes, or 
depleting antibodies could be used to dissect the relative contribution of macrophages to 
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overall anti-tumour efficacy. In either case it is likely that cells would need to be depleted 
from the periphery, before reaching the tumour site, as the presence of the BBB can limit 
drug and antibody penetrance (542). Depletion of macrophages from the periphery 
before they enter the tumour may also provide valuable insight into the relative 
contribution microglia within the CNS play in anti-tumour immunity following CTLA-4 
blockade combined with vaccination. 
 
Certainly, inducing allergic encephalopathy is a risk with vaccine strategies, and reports 
have documented in the induction of allergic encephalopathy in primates and guinea pigs 
following vaccination with human GBM in complete freund’s adjuvant (543). 
Encouragingly, no signs of adverse immune related advents were observed in tumour 
bearing mice treated with vaccination, nor were they observed in combination with 
CTLA-4 blockade, suggesting that, at least in this setting, α-CTLA-4 and vaccination 
induces potent anti-tumour responses without induction of encephalomyeopathy. This is 
in agreement with another study using α-CD25 administration combined with DC 
vaccination in SMA-560 bearing VM/Dk mice (544). Intriguingly, α-CD25 administration 
did not deplete Tregs in this study but rather impaired their suppressive ability, which is 
in agreement with other reported studies examining α-CD25 administration (544, 545). 
Conversely, Treg depletion following α-CD25 administration has been observed, as 
measured by a decrease of the number of CD4+FoxP3+ T cells in the blood (29). 
Differences between these results are likely attributed to differences in mouse genetic 
background, antibody clones and isotypes used for depletion, and the methods used to 
detect Tregs (546, 547). While depletion or modification of Treg function provides 
valuable insight into the role of Tregs in tumour-burdened hosts, no clinical Treg 
depletion method exists yet. 
 
In contrast to other studies, no survival benefit was observed when α-CTLA-4 and α-
PD-1 were used as monotherapies against established tumours in the intracranial setting. 
In keeping with this, a previous report showed that α-CTLA-4 alone could not provide 
protection against intracranial GL261 tumours once established, but could induce limited 
protection when multiple treatments were started only three days after implantation. 
 173 
Established tumours could be effectively treated when α-CTLA-4 was combined with a 
vaccine comprised of GM-CSF-transfected glioma cells (392). However, another study 
showed that α-CTLA alone could be used to treat SMA-560 glioma in VM/Dk mice 
(393). The authors attributed the activity of α-CTLA-4 in this model to enhancement of 
T cell-proliferative capacity, which was otherwise severely reduced in the presence of this 
tumour. A feature of these studies is that α-CTLA-4 appears to mediate its effects on 
glioma through alteration of immune cells in the lymphoid compartments. In contrast, α-
PD-1 is generally thought to mediate its anti-tumour effect through preventing regulation 
of T cells in the tumour (160, 394, 395). 
 
Further work within my research group has revealed that α-PD-1 can induce regression 
in subcutaneous GL261 tumours, even when they are quite large (> 100 mm in diameter, 
Lindsay Ancelet, personal communication), suggesting that this form of regulation is still 
of high relevance in glioma. It is therefore likely that efficacy could be improved by 
enhancing access of blocking antibodies or other PD-1 inhibitors to effector cells in the 
brain, although strategies to improve penetrance of drugs and antibodies still remain in 
the early stages of development (396). This is an issue of high relevance, as the clinical 
failure of antibodies to VEGF-A in glioma patients may also have been due to minimal 
antibody penetrance (280, 397, 398). It may be possible that the timing of antibody 
delivery with radiotherapy could improve access to brain tumour tissue. One study 
demonstrated successful treatment of murine glioma when administration of α-PD-1 was 
delivered with stereotactic radiation (371). In accordance with this concept, MRI of 
glioma patients following radiotherapy demonstrated increased uptake of gadolinium 
DPTA at the tumour site, indicative of increased vascular permeability (399). In the 
absence of further improvements to penetrating the blood-brain barrier, inhibitors of 
immune checkpoints that regulate immune priming in peripheral lymphoid organs, such 
as CTLA-4, OX40 and VISTA, will likely be of more therapeutic benefit in glioma than 
inhibitors that target immune checkpoints on intra-tumoural effector T cells such as PD-1 
or TIM-3 (191). 
 
 174 
It is worthwhile to note that murine tumour models do have their limitations. Although 
GL261 is used widely to assess immunotherapeutic regimes for glioma, and is described 
as the “gold standard” model for glioma (382), there are many ways in which GL261 
differs from human GBM. Histologically, GL261 tumours are highly cellular, and vascular, 
with areas of necrosis (548). Conversely, human GBM is highly invasive and readily 
infiltrates local brain tissue whereas GL261 can only be considered moderately invasive 
(548). Histology examined in Chapter 3 revealed dense infiltrating tumours with tumour 
margins extending past the periphery of the main tumour mass, supporting the 
moderately invasive phenotype. Similarly to human GBM, GL261 harbours activating 
mutations of the K-ras oncogene as well as mutations of the p53 tumour suppressor gene 
(549-552). As a tumour of glial origin, glial fibrillary acidic protein (GFAP) and S-100 
proteins can be detected by IHC staining (354). However, the expression of GFAP is 
undetected in some reports, or is only detected under special conditions (370, 553). 
Absence of GFAP expression in some research groups may be a consequence of serial 
passage number of tumour cells. 
 
Immunologically, Tregs are recruited to GL261 tumours (265, 554), reflecting the clinical 
situation (555), where Tregs actively dampen immune responses. Additionally, 
macrophages and myeloid-derived suppressor cells are recruited from the periphery to the 
tumour site and have been associated with poor clinical outcome (556, 557). Partial 
immunogenicity is conferred due to the high expression of MHC-I on GL261. As 
mentioned above, expression of MHC-II can be observed in vitro after IFN-γ exposure, 
and can also be observed ex vivo from resected tumour cells (29) whereas expression of 
CD80 and CD86 is limited (549). Evidence of immunogenicity can be observed when 
mice are subcutaneously vaccinated with at least 106 irradiated cells before intracranial 
challenge, however protection is lost when mice are vaccinated on the day of, or 3-7 days 
following challenge (549). Many tumour associated antigens have been defined in GL261 
including Trp-2, and gp100 (558), survivin (559), EphA2 (560) and GARC-1 (561). While 
these antigens are shared across many tumour types, the immunodominant antigens 
present within GL261 are under investigation as they are presently unknown. 
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The discrepancies in tumour response to therapy between the orthotopic implantation 
and subcutaneous challenge settings are highly important. The main disadvantage of the 
I.C model is the inability to monitor tumour development over time. Repeat MRI 
scanning is impractical and costly without a small animal-imaging platform and there is 
evidence anaesthetic drugs including ketamine are immunosuppressive (562). 
Transduction of GL261 to allow in vivo bioluminescence is possible but only provides a 
semi-quantitative measure and still requires mice to be anaesthetised (563). Indeed, in this 
study mice were monitored daily until they reached a moribund state suggesting 
bioluminescence imaging is a luxury but relying on other signs of neurologic deficit or 
weight loss still provide a robust readout of disease progression (563). Adopting a S.C 
route of administration provides an easy means of challenge but subverts many of the 
advantages of intracranial challenge. Whereas intracranial implantation resulted in 100% 
tumour penetrance in mice, subcutaneous tumour growth could be variable and 
exponential tumour growth was not seen. As mentioned previously, expression of MHC-I 
and MHC-II on GL261 in vivo render these cells moderately immunogenic. Regression of 
S.C tumours following α-PD-1 administration, in the absence of a vaccine stimulus 
suggests antigen recognition can occur and anti-tumour immunity is promoted when PD-
1 signalling is blocked. 
 
The difficulties in using a surgically implantable tumour model include the sterile 
inflammation induced following implantation, potentially inducing an innate immune 
response, which is exacerbated following treatment to promote anti-tumour immunity. In 
addition, utilisation of a cell line allows rapid tumour growth, limiting the reciprocal 
interactions between tumour cells, stromal cells and immune cells which would otherwise 
occur in human patients. Spontaneous murine models alleviate some of these concerns, as 
genetic mutations are introduced which correspond with the human counterpart, 
supposedly resulting in a more human-representative tumour than carcinogen induced 
models. As mutations are introduced into germline cells, the possibility for off target 
effects is present. Conditional models permit tissue specific deletion of tumour 
suppressor genes and evade some of the problems faced by spontaneous models, 
however these systems have practical limitations including higher costs, variable time to 
tumour appearance, and variations in tumour grade (564, 565). In a study comparing the 
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immunogenicity of murine tumour models, 4/31 (IFN-γ, PD-L1, VEGF and STAT3) 
intratumoural immune-related genes were found to be different between GL261, and a 
spontaneous brain tumour induced by intracerebral injection of oncogene containing 
plasmids into brains of neonatal mice (566). This study suggests the immune infiltrate and 
degree of immune-editing occurring within the tumour is relatively comparable between 
GL261 and a spontaneous model. Immunodeficient xenograft models are unsuitable for 
evaluating immunotherapy and while “humanised” mouse models can be useful for 
investigating some immunotherapies, recapitulation of the complete human immune 
system in a mouse is impossible, as this requires interactions with human stromal cells 
(567).  
 
Recent evidence suggests carcinogen-induced tumours respond better to checkpoint 
blockade therapy, due to the higher mutation load generally resulting in increased 
neoepitopes available for immune priming (567-569). Adoption of appropriate tumour 
models relies heavily on the question being investigated and hypothesis being challenged. 
Genetic ablation models are likely more suitable for investigating the events and 
interactions between cells during early transformation (567). Similarly, conditionally 
induced models, featuring targeted mutations in particular pathways or tumour 
suppressor proteins may be ore appropriate for investigating targeted inhibitors. In light 
of these considerations, implantation of GL261 cells in an orthotopic setting remains a 
valid option for the development and characterisation of novel immunotherapy 
approaches. Indeed, based on the number of somatic mutations identified within tumour 
samples, GBM could be categorised as having an occasional likelihood of acquiring 
neoantigen formation (569, 570). In this case, the limited frequency of somatic mutation 
would limit neoantigen generation, thereby decreasing the probability of checkpoint 
antibodies generating anti-tumour response as monotherapies. Even in the case of 
melanoma, which has the highest frequency of somatic mutation, response rates to 
checkpoint blockade monotherapy remains relatively modest (153). Thus, the addition of 
vaccination strategies to checkpoint blockade schedules is paramount for the induction of 
anti-tumour immunity. 
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The ultimate goal of preclinical research is translational application. Vaccination of glioma 
patients with autologous DCs pulsed with tumour lysate has been performed in various 
clinical trials (286). One deterrent to using whole tumour cells is that they will contain 
self-antigens, and therefore present the risk of inducing autoimmunity. However, tumour 
lysate preparations also carry this danger and yet, DC vaccination approaches are the 
most commonly used form of anti-tumour vaccination (286). Until understanding of the 
immunodominant epitopes within GBM are known, whole tumour cell, or lysate 
preparations are the most attractive approach for preparing tumour vaccines. To 
circumvent the need to sequence GL261 and determine appropriate antigens for 
generation of a synthetic vaccine, whole tumour cells were loaded with α-GalCer and 
irradiated before being cryopreserved. Here, the entire antigenic repertoire of GL261 is 
expressed. In the absence of defined antigens, it is challenging to assess vaccine-induced 
responses. 
 
Undoubtedly, the definition and validation of discrete biomarkers to measure vaccine 
responses precedes clinical application, as new therapies must first be tested for safety 
and efficacy. Recently, the percentage of ICOS+ polyclonal T cells within the blood of 
patients has been suggested as a measure of vaccine efficacy (571). In the murine setting, 
an OVA-expressing GL261 cell line could be used (557, 572), permitting vaccine-specific 
responses to be tracked using OT-I and OT-II T cells. Similarly, peptides to known 
antigens could be incorporated into the vaccine for clinical applicability. Cytomegalovirus 
is a member of the Herpesviridae family, and latent infection is highly prevalent within 
the human population (573-575), therefore adopting CMV antigens into a whole vaccine 
preparation may allow for monitoring vaccine responses over time. Further work would 
need to be performed to ensure the incorporation of defined antigens would not affect 
vaccine efficacy. Additionally, it is possible the “indicator” antigens may be the dominant 
vaccine-induced response, rendering the vaccine otherwise incompetent. In this case, 
whole tumour cells could be combined with a library of overlapping synthetic long 
peptides (SLP) to glioma-associated antigens including EGFRvIII, survivin, gp100 or 
TRP-2 (576-578). While this would require the synthesis of peptides, negating the relative 
ease of vaccine generation described in this thesis, SLP vaccines covering the E6 and E7 
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proteins of HPV16 have shown to provide beneficial anti-tumour responses in patients 
with vulvar intraepithelial neoplasia (579).  
 
Currently, there is a strong focus on identifying neoantigens within tumours to generate 
patient specific vaccines for immunotherapy. As neoantigens are tumour specific, they 
provide a unique therapeutic opportunity however the identification and functional 
testing of these can be difficult. In a recent study of the neoantigens within a mutagen-
induced sarcoma, 62 predicted epitopes were screened before two were isolated based on 
functional analysis (316). Synthetic vaccines generated based on these peptides were 
found to be effective in a therapeutic setting, with 85% of mice showing complete 
rejection (316). It is remarkable that targeting just two epitopes could induce complete 
tumour rejection. Additionally, the nature of neoantigen peptide selection has thus far 
resulted in MHC-I binding epitopes being selected. 
 
Recent work has revealed human CD4+ T cells have the capacity to recognise mutated 
tumour neoantigens (580, 581). Whereas irradiated splenocytes have been used to 
perform functional analysis for MHC-I binding epitopes in murine studies (316), 
oncogene-immortalised autologous B cells can serve as APCs to allow for functional 
analysis of human CD4+ T cells to be performed (581). While these are showing 
remarkable clinical success, peptide generation and screening is still relatively 
cumbersome. As generation of a patient specific mutanome requires sequencing of a 
tumour, mutations identified by exome-sequencing can be selected as vaccine targets and 
synthetic poly-neoepitope mRNA vaccines can be generated. Using this approach, 
tumour-bearing mice showed a reduction in growth when vaccines were delivered in a 
therapeutic setting, with responses dependent on CD4+ T cells (381). It is not 
unreasonable to propose that the CD4+ T cell responses observed within this thesis were 
resulting from recognition of MHC-II neoantigens within the whole cell vaccine. 
 
Prior work has demonstrated vaccine toxicity when cells are delivered at high doses 
intravenously, with toxicity alleviated by heparin pre-treatment (Martin Hunn, personal 
communication). Toxicity in this setting was attributed to the pro-coagulant Tissue Factor 
(582, 583). To overcome this hurdle, alternate delivery methods should be examined such 
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as intradermal or subcutaneous vaccination routes. While these may overcome toxicity 
issues, the appeal of intravenous administration is that the large population of iNKT cells 
within the liver and spleen are targeted, promoting anti-tumour immunity. Secondly, 
priming of immune responses in the skin-draining lymph nodes may induce 
“inappropriate” responses, compared to targeting the secondary lymphoid organs where 
T cell priming may result in a CNS homing phenotype (103, 584, 585). In keeping with 
this, early work examining CTLA-4 blockade with different vaccine administration routes 
do not appear to offer superior, nor comparable protection, compared to intravenous 
administration (Lindsay Ancelet, personal communication), however this may be a result 
of antigen dose and higher doses may be required. As NKT cells were shown to be 
required for successful therapy in this thesis, it may be that alternate routes of 
administration do not afford iNKT:DC interactions to promote sufficient licensing. If 
this is shown to be the case, administration of α-CD40 antibodies, in combination with 
α-CTLA-4 and vaccination may overcome the requirement for iNKT cell licensing. 
Alternatively, the inclusion of ligands for other innate like T cells, including γδ T cells, or 
mucosal associated invariant T (MAIT) cells may permit DC licensing. 
 
Alternatively, redirecting immune priming may allow NKT cell targeting without 
intravenous vaccine administration. An intranasal delivery system may represent a 
solution to overcome this. As the brain lymphatics drain to the deep and superficial 
cervical lymph nodes (340, 443), and the mediastinal lymph nodes are required for T cell 
reprogramming (103), an aerosolised vaccine could be inhaled, reaching both the tumour 
draining lymph nodes, as well as the lung draining MdLN to induce T cell priming. Virus-
like particles (VLPs) can be coupled with α-GalCer to induce iNKT cell activation and 
DC licensing, resulting in antigen specific T cell responses (586). Using a similar system, 
RNA could be packaged inside a VLP, coated with α-GalCer and then administered as an 
aerosol. Combined with checkpoint blockade antibodies this may represent a novel 
approach for inducing anti-tumour immunity in patients. Whether this has any 
therapeutic feasibility remains to be investigated. 
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To conclude, checkpoint blockade has afforded significant advances for cancer patients 
and reinvigorated the field of immunotherapy. The potential for these successes to apply 
to GBM patients is of great interest. Combination treatment for GBM patients involving 
vaccination with irradiated α-GalCer loaded, autologous tumour cells, combined with 
checkpoint blockade, may represent the best application of a novel therapy for a cancer 
for which current treatment options are limited. 
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